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The Wilms' Tumour Suppressor gene 1, WT1, encodes for a complex protein which 
is essential in mammals throughout life. Its roles vary with the developmental stages: 
in the embryo, it regulates the epithelial-mesenchymal balance required for a correct 
organogenesis and acts as a tumour suppressor; in the adult, it is involved in the 
maintenance of tissue homeostasis and has been controversially considered as an 
oncogene. 
Breast cancer is one of the adult tumours in which WT1 oncogenic function was first 
hypothesised. This malignancy is the most common in women, with more than one 
million cases being diagnosed worldwide every year, and represents the leading 
cause of cancer related deaths.  
Because of its major health burden, this disease has been extensively studied and 
special attention has also been paid to normal mammary gland biology: several 
works have shown that breast cancer can be divided into many molecular subtypes, 
which may reflect the cell of origin of the tumour; moreover, many genes involved in 
the normal development of the mammary gland have been proven to also play a role 
in breast tumorigenesis. 
WT1 expression has been previously reported in both healthy mammary glands and 
breast cancer samples, however, its function in this context is not well understood 
and the evidence gathered so far is extremely contradictory.  
This thesis aimed to investigate the exact role played by WT1 in both mammary 
gland and breast cancer biology, using a combination of in vivo and in vitro 
techniques.  
Following flow cytometry isolation, Wt1 mRNA expression was detected in the 
myoepithelial and stem cell subpopulations of the healthy gland. To investigate the 
effects of WT1 loss, Wt1 conditional mice were crossed with two different mammary 
specific Cre lines: the knockout animals developed, bred and lactated normally, 
however, they showed a significant increase of ductular branches during pregnancy, 
suggesting that WT1 may be involved in the regulation of branching morphogenesis. 
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In order to study WT1 role in mammary tumours, the gene was knocked out in a 
breast cancer mouse model and knocked down in several breast cancer cell lines, 
using both constitutive and inducible lentivirus-based systems. WT1 loss did not 
seem to affect cell proliferation, but resulted in a significant increase in cell 
migration in vitro and in the upregulation of mesenchymal markers. 
Furthermore, bioinformatics analysis showed that the WT1-positive tumours mainly 
belong to the luminal/ER-positive subtypes and express lower levels of mesenchymal 
markers than the WT1-negative tumours. 
As a whole, the findings of this thesis characterise WT1 expression in the healthy 
mammary gland and provide the first evidence of its possible function in this organ; 
moreover, this work seems to rule out an oncogenic role for WT1 in breast cancer, 
while suggesting that it could be an upstream regulator of cell migration. Additional 
experiments are required to confirm this result in vivo and verify whether it could 
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Chapter 1: Introduction 
 
1.1 Overview 
Breast cancer is the most frequent malignancy in women, with more than one million 
cases being diagnosed worldwide every year (Parkin and Fernández 2006, 
Soerjomataram, Lortet-Tieulent et al. 2012). Despite all the recent progress made in 
the therapeutic field, breast cancer still accounts for 14% of cancer deaths and kills 
annually more than 410,000 women (Coughlin and Ekwueme 2009).  
The heterogeneity of this disease, which can be divided into many histological and 
molecular subtypes, represents a major challenge and a lot of effort is being put into 
finding new biomarkers and therapy targets that would help treat the patients 
according to their subtype of breast cancer.  
Given the strong links between tumour and developmental biology, another line of 
research has focused on the normal mammary gland and its signalling pathways, 
showing that many genes involved in the normal development of the mammary gland 
also play a role in breast cancer (Dickson, Creer et al. 2000, Lanigan, O'Connor et al. 
2007). 
One such gene may be the Wilms' Tumour Suppressor gene 1, WT1, which encodes 
for a complex protein essential for mammalian development.  
WT1 has been extensively studied in the fields of embryology, oncology and renal 
disease, however its role in both normal and cancerous mammary glands remains 
unclear: its expression has been reported in the myoepithelium and in the ductal 
lumen of the normal gland (Silberstein, Van Horn et al. 1997, Silberstein, Dressler et 
al. 2002) as well as in breast cancer, where it is at the centre of a controversy over a 
potential oncogenic or tumour suppressing function (Cheng, Wu et al. 2001, Loeb, 
Evron et al. 2001, Zhang, Yu et al. 2003, Wang and Wang 2008). 
This project aims to shed some light on the exact role of Wt1 in both normal gland 
development and breast cancer; to do so a combination of in vivo and in vitro 
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approaches have been used, including mammary-specific Wt1 conditional knockout 
mice and a breast cancer mouse model in which Wt1 was selectively ablated. 
This introduction will try to provide some context for my work and will include: 
 an overview of the WT1 gene (expression pattern, isoforms, role in 
development and in cancer) 
 a review of mammary gland biology (normal development and breast cancer) 
 a critical analysis on the current knowledge about the role of WT1 in both 

















1.2 The Wilms’ Tumour Gene 1, WT1 
 
The Wilms’ Tumour Gene, WT1, is located on the short arm of the human 
chromosome 11 (11p13) and was first identified in 1990, when a series of papers was 
published by the Housman group (Call, Glaser et al. 1990, Haber, Buckler et al. 
1990, Rose, Glaser et al. 1990). Their work linked deletions of the WT1 locus to 
Wilms’ tumour (the eponymous paediatric kidney cancer) and the WAGR syndrome 
(Wilms’ tumour predisposition, Aniridia, Genitourinary anomalies and mental 
Retardation). 
 
1.2.1 Gene structure, function and expression pattern 
The WT1 gene consists of ten exons and encodes a 52-54 kDa protein product with 
two major domains:  the N-terminal is rich in proline and glutamine residues and has 
a transcriptional regulatory function, the C-terminal is composed of four Cys2His2 
zinc fingers and allows sequence-specific nucleic acid binding (Figure 1.1) (Gessler, 
Poustka et al. 1990, Haber, Sohn et al. 1991). 
 
 
Figure 1.1 Schematic of the WT1 protein.    
The C-terminal of the WT1 protein is characterised by four zinc-fingers, while the N-terminal 
includes an RNA recognition motif, a repression and an activation domain. 
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WT1 is expressed in a tightly regulated time- and tissue-specific manner: in the 
mammalian embryo, it is found in many tissues of mesodermal and ectodermal 
origin, including kidneys, gonads, heart, spleen, spinal cord, limb, brain and 
mesothelium (Pritchard-Jones, Fleming et al. 1990, Armstrong, Pritchard-Jones et al. 
1993, Moore, Schedl et al. 1998).  
Consistent with this expression pattern, homozygous Wt1 knockout mice die in utero 
at E13.5 from heart malformations and show extensive defects of the urogenital 
system; the kidneys fail to develop owing to apoptosis of the early renal precursor 
cells and developmental abnormalities are also observed in the liver, spleen, 
diaphragm and adrenal glands (Kreidberg, Sariola et al. 1993, Moore, McInnes et al. 
1999).  
In the adult, Wt1 expression was initially thought to be confined to kidney podocytes, 
mesothelium and granulosa/Sertoli cells of ovaries/testis (Pelletier, Schalling et al. 
1991, Mundlos, Pelletier et al. 1993, Walker, Rutten et al. 1994); over the years, 
however, Wt1 was also detected in the epithelial cells of the mammary gland, in the 
bone marrow and in the Schwann cells of human nerves (Silberstein, Van Horn et al. 
1997, Hosen, Shirakata et al. 2007, Schittenhelm, Thiericke et al. 2010). In all these 
adult tissues, Wt1 expression is restricted to a very small percentage of cells; 
nevertheless, inducible deletion of Wt1 in adult mice leads to a drastic phenotype: 
within a week, the knockout animals show spleen and pancreatic atrophy, severe 
bone and fat reduction, kidney failure and impaired erythropoiesis (Chau, 
Brownstein et al. 2011). 
All these observations suggest different roles for Wt1 throughout development: while 
in adulthood it seems to regulate tissue homeostasis, in the embryo it prevents 
apoptosis and promotes cell differentiation (as discussed in more detail in chapter 
1.2.2).  
Additional complexity is introduced by the fact that, depending on the tissue and the 
context, WT1 has also been shown to act as a transcriptional activator or repressor, a 
tumour suppressor gene or an oncogene, to be involved in the differentiation or 
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maintenance of progenitor cells and in RNA metabolism (Hohenstein and Hastie 
2006).   
These different functions are achieved, at least in part, through the expression of 
multiple isoforms: these protein variants result from combinations of alternative start 
codons, RNA editing processes and alternative splicing events (Figure 1.2).  
The WT1 locus encodes a theoretical maximum of 36 isoforms, all of which express 
the zinc-finger region in exons 7-10; the majority of these protein configurations, 
however, has not yet been characterised.  
 
 
Figure 1.2 Schematic of the WT1 gene.  
The alternative exons, start codons and splicing sites are shown in red while the affected functional 
domains are in green (from Hohenstein & Hastie 2006).   
 
The best studied isoforms derive from two alternative splice donor sites at the end of 
exon 9, which include or omit 9 nucleotides encoding for lysine, threonine and serine 
(KTS) (Haber, Sohn et al. 1991); NMR studies have revealed that the insertion of 
these three amino acids increases the flexibility of the zinc finger region, which 
results in a much higher binding affinity for RNA than DNA (Caricasole, Duarte et 
al. 1996, Laity, Chung et al. 2000). The +KTS variants have been shown to co-
localise and directly interact with proteins of the splicing machinery such as U2AF65 
and RBM4 (Englert, Vidal et al. 1995, Larsson, Charlieu et al. 1995, Davies, Calvio 
et al. 1998, Ladomery, Slight et al. 1999, Markus, Heinrich et al. 2006) and also to 
bind the mRNA of IGFR2, ACTN1 and SCRB (Caricasole, Duarte et al. 1996, 
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Morrison, Venables et al. 2006, Wells, Rivera et al. 2010), supporting the idea that 
they mainly act at a post-transcriptional level. Despite its role in RNA processing, the 
best characterised WT1 function is that of a transcription factor: morphological and 
biochemical studies have shown that this role is predominantly exerted by the –KTS 
isoforms (Larsson, Charlieu et al. 1995, Laity, Chung et al. 2000) and two different 
consensus DNA sequences have so far been described (Rauscher, Morris et al. 1990, 
Madden, Cook et al. 1991). 
Many different approaches have been used to identify the transcriptional targets of 
WT1, from in vitro reporter assays and overexpression experiments, to ChIP and 
transgenic mouse models; all these studies have recognised a series of candidate 
genes, which include other transcription factors, growth factors and their receptors, 
signal transducers, extracellular matrix and cell adhesion molecules as well as genes 
regulating the cell cycle and the apoptotic pathways (Table 1.1). 
Depending on the cellular and temporal context, WT1 can either activate or repress 
the transcription of its target genes: this dichotomous behaviour was first described 
in vitro in relation to the platelet-derived growth factor (Gashler, Bonthron et al. 
1992, Wang, Madden et al. 1992, Wang, Qiu et al. 1993) and then observed also for 
the Insulin-like growth factor II (Drummond, Madden et al. 1992, Nichols, Re et al. 
1995, Ward, Pooler et al. 1995), MYC (Hewitt, Hamada et al. 1995, Udtha, Lee et al. 
2003, Han, San-Marina et al. 2004), SNAI1 (Martinez-Estrada, Lettice et al. 2010), 
CDH1 (Hosono, Gross et al. 2000, Martinez-Estrada, Lettice et al. 2010) and BCL-2 
(Hewitt, Hamada et al. 1995, Heckman, Mochon et al. 1997, Mayo, Wang et al. 
1999). 
The molecular basis for this dual role of WT1 have only recently been elucidated by 
a study on the WNT4 gene: Essafi and colleagues have shown that in the developing 
kidney WT1 activates WNT4 by recruiting p300 and Cbp as co-activators and by 
maintaining the chromatin of the Wnt4 locus in an active conformation; conversely, 
in the developing heart, Wt1 recruits the co-repressor Basp1 and switches the 
chromatin to a repressed state, which leads to Wnt4 downregulation (Essafi, Webb et 
al. 2011).   
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Table 1.1 Transcriptional targets of WT1 
Target Effect Reference 
Growth factors 
Insulin-like growth factor II 
 
Amphiregulin 
Platelet derived growth factor A 
 
Colony stimulating factor 1 




Connective tissue growth factor 
Vascular endothelial growth factor 
 
Receptors 





Insulin-like growth factor 1 receptor 
 













































Nichols et al. 1995, Ward e al. 
1995, Drummond et al. 1992 
Lee et al. 1999 
Wang et al. 1992, Gashler et al. 
1992, Wang et al. 1993  
Harrington et al. 1993 
Dey et al. 1994 
Hsu et al. 1995 
Adachi et al. 1996  
Shimamura et al. 1997  
Stanhope-Baker et al 2000 
Hanson et al. 2008, McCarty et 
al. 2011 
 
Menke et al. 1997, Englert et 
al. 1995 
Zaia et al. 2001  
Webster et al. 1997, Menke et 
al. 1997 
Werner et al. 1993, Werner et 
al. 1994 
Goodyer et al. 1995 
Lee et al. 2001, Maurer et al. 
2001, Wagner et al. 2001  
 
Rupprecht et al. 1994 
McCann et al. 1995 
Hewitt et al. 1995, Udtha et al. 
2003, Han et al. 2004 
Ryan et al. 1995 
Madden et al. 1991  




Table 1.1 (continued) 




































































Hosono et al. 2000, Martinez-
Estrada et al. 2009 
Dejong et al. 1999 
Cook et al. 1996 
 
 
Palmer et al. 2001 
Gross et al. 2003 
Sim et al. 2002, Essafi et al. 
2011 
Hossain et al. 2001 
Han et al. 2003 
Kim et al 1999 
 
 
Hewitt et al. 1995, Heckman et 
al. 1997, Mayo et al. 1999 
Morrison et al. 2005 
Simpson et al. 2006 
Cesaro et al. 2010 
 
 
Englert et al. 1997 
Loeb et al. 2002 
Wagner et al. 2001 
 
 
Dame et al. 2006 
Moshier et al. 1996, Li et al. 
1999 
Minc et al. 1999 




Transgenic mouse models in which either the + or the –KTS proteins are specifically 
ablated show different phenotypes and demonstrate that the ratio of the different 
isoforms is crucial for development (Hammes, Guo et al. 2001).  
Under normal physiological conditions, the ratio between + and – KTS splice 
variants is of approximately 5:1 in the embryo and 2:1 in the adult (Haber, Sohn et 
al. 1991); perturbations of this proportions either lead to kidney hypoplasia and 
streak gonads (if the mice only express the – KTS), or to renal failure and complete 
XY sex reversal (if they only express the + KTS). 
In both cases, however, the homozygous knockout mice do not develop such a severe 
phenotype as the complete null: the pups survive embryonic development and die 
within 24 hours after birth, which suggests that the KTS isoforms of WT1 have both 
distinct and overlapping functions (Hammes, Guo et al. 2001). 
Another splicing event of particular importance results in the optional transcription 
of exon 5, which encodes for a mammal specific 17-amino acid sequence whose 
function is not yet fully understood (Haber, Sohn et al. 1991).  
Renshaw reported that this differential splicing appears to be regulated in a tissue-
specific manner and that the highest expression levels for exon 5 are observed in the 
testis, kidneys and haematopoietic system (Renshaw, King-Underwood et al. 1997). 
Different studies have linked the function of the +Exon 5 variants to cell cycle 
regulation and apoptosis, even though conflicting results were observed: in 
osteosarcoma cell lines, these isoforms are the most potent at inducing TP53-
independent apoptosis (Englert, Hou et al. 1995) and their overexpression in mouse 
embryonic fibroblasts blocks cell cycle progression (Kudoh, Ishidate et al. 1995); 
however, the same +Exon 5 proteins are the only WT1 isoforms that can rescue 
HEK293 cells from the apoptotic signal induced by UV light treatment (Richard, 
Schumacher et al. 2001). These contradictory results can be partially explained by 
the fact that the Exon 5 region contains a transcriptional activation domain which 
requires a direct interaction with the prostate apoptosis response factor PAR4 
(Richard et al. 2001): since the nuclear levels of PAR4 depend on the cellular and 
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experimental context, the Exon 5-mediated response to apoptosis may vary 
accordingly. 
To better characterise this isoform, Natoli and colleagues generated a mouse strain 
that specifically lacks Exon 5; given that this variant is only present in placental 
mammals, a possible role in mammal-specific reproductive functions had been 
hypothesised: surprisingly, however, the knockout mice show no obvious phenotype, 
and they develop, breed and lactate normally (Natoli, McDonald et al. 2002). This 
finding suggests that there is a degree of functional redundancy among the different 
isoforms and that, at least under physiological conditions, Exon 5 has no essential 
function.  
In addition to the four major isoforms just described (+/- KTS and +/-Exon 5), other 
WT1 configurations derive from a maternally-imprinted alternative exon 1 (exon 1A, 
Dallosso et al. 2004), a cryptic promoter in intron 5 (Dechsukhum, Ware et al. 2000) 
and two alternative translation start sites (Bruening and Pelletier 1996, Scharnhorst, 
Dekker et al. 1999). Very little is known about these isoforms, which seem much less 
abundant than those translated starting from the main ATG site; noteworthy, 
however, is the expression profile of the truncated transcript starting from intron 5: 
this short protein, in fact, has only been detected in breast and pancreatic cancer cell 
lines and in the blood of patients affected by acute leukaemia (Bae, Jackson-Cook et 
al. 1994, Dechsukhum, Ware et al. 2000), suggesting that it might be a tumour-
specific isoform. 
 
1.2.2 WT1 in development: regulation of the epithelial-
mesenchymal balance 
As previously mentioned, WT1 plays a crucial role during embryonic development 
and its expression in mice can be detected as early as E8.5: at this stage WT1 is 
found in the intermediate and lateral plate mesoderm, which will later give rise to 
kidneys, gonads and adrenal glands. At E9.5 WT1-positive cells are also spotted in 
the septum transversum, the mesenchymal structure which contributes to the 
formation of the liver mesothelium, diaphragm, ventricular myocardium, peri and 
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epicardium (Armstrong, Pritchard-Jones et al. 1993, Moore, McInnes et al. 1999, 
Chau and Hastie 2012). 
Embryonic development is characterized by a series of bidirectional conversions 
between epithelial and mesenchymal phenotypes, respectively called epithelial to 
mesenchymal transition (EMT) and mesenchymal to epithelial transition (MET). 
Both these processes are essential for organogenesis and allow the embryonic cells to 
migrate, relocate themselves and differentiate (reviewed in Perez-Pomares and 
Munoz-Chapuli 2002, Thiery, Acloque et al. 2009).  
During development, the vast majority of WT1-expressing tissues undergoes an 
EMT or an MET, and most of the developmental defects observed in the Wt1-
deficient embryos can be explained by disturbances of these processes (reviewed in 
Miller-Hodges and Hohenstein 2012). 
The epicardial cells, for example, go through an EMT and then migrate into the 
heart, where they differentiate into cardiomyocytes and cells of the coronary 
vasculature (Mikawa and Gourdie 1996, Zhou, Ma et al. 2008).  
This epicardial EMT is regulated by WT1 through the direct repression of the 
epithelial marker CDH1 and the activation of SNAIL, a pro-EMT transcription 
factor. In epicardial-specific Wt1 knockout mice, the epicardium develops normally 
but the EMT is impaired: as a result, the number of mesenchymal progenitor cells 
and their derivatives is drastically reduced, which leads to thinner heart walls, 
pericardial hemorrhage and, ultimately, heart failure (Martinez-Estrada et al. 2009). 
Also the liver abnormalities of the Wt1 null have been linked to a disturbed EMT: 
Ijpenberg and colleagues have shown that the Wt1-positive mesothelium of the 
developing liver undergoes an EMT and the resulting mesenchymal cells invade the 
liver parenchyma to give rise to hepatic stellate cells; in Wt1 knockout mice, 
however, the stellate cells show an anomalous differentiation and the liver size is 
reduced (Ijpenberg, Perez-Pomares et al. 2007). 
More complicated and diverse seems the role of WT1 in kidney development, which 
therefore deserves a more detailed analysis. 
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The early stages of nephrogenesis are characterized by reciprocal interactions 
between the metanephric mesenchyme and the ureteric bud, precursors of the 
nephron and the collecting duct system respectively. The kidneys start to develop 
when the epithelial ureteric bud forms an outgrowth from the Wolffian duct into the 
metanephric mesenchyme. In mice the first contact between the ureteric bud and the 
mesenchyme is approximately at E10.5-11 and it is followed by the condensation of 
the mesenchymal cells that surround the tips of the ureteric bud (Figure 1.3): these 
cells aggregate around the tips of the ureteric bud, undergo an MET, and then form 
the renal vesicle. The differentiation and elongation of the renal vesicle lead to the 
comma and S-shaped bodies, which eventually produce the renal corpuscle (or 
glomerulus), the proximal tubule and the loop of Henle (Saxen and Sariola 1987, 
Vainio and Lin 2002).    
 
 
Figure 1.3 Embryonic kidney development (adapted from Scholz & Kirschner 2005).      
Nephrogenesis starts with the ureteric bud invasion of the metanephric mesenchyme; the 
mesenchymal cells around the branching ureteric bud condense, switch towards an epithelial state and 
give rise to the complex structures of the mature kidney. 
                          
In the Wt1 knockout mice, the Wolffian duct develops normally but the ureteric bud 
is absent and the cells of the metanephric mesenchyme undergo extensive apoptosis 
at E11 (Kreidberg, Sariola et al. 1993): Wt1 is therefore required in the early stages 
of nephrogenesis for the survival and differentiation of the renal progenitor cells.  
Besides its early role as a survival factor, Wt1 expression pattern implies also a role 
in later stages of kidney development, including the MET: its expression gradually 
increases from the metanephric mesenchyme stage till the S-shaped body and is then 
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restricted to the proximal nephron (Armstrong, Pritchard-Jones et al. 1993); the 
complete absence of kidneys in the knockout embryos, however, has made the 
investigation on the late Wt1 functions quite challenging.  
To overcome these limitations, different approaches have been used: a 
complementation study has shown that a human-derived WT1 YAC construct can 
partially rescue the kidney defects of the knockout mice, providing also evidence for 
a continuous Wt1 requirement throughout nephrogenesis (Moore, McInnes et al. 
1999). Furthermore, Wt1 siRNAs applied to kidney rudiments at the stage between 
ureteric bud invasion and mesenchyme condensation, block nephron development at 
the pre-epithelial stage, demonstrating that in organ culture experiments Wt1 is 
indispensable for MET (Davies, Ladomery et al. 2004).  
Recently, these findings have been confirmed in vivo, using a conditional Wt1 
knockout model and three different Cre lines that selectively inactivate the gene at 
different stages of nephron development (Berry et al. manuscript submitted). 
Hence, the kidney phenotype of the Wt1-null mice cannot be linked to a defective 
MET, given that the metanephric blastema degenerates before reaching this stage; 
deleting Wt1 later in development, however, has revealed that this gene plays a 
crucial role in the epitheliasation of the metanephric mesenchyme and it does so by 
directly activating Wnt4 (Essafi et al. 2011), whose expression is both necessary and 
sufficient for the nephron MET to occur (Stark, Vainio et al. 1994, Kispert, Vainio et 
al. 1998).  
In summary, WT1 can rightfully be considered as a major regulator of the epithelial-
mesenchymal balance during development and its functions vary according to the 
tissue and the developmental stage. 
 
1.2.3 Wt1 in cancer   
Since its identification more than two decades ago, WT1 has been extensively 
studied in the field of cancer biology: initially discovered as a causative gene of 
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Wilms’ tumour, it has later been associated to acute leukaemias and, more recently, 
to many adult solid tumours, including breast, pancreatic and colorectal cancer. 
This section aims at reviewing the current knowledge of WT1 role in tumorigenesis 
and comparing its functions in the different types of cancer in which it is expressed/ 
mutated. 
 
1.2.3.1 Wilms’ tumour 
Wilms’ tumour, or nephroblastoma, is the most common paediatric kidney cancer, 
with an incidence of 1 in 10,000 children (Miller, Young et al. 1995). It is named 
after Dr. Max Wilms, the German pathologist who, in the far 1899, realised the 
embryonic origin of this malignancy; later studies confirmed that Wilms’ tumour 
derives from pluripotent renal precursor cells, a reason why it is frequently cited as 
an example of defective differentiation leading to tumorigenesis (Zhuang, Merino et 
al. 1997).  
Along with retinoblastoma and neuroblastoma, Wilms’ tumour was one of the 
paediatric cancers upon which Knudson based his ‘two-hit’ model of tumour 
suppression, which suggests that two rate-limiting genetic events are required to 
initiate tumorigenesis (Knudson 1971, Knudson and Strong 1972). 
The first gene found to be inactivated in Wilms’ tumour was WT1: in accordance 
with the two-hit hypothesis, Haber and colleagues described a case of sporadic 
unilateral Wilms’ tumour with an intragenic WT1 deletion in one allele and a loss of 
heterozygosity in the other (Haber et al. 1990). 
Subsequently, WT1 mutations were detected in 10–15% of patients (Varanasi, 
Bardeesy et al. 1994) and were found to be quite heterogeneous, including whole or 
partial gene deletions, insertions, nonsense, missense and splicing-affecting 
mutations (Little and Wells 1997); all these abnormalities, however, lead to a loss of 
function, which clearly demonstrates that WT1 behaves as a classic tumour 




More controversial is the role of WT1 in both normal and malignant hematopoiesis 
(reviewed in Ariyaratana and Loeb 2007, Yang, Han et al. 2007). 
Research on this topic was sparked by the finding that in adult mice both thymus and 
spleen show Wt1 expression (Buckler, Pelletier et al. 1991), later detected also in the 
bone marrow, where it is restricted to approximately 1% of the CD34+ multipotent 
progenitor cells (Hosen, Sonoda et al. 2002). The use of a WT1-GFP knockin 
reporter mouse has helped characterise this WT1+ population of short-term stem 
cells, showing that it comprises both uncommitted, quiescent CD38– and committed, 
proliferating CD38+ cells (Hosen, Shirakata et al. 2007); methylcellulose-based 
cultures have also demonstrated that these WT1+ cells can differentiate in 
erythrocytes, leukocytes and granulocytes, while defective haematopoiesis is 
observed upon inducible deletion of Wt1 in adult mice (Chau, Brownstein et al. 
2011).   
Multiple studies have shown that, following differentiation of the progenitor cells, 
Wt1 is downregulated to such an extent that it is almost undetectable in mature blood 
cells (Sekiya, Adachi et al. 1994, Menssen, Renkl et al. 1997, Hosen, Shirakata et al. 
2007), which suggests that it may play a role in the regulation of early hematopoietic 
differentiation. 
Additional, but controversial evidence, is provided by the fact that wildtype WT1 is 
strongly expressed in the immature tumour cells of almost all acute leukaemias, 
whereas it is absent in non-Hodgkin’s lymphoma, whose cells originate from a more 
mature lymphoid population (Inoue, Sugiyama et al. 1994). However, WT1 
expression in acute myelogenous and lymphocytic leukaemias, as well as in the blast 
crisis of chronic myeloid leukemia, has been interpreted by some investigators as an 
indicator of an oncogenic role for WT1 and not as a marker of their original cell 
lineage.   
Data in this field have been extremely contradictory, as illustrated by the correlation 
between WT1 expression and prognosis: elevated WT1 levels in leukemia patients 
have been associated to either positive (Rodrigues, Oliveira et al. 2007) or negative 
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(Inoue, Sugiyama et al. 1994, Bergmann, Miething et al. 1997, Trka, Kalinova et al. 
2002, Barragan, Cervera et al. 2004) outcomes, but also described to be of no 
prognostic value whatsoever (Schmid, Heinze et al. 1997, Yanada, Terakura et al. 
2004). These conflicting results are unlikely to reflect real biological functions of 
WT1: the discrepancies are more probably due to the presence of confounding 
factors, such as differences in the patient age, detection techniques and 
histological/cytogenetic tumour subtypes. 
Weighing in favour of an oncogenic WT1, is the fact that its expression levels are 
much higher in leukemia than in physiologic conditions (Inoue, Ogawa et al. 1997, 
Menssen, Renkl et al. 1997); as a consequence of this overexpression in the 
malignant phenotype, WT1 is considered as a robust marker for the detection of 
minimal residual disease (Inoue, Sugiyama et al. 1994, Ogawa, Tamaki et al. 2003) 
and also an independent risk factor for relapse (Inoue, Ogawa et al. 1996, Lapillonne, 
Renneville et al. 2006).  
In keeping with these findings, treatment with WT1 antisense oligomers has been 
shown to inhibit the proliferation of leukemic cells in vitro and to induce apoptosis 
(Algar, Khromykh et al. 1996, Yamagami, Sugiyama et al. 1996).  
Moreover, WT1 has recently been indicated as a promising tumour antigen that can 
be targeted through immunotherapy (reviewed in Keilholz, Menssen et al. 2005). 
Several studies in mice revealed that the immunization with WT1 peptide or cDNA 
triggers the response of cytotoxic T-lymphocites which selectively kill the WT1 
expressing tumour cells, leading to prolonged survival (Gaiger, Reese et al. 2000, 
Oka, Udaka et al. 2000, Tsuboi, Oka et al. 2000). 
These observations have paved the way to human WT1 vaccine for patients affected 
by leukemia (Mailander, Scheibenbogen et al. 2004, Oka, Tsuboi et al. 2004). The 
clinical studies, mainly performed in Japan and Germany, are now in phase-II and 
have so far obtained encouraging results: a statistical analysis carried out on all the 
WT1-based vaccine trials published until 2012, reveals that out of the 83 patients 
with haematological malignancies, 13 achieved complete remission and an additional 
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18 showed stabilization of the disease after vaccination (Van Driessche, Berneman et 
al. 2012). 
Some findings, however, are difficult to reconcile with a presumed oncogenic 
function and would support a tumour-supressing role: firstly, WT1 mutations have 
been found in 15-20% of leukemia patients (King-Underwood, Renshaw et al. 1996), 
similar to what is observed in Wilms’ tumour; these alterations include nonsense, 
missense, and frameshift mutations and are predicted to produce a truncated protein 
with defective DNA-binding ability (King-Underwood et al. 1996). 
Secondly, several independent studies have associated these mutations to poor 
prognosis, and hypothesised that they may confer drug resistance by altering the 
apoptotic response to cytotoxic agents (King-Underwood and Pritchard-Jones 1998, 
Summers, Stevens et al. 2007, Paschka, Marcucci et al. 2008, Hollink, van den 
Heuvel-Eibrink et al. 2009). Lastly, Wilms’ tumour survivors have a high risk of 
developing secondary malignances, 20% of which are haematological (Breslow, 
Takashima et al. 1995, Shearer, Kapoor et al. 2001); these statistics could merely 
reflect the higher susceptibility of bone marrow cells to chemo/radiotherapy, but the 
hypothesis that WT1 mutations may represent a predisposition factor for leukemia 
cannot be ruled out.  
All in all, at the actual state of research, uncertainty remains over the exact role of 
WT1 in leukemogenesis and further investigation is required. 
 
1.2.3.3 Adult solid tumours 
Over the past few years, WT1 expression has been detected not only in leukaemia, 
but also in a variety of non haematological malignancies, ranging from brain tumour 




Table 1.2 Expression of WT1 in solid tumours 
Tumour type Detection method Reference 
Biliary cancer 






























Pancreatic ductal adenocarcinoma 
Primary astrocytic tumour 




Renal cell carcinoma 
 
Rhabdomyosarcoma 
Soft tissue sarcoma 
Urothelial cancer  
Uterine sarcoma 
IHC 
RT-PCR, IHC, WB 
IHC 









































Nakatsuka et al. 2006 
Ueda et al. 2003 
Nakatsuka et al. 2006 
Silberstein et al. 1997, 
Loeb et al 2001, 
Nakatsuka et al. 2006, 
Gillmore et al. 2006 
Nakatsuka et al. 2006 
Koesters et al. 2004 
Oji et al. 2003 
Nakatsuka et al. 2006 
Amini Nik et al. 2005 
Nakatsuka et al. 2006 
Nakatsuka et al. 2006, Oji 
et al. 2004 
Nakatsuka et al. 2006 
Clark et al. 2007 
Ohno et al. 2009 
Oji et al. 2003a 
Oji et al. 1999, Menssen 
et al 2000, Oji et al. 2002, 
Nakatsuka et al. 2006 
Nakatsuka et al. 2006 
Kumar-Singh et al. 1997, 
Foster et al. 2001 
Denis et al. 2002 
Nakatsuka et al. 2006 
Nakatsuka et al. 2006, 
Hylander et al. 2006, 
Waldstrom et al. 2005 
Nakatsuka et al. 2006 
Oji et al. 2004a 
Oji et al. 2004b 
Oji et al. 2003b 
Nakatsuka et al. 2006, 
Devilard et al. 2006, King 
et al. 2009 
Campbell et al. 1998, 
Nakatsuka et al. 2006 
Carpentieri et al. 2002 
Nakatsuka et al. 2006 
Nakatsuka et al. 2006 
Coosemans et al. 2007 
Abbreviations: RT-PCR, Real-Time Polymerase Chain Reaction; IHC, Immunohistochemistry; SB, 
Southern Blot; NB, Northern Blot; WB, Western Blot 
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Several studies have shown that WT1 levels are much higher in the tumours than in 
the respective normal tissues and that no WT1 mutations or splicing anomalies can be 
detected in the neoplastic samples (Campbell, Kuriyan et al. 1998, Menssen, 
Bertelmann et al. 2000, Loeb, Evron et al. 2001, Dennis, Manji et al. 2002, Oji, 
Miyoshi et al. 2003, Ueda, Oji et al. 2003, Koesters, Linnebacher et al. 2004, Oji, 
Nakamori et al. 2004, Oji, Suzuki et al. 2004, Amini Nik, Hohenstein et al. 2005, 
Clark, Dos Santos et al. 2007). In some tumour types WT1 expression has also been 
reported to correlate with higher histological grade and worse prognosis (Miyoshi, 
Ando et al. 2002, Oji, Miyoshi et al. 2003, Oji, Nakamori et al. 2004, Ohno, Dohi et 
al. 2009); this observation is consistent with the fact that WT1 seems to play an 
important role in the growth of cancer cells: similarly to what observed in leukemic 
cell lines (Algar, Khromykh et al. 1996, Yamagami, Sugiyama et al. 1996), RNAi 
silencing of WT1 has been shown to inhibit proliferation and to induce apoptosis in 
cell cultures originated from melanoma, glioblastoma, fibrosarcoma, gastric, lung, 
ovarian and pancreatic cancers (Oji, Nakamori et al. 2004, Oji, Suzuki et al. 2004, 
Zamora-Avila, Franco-Molina et al. 2007, Tatsumi, Oji et al. 2008).  
An additional similarity between hematological and solid malignancies is the 
immunogenicity of the WT1 protein: in both cases this antigen can stimulate a 
response from cytotoxic T-lymphocites which is of sufficient avidity to kill the tumor 
cells (Koesters, Linnebacher et al. 2004, Gillmore, Xue et al. 2006). 
The vaccine trials, however, show a lower response rate for the solid tumours: out of 
the 75 patients in the clinical studies only two achieved a complete remission, while 
an additional eight had partial remission and decrease in tumour size (Van Driessche, 
Berneman et al. 2012). 
All these findings would suggest an oncogenic role for WT1 in adult solid tumours, 
however, once again, there are some controversial data to consider: WT1 has been 
shown to inhibit the transformed phenotype of breast cancer cells and the malignant 
progression of mammary epithelial cells (Zhang, Yu et al. 2003, Wang and Wang 
2008); moreover, a study on IDC reported that WT1 is undetectable in the vast 
majority of the tumours analysed as a result of genetic deletion and promoter 
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hypermethylation, suggesting that WT1 loss may be an important event in breast 
tumorigenesis (Cheng, Wu et al. 2001).  
Since this debate is particularly important to put my project in context, it will be 
analysed in more detail in chapter 1.4, following an introductory section on 
mammary gland biology and breast cancer. 
 
1.2.3.4 Possible roles of WT1 in tumorigenesis 
As mentioned earlier, WT1 expression seems to correlate with poor prognosis, at 
least in breast and endometrial cancer (Miyoshi et al. 2002, Ohno et al. 2009); the 
biological basis for this finding have not yet been identified, but different hypotheses 
can be formulated.  
First of all, tumours expressing high levels of WT1 may have a proliferative 
advantage since silencing WT1 leads to growth arrest and apoptosis (Yamagami et al. 
1996, Algar et al. 1996, Zamora-Avila et al. 2007, Oji et al. 2004b, Tatsumi et al. 
2008, Oji et al. 2004a). Investigations on the molecular mechanisms involved in this 
process have revealed that WT1 can modulate many genes of the bcl-2 family, 
including BAK, BAG3, A1 and BCL-2 itself (Hewitt, Hamada et al. 1995, Heckman, 
Mochon et al. 1997, Mayo, Wang et al. 1999, Morrison, English et al. 2005, 
Simpson, Burwell et al. 2006, Cesaro, Montano et al. 2010) as well as regulate the 
Fas-related death signaling pathway (Uesugi, Hiasa et al. 2013); moreover, there is 
strong evidence suggesting that WT1 can promote cell proliferation by up-regulating 
cyclin D1 (Caldon, Lee et al. 2008, Xu, Wu et al. 2013). 
A second hypothesis is related to the formation of blood vessels: WT1 has been 
detected in the vasculature of different tumour types (Timar, Meszaros et al. 2005, 
Wagner, Michiels et al. 2008) and its expression in endometrial cancer has been 
associated with the induction of angiogenesis (Dohi, Ohno et al. 2010). In addition, 
two different groups showed that WT1 directly upregulates the expression of the 
vascular endothelial growth factor (VEGF) (Hanson, Gorman et al. 2007, McCarty, 
Awad et al. 2011) and many other vascular genes have been identified as potential 
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WT1 targets, including the vascular endothelial cadherin, angiopoietin-2, vascular 
endothelial growth factor receptors 1 and 2 (Kirschner, Sciesielski et al. 2010). 
Hence, the correlation with poor outcome may be explained by a pro-angiogenic 
function of WT1: the tumours with higher levels of this gene are more abundant in 
blood vessels, which increases the proliferative rate of the cancer cells but also grants 
them easy access to the vascular system, from where they can spread and 
metastasise. 
Finally, a last hypothesis is based on the fact that WT1 is a key regulator of the 
epithelial/mesenchymal balance and therefore it may play a role in the EMT of 
tumour cells.  
The epithelial-to-mesenchymal transition is a key biological process for embryonic 
development, tissue differentiation and repair (reviewed in Thiery, Acloque et al. 
2009): it consists of a highly coordinated series of events starting with the loss of 
cell-cell adhesion and the replacement of the baso-apical polarisation by front-rear 
polarisation; the next step involves changes in the cytoskeleton organisation and the 
trigger of proteolytic enzymes such as matrix metalloproteases which alter cell-
matrix adhesion. Eventually, the cells start to secret extra-cellular matrix components 
and show a migratory phenotype (Figure 1.4) (Zavadil and Bottinger 2005).  
As a whole, these drastic changes in cell morphology are achieved through the 
synergic action of many transcription factors, including ZEB1, ZEB2, SIP1, 
TWIST1, SLUG and SNAIL, whose function is to repress epithelial markers such as 
E-cadherin and simultaneously induce mesenchymal markers like vimentin and N-
cadherin (Batlle, Sancho et al. 2000, Comijn, Berx et al. 2001, Hajra, Chen et al. 
2002, Yang, Mani et al. 2004, Peinado, Olmeda et al. 2007). 
Most scientists agree in classifying the EMT into three different types, according to 
the biological setting in which it takes place: type I is associated with embryogenesis, 
type II with wound healing and tissue regeneration while type III is observed in 





Figure 1.4 Epithelial-to-mesenchymal transition. 
The epithelial-to-mesenchymal transition is a multi-step process characterised by the progressive loss 
of epithelial markers such as E-cadherin and the gain of mesenchymal markers like vimentin and N-
cadherin. 
 
Recently, this third type of EMT has been linked to the acquisition of a malignant 
phenotype by the epithelial cancer cells: features of EMT have been described in 
breast (Trimboli, Fukino et al. 2008) and colorectal cancer (Brabletz, Jung et al. 
2005), mainly at the invasive front of the tumour (Brabletz, Jung et al. 2001, Prall 
2007), suggesting that the EMT may generate migratory cells which leave the 
primary site, invade the blood vessels and potentially metastasise (Iwatsuki, Mimori 
et al. 2010, Micalizzi, Farabaugh et al. 2010).   
This theory on EMT contribution to tumour progression (Figure 1.5) seems to be 
supported by the fact that many developmental EMT drivers, including SNAIL, 
SLUG, TWIST and ZEB1, are mis-expressed in cancer and significantly correlate 
with relapse and poor clinical outcomes (Savagner, Yamada et al. 1997, Blanco, 
Moreno-Bueno et al. 2002, Yang, Mani et al. 2004, Huber, Kraut et al. 2005, 
Wellner, Schubert et al. 2009). 
Recent work has also suggested that the EMT process may be linked to cancer stem 
cells (CSCs): the cells undergoing this transition have been shown to acquire stem-
cell properties such as the expression of stem-cell markers and an increased ability to 






Figure 1.5 EMT contribution to tumour progression. 
The epithelial-to-mesenchymal transition is believed to play a role in the formation of secondary 
tumours by promoting the motility of cancer cells. 
 
It is not clear how WT1 may come into play in this process, but investigations on the 
topic seem worthwhile, given the strong circumstantial evidence linking WT1 to the 
cancer-related EMT: among the transcriptional targets of WT1 there are many pro-
EMT genes, including SNAIL, SLUG and TGF-β (Dey, Sukhatme et al. 1994, 
Martinez-Estrada, Lettice et al. 2010, Takeichi, Nimura et al. 2013); of particular 
importance is the fact that the latter can induce an EMT in different types of tumour 
cells (Song 2007) and through multiple signalling pathways (Bhowmick, Ghiassi et 
al. 2001, Roberts, Tian et al. 2006).  
In conclusion, there are at least three possible explanations for the correlation 
between WT1 expression and poor survival in cancer patients (altered 
proliferation/apoptosis, increased angiogenesis, induction of EMT/CSCs); since these 
theories are not mutually exclusive, they may all contribute to the aggressive 
phenotype observed in the WT1 positive tumours. Further research is however 
required to validate these hypothesis, and especially to investigate a potential role of 





1.3 Overview of mammary gland biology  
Mammary glands and milk production are distinctive features of mammals and have 
evolved as a unique survival strategy that provides the offspring with both nutrition 
and immunological protection (Oftedal 2002, reviewed in Khokha and Werb 2011). 
Despite some structural differences among species, the mammary glands of all 
mammals are made up by two main compartments, the ductal epithelium and the 
surrounding stroma (Figure 1.6).  
 
 
Figure 1.6 Structure of a mammary gland duct. 
The mammary ducts are surrounded by an inner layer of luminal cells and an outer layer of 
myoepithelial cells. 
 
The epithelium of the ducts is bilayered, with an inner ring of luminal cells 
connected by tight junctions and an outer, basal layer which includes myoepithelial 
and progenitor cells. With pregnancy, the luminal sheet differentiates into secretory 
cells and rearranges to form the alveoli: during lactation these hollow cavities will 
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develop into milk-secreting lobules while the myoepithelial cells contract to facilitate 
the delivery of milk to the pups. The stroma, also called mammary fat pad, is the 
connective tissue that surrounds and supports the epithelial structures; it mainly 
consists of adipocytes but there are also fibroblasts, blood vessels and hematopoietic 
cells (reviewed in Richert, Schwertfeger et al. 2000).  
This basic organization of the mammary gland is very dynamic and undergoes 
dramatic changes throughout its existence; these remodeling programs depend on the 
physiological stimuli that characterise the different phases of sexual 
development/reproduction and, if harnessed, can lead to breast tumorigenesis 
(Lanigan, O'Connor et al. 2007). 
In this section I will cover the basics of mammary gland biology, first describing the 
development of this organ from embryogenesis to senescence, then focusing on 
breast cancer, its different histological and molecular subtypes and the treatment 
options currently available. 
 
1.3.1 Development of the mouse mammary gland 
The mammary gland is a unique organ, in that only a rudimentary ductal tree is 
present at birth, with most of the development occurring postnatally (Richert et al. 
2000). 
During mouse embryogenesis, the mammary anlage starts developing at E10.5, when 
a thickening in the ventral skin gives rise to the milk line (Figure 1.7); by E11.5 the 
mammary epithelium and mesenchyme can be distinguished and the reciprocal 
interactions between these two tissues will form a primary sprout that branches into a 
small ductal system just before birth (reviewed in Robinson 2007). This rudimentary 
gland will keep growing in an isometric way with the rest of the body until puberty.  
Unlike these earlier stages of development, which are hormone-independent, the 
phases from puberty onwards strongly rely on the action of the endocrine system and 
oestrogen, progesterone, prolactin, cortisol and somatotropine have been identified as 




Figure 1.7 Embryonic development of the mouse mammary gland (from Robinson 2007). 
The mammary gland has an ectodermal origin and derives from a thickening in the ventral skin (the 
milk line). 
 
During puberty the glands develop highly motile and proliferating structures at the 
forefront of the ducts (Figure 1.8): these terminal end buds (TEB) guide the 
elongation of the ductal tree, which forms primary ducts by invading the surrounding 
stroma until it reaches the distal portion of the fat pad; simultaneously, secondary 
and tertiary side branches are formed by lateral bud sprouting (Hinck and Silberstein 
2005, Lu, Sternlicht et al. 2006).  
This whole process of branching morphogenesis depends on the mitogenic stimulus 
of the ovarian oestrogens and their paracrine mediator amphiregulin, which regulates 
the stromal-epithelial cross-talk (Sternlicht 2006). 
After puberty the female mice reach sexually maturity and are able to reproduce but, 
like other mammals, their fertility is limited to a specific phase of the reproductive 
cycle, which in rodents is called estrous cycle. 
Despite being much shorter than the human menstrual cycle (4 vs 28 days), the 
mouse estrous cycle is regulated by the same complex network of hormones 
belonging to the hypothalamus-pituitary-ovary axis (Figure 1.9): the gonadotropin-
releasing hormone (GnRH) secreted by the hypothalamus stimulates the anterior 
pituitary gland to produce follicle-stimulating hormone (FSH) and luteinizing 
hormone (LH), which in turn induce the ovarian follicle to synthesise oestrogen and 




Figure 1.8 Stages of mammary gland remodeling (from Khokha & Werb 2011). 
Murine mammary gland wholemounts showing the remodeling occurring in this organ from the 
embryonic (E18.5) to aged stage (20 month-old). 
 
 
Figure 1.9 Scheme of the female endocrine system. 
Different endocrine glands belonging to the hypothalamus-pituitary-ovary axis secrete mammotropic 
hormones (highlighted in red). 
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Figure 1.10 illustrates how the rodent proestrus, equivalent to the human follicular 
phase, is characterised by a rise in the serum levels of oestrogen, which then triggers 
the LH surge leading to ovulation: once the ovarian follicle burst, its egg is released 
in the fallopian tube ready to be fertilised, while the ruptured follicle develops into 
the corpus luteum; this structure is responsible for the progesterone peak of the 
diestrus/luteal phase which induces the decidualization of the uterine membrane in 
preparation for a potential pregnancy. If the egg is indeed fertilised, the progesterone 
secretion will be eventually taken over by the placenta; if not, the corpus luteum will 
degenerate, leading to a drop in progesterone levels and the reabsorption of the 
uterine lining (Silverthorn 2004). 
 
 
Figure 1.10 Hormone fluctuations during the reproductive cycle. 
The graphs represent the reproductive cycles of humans (A) and rodents (B) (adapted from 
http://pubs.niaaa.nih.gov/publications/arh26-4/274-281.htm). 
 
The cyclical thickening and regression of the endometrium, however, is not the only 
morphological change induced by the fluctuations in sex hormones levels: also the 
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mammary gland undergoes remodeling with each reproductive cycle, displaying a 
peak of additional side branching and alveolar bud development in the mouse 
diestrus (Figure 1.8), most likely in response to progesterone signaling (Fata, 
Chaudhary et al. 2001).   
The most extensive remodeling, however, occurs during pregnancy, when the high 
levels of progesterone and prolactin drive epithelial proliferation and differentiation 
into secretory milk-producing cells.  
In the first stages of pregnancy the epithelial compartment undergoes a 100-fold 
increase in cell number and an intensive side branching which is induced by the 
expression of WNT4; subsequently, the alveolar buds differentiate into individual 
alveoli and group together to form lobular units, a process called 
lobuloalveologenesis (Richert, Schwertfeger et al. 2000, Oakes, Hilton et al. 2006, 
Khokha and Werb 2011). 
With parturition, the drop in progesterone levels leads to the secretion of milk from 
the fully matured alveoli into the lumen; lactation continues as long as the suckling 
stimulus does and relies on the action of two hormones: prolactin, which maintains 
milk secretion from the luminal cells, and oxytocin, which acts on the myoepithelial 
cells inducing their contraction (Neville, McFadden et al. 2002). 
Upon weaning, the build-up of milk in the glands triggers involution; this process 
restores the simple pre-gestation ductal structure and consists of two phases: the first 
is potentially reversible, if the suckling stimulus resumes within 48h involution is 
halted and lactation starts again; during this phase many luminal cells undergo 
apoptosis but the overall architecture of the gland is not altered. The second phase is 
characterized by the irreversible remodeling of the mammary structure: cell death 
intensifies, the alveoli collapse and most of the epithelial cells are replaced by 
adipocytes (Lund, Romer et al. 1996, Watson 2006). While the extracellular matrix 
remodeling depends on the activity of specific matrix metalloproteinases (mainly 
MMP-2, MMP-3, MMP-9 and MMP-11) (Green and Lund 2005), multiple pathways 
contribute to the destruction of the secretory epithelium, including canonical 
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apoptosis, phagocytosis by macrophages and epithelial cell autophagy (reviewed by 
Watson 2006). 
At the end of involution the gland is back to a pre-gestation state and is ready for the 
new round of epithelial proliferation and differentiation that will start with the next 
pregnancy. 
Finally, with aging, the reproductive cycle stops and the gland undergoes an 
irreversible lobular involution which leads to gradual loss of the mammary 
epithelium and the formation of a dormant ductal tree (Figure 1.8) (reviewed in 
Radisky and Hartmann 2009, Khokha and Werb 2011). 
 
1.3.2 Breast cancer 
1.3.2.1 Epidemiology, risk factors and genetics 
Breast cancer is the most common malignancy in women as well as the main cause 
of cancer related deaths (Soerjomataram et al. 2012, Parkin et al. 2006).  
It has been estimated that in the European Union alone there are one million women 
living with breast cancer (Dixon 2009) and this reflects in an annual economic 
burden of € 15 billion, which makes the health-care costs associated with breast 
cancer the highest of all oncology-related health-care: even colorectal cancer, the 
tumour with the highest incidence across the EU, has lower costs (€13.1 billion), 
which can be explained by different treatment regimens (surgery vs radiation) and 
also by the prohibitive price of some breast cancer drugs (Luengo-Fernandez, Leal et 
al. 2013). 
In the United Kingdom, age-standardised incidence and mortality of breast cancer 
are among the highest worldwide (Figure 1.11), probably due to risk factors like 
smoking and diet: every year this malignancy kills more than 13 000 people and the 
incidence is particularly elevated for women in their fifties, bordering a rate of 2% 
(Dixon 2009, Murray, Richards et al. 2013). 
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It has long been established that ageing is a fundamental risk factor for tumorigenesis 
and breast cancer is no exception, since the incidence increases with age and doubles 
every 10 years; unlike other tumour types, however, the rate of increase slows down 
at the onset of menopause, an observation which fits with a potential role of 
oestrogen and progesterone in the development of breast cancer (Dixon 2009).  
Several epidemiology studies have unequivocally shown that a woman’s risk of 
developing breast cancer is closely related to her lifetime hormonal exposure: early 
menarche, late menopause, nulliparity and lack of breastfeeding are all factors that 
increase a woman's total number of menstrual cycles and have all been associated to 
higher risk of breast cancer (Dixon 2009). 
Further evidence is provided by the fact that reducing the oestrogen levels with a 
bilateral oophorectomy has a protective effect (Kauff and Barakat 2007), while 
hormone replacement therapies and oral contraceptives increase the relative risk of 
developing breast cancer (Dixon 2009). 
 
Figure 1.11 Age standardised world incidence and mortality rates of breast cancer. 
The graph shows the rates calculated per 100 000 women (adapted from Cancer Stats, Cancer 




Prolonged exposure to oestrogen and progesterone is therefore an established risk 
factor and it has been shown to contribute to breast tumorigenesis in different ways: 
firstly, these steroids are key mitogens for mammary cells, their binding to specific 
membrane receptors activates the transcription of proliferation genes and with each 
cell division there is a chance for DNA mutations to occur (Clemons and Goss 
2001); secondly, estradiol, the predominant type of oestrogen in fertile non-pregnant 
women, can be metabolized to quinone derivatives that directly damage DNA (Yue, 
Santen et al. 2003). Lastly, mammary stem cells (MaSCs), which are responsible for 
the epithelial expansion during puberty, diestrus and pregnancy (Shackleton, Vaillant 
et al. 2006), are highly responsive to steroid hormone signaling (Asselin-Labat, 
Vaillant et al. 2010, Joshi, Jackson et al. 2010) and have recently been implicated in 
the initiation of breast cancer (reviewed in Tiede and Kang 2011).  
Additional risk factors are related to lifestyle and include obesity (Pierobon and 
Frankenfeld 2013), smoking (Reynolds 2013), lack of physical activity (Kossman, 
Williams et al. 2011) and excessive alcohol intake (de Menezes, Bergmann et al. 
2013). 
Alongside with these hormonal and behavioural factors, a major role is also played 
by genetic predisposition, which is responsible for approximately 10% of all breast 
carcinomas (Dixon 2009).  
Several studies have now demonstrated that mutations in specific genes are strongly 
associated with breast cancer and these susceptibility genes can be divided according 
to the relative risk that they confer (Table 1.3): interestingly, almost all of them are 
involved in the maintenance of genomic stability and in DNA damage 
signaling/repair pathways (reviewed in Tan, Marchio et al. 2008).  
The most common mutations are found in the Breast Cancer Susceptibility Gene 1 
(BRCA1) and 2 (BRCA2), which account for nearly 16% of the hereditary breast 
cancer cases (Peto, Collins et al. 1999). 
BRCA1 was first identified in the King laboratory through genetic linkage analysis of 
families with early-onset breast cancer (Hall, Lee et al. 1990); the gene was later 
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cloned by researchers from the University of Utah and Myriad Genetics (Miki, 
Swensen et al. 1994), while a collaboration headed by the Institute of Cancer 
Research led to the localisation and cloning of BRCA2 (Wooster, Neuhausen et al. 
1994, Wooster, Bignell et al. 1995).  
 
Table 1.3 Susceptibility genes linked to hereditary breast cancer. 
Breast cancer risk Gene Reference 




























Miki et al. 1994 
Wooster et al. 1994 
Li et al. 1988 
 
Meijers-Heijboer et al. 2002 
Renwick et al. 2006 
Masciari et al. 2007 
Liaw et al. 1997 
Seal et al. 2006 
Tischkowitz et al. 2007 
 
Cox et al. 2007 
Easton et al. 2007, Hunter et al. 2007 
Easton et al. 2007 
Easton et al. 2007 
Easton et al. 2007 
 
Both BRCA genes encode for very large proteins which have an essential role in the 
repair of double-strand DNA breaks (Gudmundsdottir and Ashworth 2006); 
mutations in these genes can be quite heterogeneous and show very high penetrance: 
the carriers have an 80% life-time risk of developing breast cancer and 20-40% risk 
of ovarian cancer (Narod and Foulkes 2004). 
Susceptibility genes with moderate penetrance include the cell-cycle checkpoint 
kinases CHEK2 (Meijers-Heijboer, van den Ouweland et al. 2002) and ATM 
(Renwick, Thompson et al. 2006), the cell surface glycoprotein CDH1 (Masciari, 
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Larsson et al. 2007) and two Fanconi anaemia genes (Seal, Thompson et al. 2006, 
Tischkowitz, Xia et al. 2007); moreover, inherited mutations in TP53 and PTEN 
cause multiple cancer syndromes (Li–Fraumeni and Cowden respectively) that are 
associated with a high risk of familial breast cancer (Li, Fraumeni et al. 1988, Liaw, 
Marsh et al. 1997). 
Overall, the susceptibility genes listed so far can explain approximately 20% of the 
hereditary risk of this malignancy (Thompson and Easton 2004): despite the multiple 
attempts to find a third high-penetrance breast cancer gene, no ‘‘BRCA3’’ has been 
identified so far, most likely because no single gene is responsible for the familial 
breast cancer cases that are not associated with BRCA1 or BRCA2 mutations (Narod 
and Foulkes 2004).  
The remaining 80% of hereditary risk can probably be explained by common low-
penetrance alleles, which confer smaller increases in risk but have a much higher 
population frequency (Stratton and Rahman 2008). Genome-wide association studies 
have so far identified single-nucleotide polymorphisms in five such genes and many 
more are likely to be discovered in future studies (Cox, Dunning et al. 2007, Easton, 
Pooley et al. 2007, Hunter, Kraft et al. 2007).  
 
1.3.2.2 Classification criteria 
Breast cancer is a very heterogeneous disease that can be classified according to its 
histological features, receptor status and molecular signature. 
At the histological level, grade and type are the two main classification criteria: the 
grade reflects the aggressiveness of the tumour by measuring its degree of 
differentiation and proliferation rate, while the type depends on the tumour growth 
pattern (reviewed in Weigelt, Geyer et al. 2010).  
The main distinction lies between in situ and invasive breast carcinomas, but 
pathologists have identified as many as 18 different histological types (Figure 1.12); 
the most common, which account for up to 75% of cases, is the invasive ductal 
carcinoma not otherwise specified (IDC-NOS), also called invasive ductal carcinoma 
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of no special type (IDC-NST). The so-called “special types” are rarer and include 
invasive lobular, mucinous, ductal/lobular, tubular, papillary and medullary 
carcinomas (reviewed in Malhotra, Zhao et al. 2010, Weigelt, Geyer et al. 2010). 
From a clinical perspective, however, the most important classification is based on 
the receptor status of the tumour: the malignant cells may or may not express 
oestrogen, progesterone and human epidermal growth factor receptors (ERα, PR and 
HER2), which, once bound to their ligands, transduce a mitogenic signalling to the 
nucleus and activate cell proliferation (Langlands, Horgan et al. 2013). As discussed 
in more detail in chapter 1.3.2.3, the status of these receptors helps determine which 
treatment option is the most beneficial for the patient. 
 
 
Figure 1.12 Histological classification of breast cancer. 
 
In the past decade the field of breast cancer research was revolutionised by a series of 
microarray studies showing that gene expression profiling can classify breast 
carcinomas in different molecular subtypes (Perou, Sorlie et al. 2000, Sorlie, Perou et 
al. 2001, Sorlie, Tibshirani et al. 2003). Their work conclusively demonstrated that 
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breast cancer cannot be considered as a single disease and identified five molecular 
subtypes, with a sixth one being added more recently (Herschkowitz, Simin et al. 
2007, Prat, Parker et al. 2010). 
As shown in Figure 1.13, hierarchical clustering analysis revealed that the main 
dichotomy is between ER-positive and ER-negative tumours. The former are called 
luminal because they express genes that are usually found in normal luminal 
epithelial cells, like cytokeratins 8 and 18; these tumours can be further divided in 
luminal A and luminal B: the two groups seems to be characterised by different 
histological grade and proliferation rates, however this distinction remains 
controversial and some authors prefer considering the luminal tumours as a 
continuum (reviewed in Malhotra, Zhao et al. 2010, Weigelt, Geyer et al. 2010, 
Colombo, Milanezi et al. 2011). 
 
Figure 1.13 Molecular classification of breast cancer. 
 
The ER-negative branch originally included the HER2-overexpressing tumours, the 
poorly characterised normal breast-like cancers and the basal-like subtype; the latter 
shows a gene signature usually associated with normal basal/myoepithelial cells, 
with high levels of cytokeratins 5 and 17, caveolins 1 and 2, EGFR, CD44, P-
cadherin and nestin. Recently a fourth, claudin-low group has been identified: these 
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tumours have been described as being enriched for EMT markers and cancer stem 
cell-like features (reviewed in Colombo et al. 2011, Malhotra et al. 2010, Weigelt at 
al. 2010). 
 
1.3.2.3 Treatment options  
Breast cancer management is based on several histological and clinical factors, such 
as tumour stage, size and type, axillary status, age of the patient and presence of 
lymphovascular invasion or metastasis. 
The traditional approach used to rely exclusively on local treatment of the tumour, 
mainly through surgery (lumpectomy or mastectomy depending on the tumour size), 
followed by radiotherapy. The last two decades, however, have witnessed the 
introduction of systemic therapies, which can be administered before (neoadjuvant) 
or after (adjuvant) the local treatment: these therapies are thought to tackle potential 
micro-metastasis that would otherwise spread and have so far been proved very 
beneficial, leading to a 15% drop in mortality (Dixon 2009). 
Systemic treatments include chemotherapy, monoclonal antibodies and endocrine 
therapy, which are selected according to the receptor status of the tumour. ER+/PR+ 
patients are usually given ER modulators like tamoxifen or aromatase inhibitors, 
which prevent the conversion of androgens to oestrogens, while HER2 
overexpressing cancers are treated with trastuzumab, a humanised monoclonal 
antibody against the external domain of this receptor (reviewed in Tessari, Palmieri 
et al. 2013, Charehbili, Fontein et al. 2014).  
Until recently, chemotherapy was the only option available to treat triple negative 
tumours, which lack the expression of ER/PR/HER2 and mainly display basal-like 
features. Around 30% of triple negative breast cancers are associated with BRCA1/2 
mutations (Greenup, Buchanan et al. 2013) and this specific subgroup of tumours 
seems to respond well to PARP-inhibitors, as shown by several phase III clinical 
trials (Davar, Beumer et al. 2012).  
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This new class of drugs, first described by the Ashworth group (Farmer, McCabe et 
al. 2005), blocks the repair of DNA single-strand breaks, which become double-
strand breaks after replication: this type of lesions would usually be repaired by 
homologous recombination, but this pathway is defective in BRCA-mutated cells and 
therefore the tumour cells die due to mitotic catastrophe (reviewed in Dedes, 
Wilkerson et al. 2011, Polyak and Garber 2011). 
All in all, substantial progress has been made in the treatment of breast cancer, 
however, many questions are still unanswered, especially regarding the mechanisms 
through which cancer cells can develop drug resistance and the strategies that could 
be used to overcome this resistance. 
 
1.4 Current knowledge on the role of WT1 in the 
mammary gland and in breast cancer 
Very little is known on WT1 in the context of healthy mammary cells and so far only 
two papers have reported WT1 expression in the normal gland (Silberstein et al. 
1997, 2002). 
In these studies, immunohistochemistry on human specimens showed that all the 
myoepithelial cells stain heavily with WT1 antibodies, whereas the luminal cells 
display a more scattered staining and can be divided into two populations based on 
chromatin morphology and nuclear density. Cells characterised by diffuse chromatin 
and rounded nuclei, which the authors consider as potential stem cells, are mostly 
WT1 positive, while the more differentiated cells, with condensed chromatin and 
polygonal nuclei, can be either positive or negative for WT1 staining (Silberstein et 
al. 1997). 
At the current state of research, however, no functional or knockout studies have 
been published and the role of WT1 in the mammary gland remains unknown. 
Also WT1 function in breast cancer is still unclear, despite the fact that a 
considerable body of data has been accumulated in the last fifteen years.  
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Several groups have reported WT1 expression in this type of malignancy and the 
percentage of WT1-positive tumours varies from 23 to 87%, probably due to 
differences in the detection method, antibody specificity and histological subtype 
(Table 1.4).  
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Abbreviations: RT-PCR, Real-Time Polymerase Chain Reaction; IHC, Immunohistochemistry; WB, 
Western Blot; IDC, Invasive Ductal Carcinoma; ILC, Invasive Lobular Carcinoma 
 
In the first of these studies, Silberstein reported reduced WT1 staining in most breast 
cancer samples if compared to the normal gland and suggested that the loss of WT1 




The finding that the WT1 promoter is aberrantly methylated in breast cancer further 
supported this hypothesis (Huang, Laux et al. 1997, Laux, Curran et al. 1999, Cheng, 
Wu et al. 2001); moreover, the exogenous expression of WT1 in the MDA-MB-231 
breast cancer cell line was shown to suppress the clonal growth of these cells in soft 
agar assays and to inhibit tumour formation in nude mice (Zhang, Yu et al. 2003). 
Subsequently, WT1 was also found to halt the proliferation of neoplastigenic 
mammary epithelial cells both in vitro and in vivo (Wang & Wang 2008). 
According to all these observations, WT1 would behave as a tumour suppressor gene 
in breast cancer, however, there are as many findings suggesting that it may instead 
be an oncogene. 
Firstly, Loeb and colleagues analysed WT1 expression in normal and malignant 
mammary cells using RT-PCR: only one out of the 20 healthy samples seemed to 
express WT1, while the vast majority of tumours (27 out of 31) were WT1-positive 
(Loeb et al. 2001). 
Secondly, high WT1 expression is associated with poor long-term survival in breast 
cancer patients, indicating that the mRNA levels of WT1 can be used as a significant 
prognostic factor (Miyoshi et al. 2002); lastly, down-regulation of WT1 through  
antisense oligonucleotides has been shown to lead to growth inhibition in several 
breast cancer cell lines (Zapata-Benavides, Tuna et al. 2002). 
All these contradictory findings seem hard to reconcile, but they may be explained, at 
least in part, by the complexity of the WT1 protein: Burwell and colleagues have in 
fact reported that the ectopic expression of different WT1 isoforms has opposite 
effects on the mammary epithelial cell line H16N-2. 
In their study, the +Exon 5/+KTS variant displays oncogenic features such as 
induction of EMT and redistribution of CDH1 from the cell membrane to the 
cytoplasm; in contrast, overexpression of the –Exon 5/-KTS isoform decreases 
proliferation by causing a cell cycle arrest in G2 and up-regulating p21 (Burwell, 
McCarty et al. 2006).  
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Of particular importance is also the fact that the ratio between + and – KTS splice 
variants is different between breast cancer cell lines and the developing kidney, 
where WT1 acts as a tumour suppressor (Haber, Sohn et al. 1991, Caldon, Lee et al. 
2008): the ratio is of 5:1 and 14:1 respectively, which could indicate that the higher 
relative levels of the +KTS isoforms observed in breast cancer may push towards an 
oncogenic function. 
Additional evidence is however required to validate this hypothesis, as well as to 
unveil the exact role played by WT1 in both mammary gland development and breast 
cancer progression. 
 
1.5 Conclusion and aim of the project 
The Wilms' Tumour Suppressor gene 1, WT1, encodes for a complex protein which 
plays a crucial role in the regulation of the epithelial-mesenchymal balance during 
development, whereas in the adult it is involved in the maintenance of tissue 
homeostasis. 
WT1 expression has been reported in both healthy mammary glands and breast 
cancer samples, however its function in this context is not well understood and the 
evidence gathered so far is extremely contradictory. 
This project aims to clarify the role of WT1 in normal and malignant mammary cells 
by answering the following questions: 
• Which specific cell types express WT1 in the mammary gland? 
• Does WT1 expression change throughout the different phases of mammary gland 
remodeling?  
• Is WT1 an essential gene for the post-natal development of the mammary gland?  
• Is WT1 expression associated with a specific molecular subtype of breast cancer? 
• How does WT1 loss affect breast cancer cells both in vivo and in vitro? 
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• Is WT1 loss associated with any phenotypic change linked to a disrupted epithelial-
mesenchymal balance? 
 
The original research topic chosen for this PhD was the role of WT1 in breast cancer. 
However, the results section will start by describing the experiments performed to 
study WT1 in the normal gland. Since this part was only added during the last year of 
the PhD, this work is still at an early stage, but will provide a clear picture of WT1 in 
the healthy mammary tissue and serve as an introduction to and framework for the 



















Considerable evidence supports the existence of an epithelial hierarchy within the 
mammary gland: mammary stem cells (MaSCs), which are usually found in the basal 
layer, have the ability to self-renew and to differentiate into committed progenitor 
cells, which ultimately give rise to the mature myoepithelial and luminal cells 
(Figure 2.1) (reviewed in Prat and Perou 2009, Visvader 2009). 
The identification of cell-surface molecular markers, which are specific for the 
different populations, was a major breakthrough in mammary gland biology and, 
similarly to what happened with the study of haematopoietic lineages, it is now 
possible to isolate the different cell types through fluorescence-activated cell sorting 
(FACS) (reviewed in Regan and Smalley 2007).  
As mentioned in chapter 1.4, very little is known on WT1 in the context of healthy 
mammary cells and there are conflicting reports comparing its expression in normal 
and neoplastic mammary tissue: the breast cancer samples are described to be 
overexpressing WT1 (Loeb et al. 2001), but also to be characterised by reduced 
staining (Silberstein et al. 1997). 
Immunohistochemistry performed on human specimens has showed that all the 
myoepithelial cells stain heavily for WT1, while the luminal compartment displays a 
more scattered staining: based on the position and morphology of the stained cells, 
the authors suggest that the WT1-positive luminal cells may be potential stem cells 
(Silberstein et al. 1997). 
However, since uncertainty remains over the exact lineage of the WT1-positive cells, 
it would be interesting to assess Wt1 expression levels in the different populations 





Figure 2.1 Model of the differentiation hierarchy in the mammary epithelium. 
Mammary stem cells give rise to bi-potent progenitors, which will then commit to the myoepithelial 
or luminal lineage. 
 
Moreover, several established WT1 target genes are known to play important roles in 
the mammary gland: Areg is an essential paracrine mediator of the mitogenic 
stimulus triggered by oestrogen during puberty (Ciarloni, Mallepell et al. 2007), 
Wnt4 mediates progesterone signalling and is necessary for the side-branching which 
occurs at the early stages of pregnancy (Brisken, Heineman et al. 2000), Snai1 and 
Snai2 are also involved in the epithelial branching morphogenesis (Kouros-Mehr and 
Werb 2006, Lee, Gjorevski et al. 2011). 
All in all, it is not clear if WT1 has any role in the mammary gland, but at the current 






The aims of the experiments described in this chapter were: 
• to identify which specific mammary gland cell types express Wt1   
• to determine if Wt1 expression changes throughout the different phases of 
mammary gland remodeling 
• to develop mammary-specific Wt1 conditional knockout and knockin models 
• to analyse the consequences of Wt1 loss and overexpression in these models, 
paying particular attention to the mammary branching morphogenesis which occurs 
during pregnancy. 
 
2.3 WT1 expression in the mammary gland 
In order to determine the spatial and temporal distribution of WT1 in the healthy 
gland, human and murine samples were examined through different techniques. 
Firstly, RT-PCR of FACS-purified populations and immunohistochemistry were 
performed on the glands of 10-week-old virgin female FVB mice; secondly, an in 
silico analysis was carried out to determine if Wt1 expression levels change 
throughout the different phases of mammary remodeling.  
Lastly, RT-PCR was performed on samples obtained from breast cancer patients and 
healthy donors, to verify if WT1 expression is higher in the healthy or the neoplastic 
mammary tissue. 
Unfortunately, no reliable antibody for Western blot was available during my PhD, 






2.3.1 Wt1 expression in the murine gland 
In order to identify which specific cell types express Wt1, RT-PCR was performed 
on different mammary gland populations isolated through FACS. 
The isolation was carried out in the Smalley laboratory (European Cancer Stem Cell 
Research Institute, Cardiff), while the retrotranscription was performed by our 
collaborator Dr. Sproul (MRC HGU, The University of Edinburgh). 
In brief, single cells were prepared from the fourth mammary fat pads of 10-week-
old virgin female FVB mice, incubated with the antibodies for the cell-surface 
markers and sorted by flow cytometry according to the following molecular profiles 
(Regan, Sourisseau et al. 2013): 
• Mammary Stem Cells = CD45- CD24+/Low Sca-1- CD49fHigh c-Kit- 
• Myoepithelial = CD45- CD24+/Low Sca-1- CD49fLow c-Kit- 
• Luminal ER- progenitor = CD45- CD24+/High Sca-1- c-Kit+ 
• Luminal ER+ differentiated = CD45- CD24+/High Sca-1+ c-Kit- 
RT-PCR was performed using primers that target the zinc-finger domain and can 
therefore amplify all the known isoforms: as shown in Figure 2.2, Wt1 is expressed 
in the MaSCs and, at lower levels, in the myoepithelial compartment, but cannot be 
detected in the luminal cells, independently of their differentiation status.  
The myopithelial expression of WT1 was also confirmed through 
immunohistochemistry using the C19 polyclonal antibody from Santa Cruz, which 
recognises the last 19 residues of the fourth Zinc finger. 
Consistently with what observed for the human gland (Silberstein et al. 1997), the 
myoepithelial cells stain heavily for WT1, while the luminal compartment is 
characterised by fainter and less frequent signal; intense staining can also be 




Since the MaSCs are usually found in the basal layer, they could not be distinguished 
from the myoepithelial cells and a WT1/CD49f double staining should be performed 
to identify the WT1-positive stem cells. 
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Figure 2.2 Quantitative RT-PCR for Wt1 mRNA expression in different mammary cell 
populations. 
Quantitative RT-PCR for Wt1 mRNA expression using primers binding to the transcripts of exon 7 
and 8; the different mammary cell populations of 10-week-old virgin FVB mice were isolated through 
FACS by the Smalley lab. Data points represent the relative expression of Wt1, error bars represent 






Figure 2.3 WT1 immunohistochemistry of mammary glands in virgin FVB mice. 
The mammary glands of 10-week-old virgin female FVB mice were stained using the C19 polyclonal 
antibody from Santa Cruz, which recognises the last 19 residues of the fourth Zinc finger. Positive 
staining can be observed in both the myoepithelial and luminal layers (black arrows and asterisks 
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2.3.2 Bioinformatics analysis of Wt1 expression in the mouse 
mammary gland 
The expression profile of the mammary gland changes extensively throughout life 
and the genes required for a specific stage usually undergo the most dramatic 
modulation (Stute, Sielker et al. 2012).  
In order to determine whether Wt1 expression levels change throughout the different 
phases of mammary gland remodeling, I analysed the publicly available microarray 
data published by the Watson group (Clarkson, Wayland et al. 2004). 
Their work investigated the transcriptional changes which occur during the mouse 
pregnancy cycle using an Affymetrix MGU74ver2a chip and included a total of 12 
time-points (8-week-old virgin; day 5, 10 and 15 of gestation; day 0, 5 and 10 of 
lactation; hour 12, 24, 48, 72 and 96 of involution). 
The expression profile based on the microarray data shows that Wt1 mRNA in the 
mammary gland peaks at the beginning of involution, while slightly lower levels can 
be observed at gestation day 5 and lactation day 5 (Figure 2.4).  
However, the graph becomes more informative if the expression profile of Wt1 is 
plotted next to some of its potential targets: from this comparison, it becomes evident 
that the Wt1 RNA levels are constant throughout the different phases, unlike Areg 
and Snai2 which are drastically overexpressed at 8 weeks and late gestation 





Figure 2.4 Expression profiles relative to the different phases of mammary gland remodelling. 
The graphs show the analysis of Wt1 expression (top) as well as some of its potential target genes 



































































2.3.3 Comparing WT1 expression in healthy and neoplastic 
mammary tissues 
An RNA sample of human adult mammary gland was purchased from AMSBIO and 
retrotranscribed; the specimen consisted of a pool from 5 healthy donors of different 
age (36, 57, 76, 78 and 83 years old). 
In parallel, 50 fresh frozen breast cancer samples were obtained through a 
collaboration with Dr. Katz (see chapter 3 for their molecular classification) and 
compared to the normal gland through RT-PCR. 
As shown in Figure 2.5, WT1 mRNA was more abundant in the healthy tissue, which 
had higher expression levels than any of the tumour samples (Figure 2.5). 
This finding is in line with what observed by Silberstein (Silberstein et al. 1997), 
however, it must be noted that the pool of healthy donors is clearly skewed towards 
post-menopause subjects; since the expression profile of the mammary gland 
changes dramatically throughout life stages (Stute et al. 2012), this imbalance may 
represent a confounding factor.  
In order to verify the biological relevance of this result, WT1 expression should be 
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Figure 2.5 Quantitative RT-PCR for WT1 mRNA expression. 
The graph compares the WT1 levels in the normal mammary gland (hNG) and breast cancer samples 
(hBC). Data points represent the relative expression of WT1, error bars represent the standard 




















2.4 Generation of a mammary-specific Wt1 
conditional knockout 
In order to characterise WT1 role in the mammary gland, we chose to study the 
effects of its loss in a mammary-specific conditional knockout model. 
Our group had already generated a Wt1 conditional mouse, in which Exon 1 is 
flanked by LoxP sites and can therefore be deleted through Cre-mediated 
recombination (Martinez-Estrada et al. 2010).  
In this study, the conditional Wt1 knockout mice were separately crossed with two 
different Cre lines, the MMTV-Cre and a C3(1)-driven doxycycline-inducible Cre, 
creating the MMTV-Co and C3-Co lines respectively.  
Given the increasing number of reports on the off-target and toxic effects of Cre 
recombinase (Schmidt, Taylor et al. 2000, Loonstra, Vooijs et al. 2001, Semprini, 
Troup et al. 2007, Huh, Mysorekar et al. 2010), we also included a Cre control 
group; as a whole, three groups of experimental animals were generated for each Cre 
line and they will be addressed with the following terminology: 
CONTROL – Cre-negative Wt1co/co  
KNOCKOUT – Cre-positive Wt1co/co  
Cre CONTROL – Cre-positive Wt1+/+  
 
2.4.1 MMTV-Cre line 
In this line (a kind gift from Dr. Brunton, CRUK, The University of Edinburgh), Cre 
recombinase is under the transcriptional control of the mouse mammary tumour virus 
long terminal repeat (MMTV-LTR), which is predominantly active in secretory cell 
types (Wagner, McAllister et al. 2001). 
The MMTV-Cre line is extensively used in mammary gland biology because high 
levels of recombination are observed in both epithelial and myoepithelial cells 
throughout all the different stages from puberty to involution (Wagner et al. 2001).  
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2.4.1.1 Characterisation of the MMTV-driven Wt1 knockout  
Control, knockout and Cre control animals were culled at different stages of the 
pregnancy cycle (virgin, day 8.5 and 16.5 of gestation, hour 24 and 48 of involution) 
and the mammary tissue was harvested as follows: the fourth gland was fixed in 4% 
PFA, the fifth and tenth were preserved in RNAlater, the ninth was fixed in Carnoys 
solution for wholemount analysis. 
Unfortunately, difficulties were encountered during RNA extraction, most likely due 
to the limited compatibility of RNAlater with fatty tissues; additional samples have 
been collected and snap frozen, but not yet processed.  
Since no good quality RNA was available for RT-PCR, the efficiency of the Wt1 
knockout could not be verified; nonetheless, we proceeded with the analysis of the 
samples, which showed no significant differences in the gland morphology of virgin 
mice (data not shown).  
The animals of all three experimental groups would develop, breed and nurse their 
pups normally, however, during pregnancy, the putative knockout glands showed a 
significant increase in the number of ductular branches if compared to both control 
and Cre control samples.  
The branching analysis was performed by Dr. Del Pozo and Dr. Morrison (The Royal 
School of Veterinary Studies, The University of Edinburgh) and revealed that the 
increase is limited to the primary branches at GD 8.5 and the secondary branches at 
GD 15.5 (Figure 2.6). 
As mentioned above, all the females seemed able to lactate normally, and this 
observation was confirmed by the weight of the pups: as shown in Figure 2.7, the 
pups of three different litters per experimental group were weighed when three-
week-old (right before weaning) and no statistically significant difference was 
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Figure 2.6 Branching analysis of the MMTV-driven Wt1 knockout mammary glands. 
Representative images of mammary gland wholemounts of MMTV-Cre and MMTV-Co mice at GD 
8.5 and 16.5 (A), quantification and statistical analysis of the primary branches (B), quantification and 
statistical analysis of the secondary branches (C) (* p<0.05). 
 
 






















Figure 2.7 Average pup weight in the litters of MMTV-Cre and MMTV-Co mice. 
The pups of three different litters per experimental group were weighed when three-week-old and no 





The analysis of the samples collected at the involution stage is still ongoing and has 
mainly been focused on the size of the glands at 24 and 48 hours after lactation is 
halted.  
As mentioned earlier, involution is characterised by extracellular matrix remodeling 
and extensive apoptosis of the secretory epithelial cells, which bring the mammary 
tissue back to its pre-gestation state: if Wt1 loss affects involution, either by causing 
an acceleration or a delay of the whole process, the size of the knockout glands 
would differ significantly from the controls.  
However, a very preliminary analysis has revealed that the size of the gland is 
characterised by high inter-individual variability, which complicates the comparison 
between the different experimental groups (data not shown). 
 
2.4.2 C3(1)-Cre line 
This inducible Cre (a kind gift from Dr. Els Robanus, LUMC, Leiden, The 
Netherlands) allows temporal and cell-type specific control of DNA recombination 
by combining the advantages of tetracycline-mediated transcriptional activation and 
the Cre-LoxP system. 
Tetracycline-controlled gene expression is a tool that relies on the antibiotic 
tetracycline (or its semisynthetic derivative doxycyline) to selectively activate or 
inhibit the transcription of a specific gene (Gossen and Bujard 1992).  
In a Tet-On system like the one used in this project, Cre expression is activated by 
the rtTA protein, which can successfully bind to the rtTA-responsive promoter 
“TetO” only in the presence of doxycycline (Figure 2.8). 
The C3(1)-Cre line, originally designed by Dr. Hohenstein, is based on a construct 
which integrates both the rtTA and “TetO”-Cre cassettes in a single transgene 
(Utomo, Nikitin et al. 1999) and was obtained by cloning the C3(1) promoter in the 





Figure 2.8 Scheme of the C3(1)-Cre transgene. 
The C3(1)-Cre line is based on a construct which integrates both the rtTA and “TetO”-Cre cassettes in 
a single transgene regulated by the C3(1) promoter. 
 
2.4.2.1 C3(1)-Cre reporter study 
In this line, the expression of Cre recombinase is under the control of the C3(1) 
promoter, which is active in the epithelium of both prostate and mammary glands 
(Maroulakou, Anver et al. 1994). 
In order to fully characterise this line, C3(1)-Cre animals were crossed with a 
reporter strain where a LoxP-flanked stop sequence and the EYFP cDNA had been 
targeted into the Rosa26 locus (Rosa26RYFP/YFP) (Srinivas, Watanabe et al. 2001); 
upon Cre-mediated DNA recombination, the stop sequence is excised and EYFP 
becomes permanently expressed. 
The experimental animals were dosed with doxycycline for 5 consecutive weeks 
(from the third to the eight after birth) and culled at ten weeks of age: once harvested, 
the mammary tissue was frozen for cryosectioning and then analysed for EYFP 
expression. 
The fluorescent signal appears to be localised to the ductal epithelium and can be 
detected in approximately half of the luminal cells, while no significant expression is 




Figure 2.9 C3(1)-Cre-mediated EYFP expression in the mammary gland. 
C3(1)-Cre animals crossed with a EYFP reporter strain were dosed with doxycycline from the third to 
the eight week after birth and culled at ten weeks of age: the representative images of mammary tissue 
show that the fluorescent signal is localised to the ductal epithelium (white arrows) and can be 
detected in approximately half of the luminal cells (Scale bars represent 10µm). 
 
2.4.2.2 Characterisation of the C3(1)-driven Wt1 knockout  
The experimental animals were dosed with doxycycline for 5 consecutive weeks 
(from the third to the eight after birth) and either mated or culled at ten weeks of age; 
the pregnant mice were sacrificed at gestation day 8.5 and harvested for tissue as 
previously described.  
Good quality RNA could be extracted from snap-frozen samples and used to assess 
the efficiency of the knockout through RT-PCR: as shown in Figure 2.10, up to 80% 
reduction of Wt1 expression was achieved in the knockout glands. 
Similarly to what observed for the MMTV-driven knockout, the loss of Wt1 did not 
affect gland morphology in virgin mice (data not shown), but led to increased 
ductular branching during pregnancy. 
The knockout glands show higher numbers of primary and secondary branches if 
compared to the control samples (the Cre control wholemounts have not yet been 
analysed); the increase, however, is statistically significant only for the secondary 
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Figure 2.10 Quantitative RT-PCR for Wt1 mRNA expression in the mammary glands of C3(1)-
Cre and C3-Co mice. 
Quantitative RT-PCR for Wt1 mRNA expression using primers binding to the transcripts of exon 7 
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Figure 2.11 Branching analysis of the C3(1)-driven Wt1 knockout mammary glands at GD 8.5. 
Representative images of mammary gland wholemounts of C3(1)-Cre and C3(1)-Co mice at GD 8.5 










2.5 Multiple gestations and ectopic Wt1 expression  
The results obtained so far indicate that Wt1 may be involved in the side branching 
which occurs during pregnancy and two additional experiments have been performed 
to further study this potential role. 
Firstly, MMTV-Co mice were allowed to complete one full pregnancy cycle (from 
fertilisation to involution) and were culled at gestation day 8.5 or 15.5 during their 
second pregnancy.  
The “multiple pregnancies” strategy is often used in mammary gland biology 
because it can either rescue or exacerbate a knockout phenotype, depending on 
whether compensative mechanisms can be activated (Liu, Gallego et al. 1998, 
Wagner, Krempler et al. 2004, Atabai, Fernandez et al. 2005, Choi, Chakrabarti et al. 
2009). 
Secondly, C3(1)-Cre mice were crossed with a Wt1 knockin model where the -KTS 
isoforms are ectopically overexpressed (Bandiera, Vidal et al. 2013).  
This line was generated by targeting the Wt1-KTS cDNA to the Rosa26 locus (Figure 
2.12): upon Cre-mediated excision of the STOP cassette, the Wt1-KTS cDNA is 
linked to the first exon of the Rosa26 locus and transcripted in a chimeric mRNA, 
but, since the endogenous Rosa26 sequences are not translated into protein, only the 
WT1-KTS peptide is synthesised (Hohenstein, Slight et al. 2008).  
 
 
Figure 2.12 Scheme of the Wt1-KTS knockin construct targeted to the Rosa26 locus. 
In the presence of Cre recombinase, the Wt1-KTS cDNA targeted to the Rosa26 locus is linked to the 




C3-Rosa26:Wt1-KTS mice were continuously kept on doxycycline to activate Wt1 
overexpression, mated and culled and different stages of gestation. 
At the time of writing, the samples obtained from both experiments had been 






















The experiments described in this chapter identify the stem cell and myoepithelial 
compartments as the main sites of WT1 expression in the mammary gland, providing 
the first molecular evidence for what had been hypothesised almost two decades ago 
(Silberstein et al. 1997).  
The finding that WT1 is expressed in MaSCs is intriguing, especially since this gene 
is required for the differentiation of renal and hematopoietic progenitor cells 
(Kreidberg et al. 1993, Chau et al. 2011). Gene expressed in MaSCs are ususally 
important regulators of mammary cell fate and their knockout affects the expansion 
and differentiation of the stem cell compartment (Chakrabarti, Wei et al. 2012, Chen, 
Li et al. 2014); to determine if this is the case for WT1, FACS analysis should be 
performed to compare the abundance of the different mammary populations in 
knockout and control glands. 
Based on the immunohistochemistry staining, WT1 seems to be expressed also in 
some cells of the luminal layer, however, the RT-PCR performed on the luminal ER- 
progenitor and ER+ differentiated populations gave negative results. This 
discrepancy may be explained by the presence of a third luminal cell type, the ER+ 
progenitor cells, which are characterised by a Sca-1+ c-Kit+ phenotype (Regan, 
Kendrick et al. 2012); in order to verify if these are indeed the WT1-positive luminal 
cells observed through immunohistochemistry, RT-PCR should be performed on a 
FACS-isolated sample of this population. 
Despite being at an early stage, the characterisation of the mammary Wt1 knockouts 
has obtained encouraging results and revealed a branching phenotype in both models 
analysed (even though Wt1 expression levels in the MMTV-Co line remain to be 
assessed). 
At both GD 8.5 and 15.5, the Wt1 knockout glands display a higher number of 
branches and the difference is statistically significant despite the small population 
size analysed so far (n≤3 for each experimental group), which would suggest that 
higher significance could be achieved with the analysis of the outstanding samples. 
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The potential involvement of Wt1 in the regulation of mammary branching may be 
related to its role as a regulator of the epithelial-mesenchymal balance: partial EMT 
has been detected at the tips of growing branches and has been hypothesised to be 
necessary for their invasion into the extracellular matrix (Micalizzi, Farabaugh et al. 
2010, Nistico, Bissell et al. 2012). 
In this scenario, the loss of Wt1 may push the mammary cells towards a more 
mesenchymal phenotype, facilitating the EMT process at the tips of the branches and 
therefore causing increased branching. 
In terms of potential mechanisms through which Wt1 may act, several hypotheses 
can be made: as previously mentioned, important branching regulators such as Wnt4 
and Snai1 are Wt1 targets at least in the heart and kidneys (Essafi et al. 2011, 
Martinez-Estrada et al. 2009) and ChIP experiments could verify if they are in the 
mammary tissue as well.  
Moreover, the RNA-sequencing described in chapter 4.4.1 has revealed that, upon 
WT1 knockdown, the human breast cancer line MDA-MB-157 shows significant 
upregulation of the protein disulfide isomerase AGR2, suggesting that this gene may 
be negatively regulated by WT1. Since the in vivo overexpression of Agr2 produces a 
branching phenotype similar to the one observed in the Wt1 knockout (Verma, 
Salmans et al. 2012), Agr2 may lie downstream of Wt1 in a branching regulatory 
pathway. 
All in all the experiments described in this chapter identified for the first time a 
potential role for Wt1 in the mammary gland. Further work is however required: 
firstly, lineage tracing experiments should be performed to determine which cell 
lineage originates from the WT1-expressing MaSCs; secondly, the Wt1 knockout 
glands need to be analysed for the expression of epithelial and mesenchymal markers 
to assess if the partial EMT occurring at the branching sites is somewhat increased.  
Lastly, ChIP should be performed in order to identify the exact mechanism through 




Chapter 3: WT1 expression in breast cancer 
 
3.1 Introduction 
Several groups have described WT1 expression in breast cancer (Silberstein et al. 
1997, Cheng et al. 2001, Loeb et al. 2001, Miyoshi et al. 2002a, Silberstein et al. 
2002, Gillmore et al. 2006, Nakatsuka et al. 2006), however, their data on the 
frequency of WT1-positive tumours are not in agreement. 
As mentioned in chapter 1, the percentage of WT1-expressing tumours varies from 
23% (Cheng et al. 2001) to 87% (Loeb et al. 2001), most likely as a result of 
differences in detection techniques and antibody specificity: four out of the seven 
publications relied on RT-PCR and used primers targeting the Zinc finger region, 
that would therefore detect all the different WT1 isoforms (Cheng et al. 2001, 
Miyoshi et al. 2002a, Gillmore et al. 2006); only one group performed Western Blot 
(Loeb et al. 2001), while the remaining three resorted to IHC (Silberstein et al. 1997, 
Silberstein et al. 2002, Nakatsuka et al. 2006).  
Interestingly, one study performed IHC using two different antibodies (the rabbit 
polyclonal C19 from Santa Cruz and the mouse monoclonal 6F-H2 from Dako) 
showing that the sensitivity differs greatly between the two, which respectively 
stained 80% and 56.5% of the breast cancer samples (Nakatsuka et al. 2006). Since 
the C19 recognises the last 19 residues of the forth Zinc finger, while the 6F-H2 is 
targeted against the N-terminus, the authors speculate that the difference in immuno-
reactivity may be caused by the presence of WT1 isoforms with an altered/truncated 
N-terminus that would not be detected by the 6F-H2 antibody (Nakatsuka et al. 
2006). 
Such WT1 isoforms have indeed been described and derive from a maternally-
imprinted alternative exon 1 (exon 1A, Dallosso et al. 2004), a cryptic promoter in 
intron 5 (Dechsukhum et al. 2000) and two alternative translation start sites 
(Bruening et al. 1996, Scharnhorst et al. 1999), however, very little is known about 
these variants, especially in relation to breast cancer: most of the literature is focused 
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on the four major WT1 configurations described in Chapter 1 (+/- KTS and +/- Exon 
5), as does the only in vitro study that assessed the expression of different WT1 
isoforms in a panel of breast cancer cell lines (Caldon et al. 2008). 
Besides the differences in detection methods and antibody specificity, it should be 
pointed out that only three of the above-mentioned publications specified the 
histological subtype of the tumours they analysed (mainly IDC, Cheng et al. 2001, 
Miyoshi et al. 2002a, Nakatsuka et al. 2006), while none reported the molecular 
subtype: given the extreme heterogeneity of breast cancer, this may represent an 
additional confounding factor and it is possible that different subtypes of the disease 
express different levels of WT1. 
In this regard, the only study that examined the relationship between WT1 expression 
and molecular subgroups claims that WT1 correlates with ER-negative, basal-like 
and HER2 breast cancers (Qi, Zhang et al. 2012); however, the analysis was 
conducted on just one microarray dataset and requires further validation. 
In particular, a possible link between WT1 and the ER/PR status of the tumour 
should be thoroughly investigated; several papers have in fact implicated WT1 in 
steroid hormone pathways: both estradiol and progesterone are known regulators of 
WT1 expression in breast cancer cells (Zapata-Benavides et al. 2002, Caldon et al. 
2008), WT1 co-immunoprecipitates with ERα in MCF7 cells (Reizner, Maor et al. 
2005) and conflicting reports have shown that it can either activate or repress ERα 
(Han, Yang et al. 2008, Kang, Wang et al. 2011). 
Overall, considering the discrepancies found in the literature, it seems worthwhile 
performing a more detailed and comprehensive analysis of WT1 expression in breast 








The aims of the experiments described in this chapter were: 
• to characterise WT1 expression in breast cancer through different approaches (in 
vitro, in vivo and in silico) 
• to verify whether WT1 is indeed associated with any specific histological or 
molecular subtype of breast cancer 
• to determine if two of the least studied isoform of WT1 (“exon 1A” and “intron 5”) 
are expressed in this malignancy. 
 
 
3.2 Expression of WT1 in a panel of breast cancer cell 
lines  
In the last decades, breast cancer cell lines have been extensively used to investigate 
the biological mechanisms underlying this disease as well as to test the efficacy of 
potential drugs. Despite its many limitations, this in vitro system has been shown to 
mirror several aspects of the primary tumours, including their genomic and 
molecular heterogeneity (Neve, Chin et al. 2006). 
For this study, a panel of thirteen different breast cancer cell lines was chosen to 
represent the variability of the disease, while the pancreatic cancer cell line Panc1, 
known to express high levels of WT1 (Takahara, Koido et al. 2011), was used as a 
positive control.  
Quantitative RT-PCR was first performed using primers targeting exon 7/8 of WT1, 
so that the assay would amplify all the known isoforms (Figure 3.1A): seven cell 
lines were found to express detectable levels of WT1, with the highest expression 
occurring in the basal triple-negative lines HBL100 and MDA-MB-157 and in the 
luminal ER+ line ZR75. 
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Additional assays were designed to specifically amplify exon 1A (Figure 3.1B) and 
the portion of intron 5 which is transcribed in the truncated variant described by 
Dechsukhum (Dechsukhum et al. 2000) (Figure 3.1C). Only the basal triple–negative 
lines BT20 and MDA-MB-231 expressed detectable levels of the intron 5 isoform, 
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Figure 3.1 Quantitative RT-PCR for WT1 mRNA expression in different breast cancer cell lines. 
Data points represent the relative expression of the respective isoform (A, exon 7/8; B, exon 1A; C, 
intron 5), error bars represent the standard deviation of three biological replicates. The schematic in D 













These results are in agreement with previous experiments carried out during my 
MSc, which detected the truncated isoform in SW480, Panc1 and MDA-MB-231 
cells; moreover, neither exon 1 nor exon 1A were found in MDA-MB-231 cells, 
suggesting that intron 5 may be the only WT1 isoform present in this breast cancer 
line (Artibani 2010). 
A comparative analysis was then carried out on all the studies that assessed WT1 
expression in the same cell lines used in this project (Table 3.1). 
Similarly to what observed for the primary tumours, conflicting results were reported 
and the discrepancies could once again be due to differences in detection techniques 
(RT-PCR, WB, NB) and antibody specificity (C19 vs 6F-H2). In this case, however, 
we should also consider the typical pitfalls of in vitro work: the cell lines from 
different laboratories may in fact have been maintained in different culture 
conditions, contaminated with other cell lines, or they may simply have accumulated 
genomic instability due to long-term-culture, all of which could affect gene 
expression and therefore WT1 mRNA/protein levels (Osborne, Hobbs et al. 1987, 
van Staveren, Solis et al. 2009). 
In this context, my RT-PCR data fit quite well with the most recent and complete 
publication (Caldon et al. 2008), with the only exception of BT20 and MDA-MB-
231 cells, which have been found WT1-positive in this study but negative by Caldon.  
Unfortunately, doubts remain over the WT1 protein levels expressed by the breast 
cancer cells: several Western blots performed during my PhD gave negative results 
(data not shown), suggesting that WT1 expression in these lines is very low. 
However, the fact that extremely faint bands were observed for the M15 positive 
control (data not shown) and that other groups have obtained positive results 
(Zapata-Benavides et al. 2002, Han et al. 2004, Tuna et al. 2005, Reizner et al. 2005, 
Caldon et al. 2008), would indicate an antibody problem and additional antibodies 




Table 3.1 Comparison of in vitro WT1 expression with previous reports. 













































































































































































Abbreviations and symbols: RT-PCR, Real-Time Polymerase Chain Reaction; NB, Northern Blot; 
WB, Western Blot; -, data not available; √, positive for WT1 expression; X, negative for WT1 




3.3 Expression of WT1 in human breast cancer 
samples  
For the in vivo part of the study, two different sets of human breast cancer samples 
were examined for WT1 expression: 
• the first set was obtained through a collaboration with Dr. Katz and consisted of 50 
fresh frozen breast cancer samples of unknown molecular and histological subtype; 
to better characterise these tumours, their ER, PR and HER2 status was assessed 
through both IHC and RT-PCR 
• the second set was obtained from the Tissue Bank in collaboration with Dr. 
McGregor and Dr. Kendall; it consisted of 60 ductal carcinomas NST of known 
grade, ER and HER2 status. 
 
3.3.1 First set of tumour samples 
In clinical practice, strict guidelines regulate the IHC protocol which is used to assess 
the ER/PR/HER2 status of breast carcinomas (Hammond, Hayes et al. 2010, 
Hammond, Hayes et al. 2011). Since some of these criteria could not be met (eg. the 
samples should be formalin-fixed and paraffin-embedded), validated RT-PCR assays 
were performed to complement and verify the IHC results (de Cremoux, Tran-
Perennou et al. 2002, de Cremoux, Tran-Perennou et al. 2003). 
For the RT-PCR experiments, the threshold for positivity was set at a relative 
expression of 0.05, while the stainings were examined under the guidance of Dr. 
Thomas (Figure 3.2): ER and PR were scored using the Allred method, which 
combines the percentage of positive cells and the intensity of the staining (Harvey, 
Clark et al. 1999, Gown 2008), HER2 overexpression was determined according to 
the HercepTest guidelines (http:// 
www.dako.com/38602_19feb10_herceptest_scoring_guidelines- breast_ihc.pdf). 
As shown in Figure 3.2A, the histological quality of the samples was extremely poor; 
nonetheless, both ER and PR stainings were informative and correlated with the RT-
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Figure 3.2 Testing the ER, PR and HER2 status of the first set of tumours. 
A) IHC of representative samples.  B) Quantitative RT-PCR for ER mRNA expression. C) 
Quantitative RT-PCR for PR mRNA expression. D) Quantitative RT-PCR for HER2 mRNA 
expression. Data points represent the relative expression of the target gene, error bars represent the 












Unfortunately, difficulties were encountered with the HER2 antibody, which failed 
to show the characteristic membrane staining pattern (Dr. Thomas, personal 
communication). In the clinical practice, the specimens with equivocal IHC results 
are usually analysed with FISH (Fluorescence In Situ Hybridisation) to detect gene 
amplification (Gown 2008); in this case, however, the poor quality of the samples 
precluded this option and the HER2 status was determined through RT-PCR (Figure 
3.2D).  
All the breast cancer samples were then analysed for WT1 mRNA expression using 
the same assays described for the in vitro experiments (Figure 3.3A, B, C).  
Variable levels of expression were detected within the tumour set and applying an 
arbitrary cut-off at 0.001, only 7 samples resulted positive for exon 7/8; similar 
results were obtained with the other two assays but, as shown in Table 3.2, some 
inconsistencies were observed: six samples expressed exon 1A and the truncated 
isoform starting from intron 5 but resulted negative for exon 7/8, which is 
unexpected, since both variants are known to include the Zinc-finger region 
comprised in exon 6/10 (Dallosso et al. 2004, Dechsukhum et al. 2000). This unusual 
result could be either due to false positive RT-PCR data or to the existence of C-
terminal truncated isoforms which have not yet been documented in the literature. 
Chi-squared tests were then performed to determine whether the expression of the 
different WT1 isoforms associates with a specific status of the ER/PR and HER2 
markers (Table 3.3): the analysis did not give statistically significant results, even 
when the tests were repeated without applying any cut-off (which raised the number 
of WT1 positive samples to 23, data not shown).   
To compare the expression levels of the different isoforms between healthy and 
neoplastic tissue, we analysed the sample of human adult mammary gland described 
in the previous chapter. The normal tissue, which consisted of a pool from 5 different 
healthy donors, expressed higher WT1 levels than any of the tumour samples (Figure 
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Figure 3.3 Assessing WT1 expression in the first set of tumours. 
A) Quantitative RT-PCR for WT1 mRNA expression (exon 7/8); samples with a relative expression > 
0.001 were considered positive. B) Quantitative RT-PCR for WT1 mRNA expression (exon 1A); 
samples with a relative expression > 0.01 were considered positive. C) Quantitative RT-PCR for 
WT1 mRNA expression (intron 5); samples with a relative expression > 0.02 were considered 
positive. Data points represent the relative expression of the respective isoform, error bars represent 












Table 3.2 Summary of ER, PR, HER2 and WT1 expression in the first set of tumour samples. 
 
Abbreviations and symbols: IHC, immunohistochemistry; RT-PCR, Real-Time Polymerase Chain 
Reaction; -, data not available; green, positive; red, negative. The inconsistencies between RT-
PCR/IHC data and among the WT1 isoforms are emphasised with asterisks. 






6 * * -
7 -
8 * * - * * *
9 * * - * * *
10 * * -
11 * * -
12 -
13 * * - * * *
14 * * * * -
15 - * * *
16 * * * * -
17 * * - * * *
18 -
19 - - - - - - -
20 -
21 - -
22 * * -
23 - * * *
24 * * - * * *
25 -
26 -
27 * * -
28 - - - - - - -
29 -
30 -




35 * * -
36 -
37 -
38 - - - - - - -
39 -
40 -
41 - - - - - - -
42 -
43 -
44 * * * * -
45 * * -
46 -
47 * * * * -
48 - - - - - - -
49 -






ER PR HER2 WT1
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Table 3.3 Chi-square tests performed on the distribution of the WT1 isoforms in the first set of 
tumour samples. 
 Exon 7/8 Exon 1A Intron 5 
ER/PR status p value = 0.977 p value = 0.992 p value = 0.986 
HER2 overexpression p value = 0.629 p value = 0.961 p value = 0.800 
 
 
3.3.2 Second set of tumour samples 
The second set of breast cancer samples was obtained from the Tissue Bank and 
consisted of 60 ductal carcinomas NST of known grade, ER and HER2 status. 
So far, WT1 immunofluorescence has been performed on half of the specimens by 
Dr. McGregor, who has also scored the number of WT1 positive cells for each 
tumour by counting the stained cells in five different regions of the slide, each one 
covering an area of 200 µm2. 
All the samples showed some degree of staining, therefore, I grouped them according 
to their grade, ER and HER status and then plotted the average number of WT1 
positive cells for each group (Figure 3.4).  
A one-way Anova conducted to compare the average number of WT1-expressing 
cells in grade 1, grade 2 and grade 3 tumours revealed no statistically significant 
difference among the groups (Figure 3.4A, p value of 0.161); similar results were 
obtained for the ER and HER2 markers (Figure 3.4B and C, p value of 0.075 and 
0.194 respectively), even though the analysis cannot be considered conclusive due to 
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Figure 3.4 WT1 expression in the second set of human breast cancer samples. 
WT1 immunofluorescence was performed on 30 tumours, the number of WT1 positive cells was 
calculated by counting the stained cells in five different regions of the slide, each one covering an area 
of 200 µm2. The average number of WT1 positive cells was plotted against the tumour grade (A), the 
Allred score for the ER status (B) and the HER2 status (C). Error bars = +/- SEM. No statistically 
significant difference was observed among the groups.  
C
  C 
B
  C 
A
  C 
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3.4 In silico analysis of WT1 gene expression in 
published breast cancer datasets 
 
Publicly available gene expression data were analysed by our collaborator Dr. Sims 
in order to complement the in vitro and in vivo work described in the previous 
paragraphs and overcome their sample size limitations. 
WT1 expression was first assessed in three microarray datasets (E-TABM-194, 
GSE10890, GSE12777), each representing a panel of breast cancer cell lines 
analysed on traditional 3’ Affymetrix GeneChips, with probes targeting the 3’ end of 
the mRNA sequence (Git et al. 2008, Hoeflich et al. 2009, Stinson et al. 2011). WT1 
was detected in 40 out of the 173 lines (Figure 3.5A) and, as observed in the in vitro 
experiments, the expression level was not significantly associated with the luminal, 
basal or claudin-low cell line subtypes (Mann-Whitney U test p>0.05) (Figure 3.5B). 
Given the extraordinary complexity of the WT1 locus, we also analysed a dataset 
representing a panel of 41 breast cancer cell lines using Affymetrix exon GeneChips 
(GSE16732, Riaz et al. 2009). Exon microarrays are designed with up to four probes 
targeting each exonic region and therefore can provide more information on 
alternative splicing and isoform variation. 
The exon array data resulted in agreement with my RT-PCR experiments, showing 
high levels of WT1 expression for ZR75, MDA-MB-157, HS578T and T47D cell 
lines (Figure 3.5C); moreover, WT1 expression in MDA-MB-231 cells seemed to be 
restricted to exons 6 to 10, which supports the hypothesis that this cell line may only 
express the truncated intron 5 isoform.  
In parallel, WT1 expression was analysed in 17 datasets of primary human breast 
cancer (Moleirinho, Chang et al. 2013) (Figure 3.6A): the transcript could only be 
reliably detected in 11% of the tumours (329 out of the total 2999) and showed the 
highest expression levels in the luminal and HER2 amplified subtypes (Figure 3.6B). 
Furthermore, amongst the samples in which it was detected, WT1 expression was 
significantly higher in ER-positive than in ER-negative tumours (Figure 3.6C, p 
value of 1e-5). 
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Since WT1 is a known regulator of the epithelial/mesenchymal balance during 
development and may play a similar role in cancer, we went on to assess whether 
WT1 expression was associated with EMT-related transcripts (CDH1, CDH3, SNAI1, 
SNAI2, VIM, TWIST1, CLDN7) (Figure 3.6A). Statistically significant differences 
were only observed for the mesenchymal markers VIM and SNAI1 (p value of 0.001 
and 0.05 respectively); both genes showed higher expression in the WT1-negative 
samples (Figure 3.7), suggesting that the lack of WT1 may be associated to a more 
mesenchymal phenotype. 
Next, significance analysis of microarray (SAM) was performed in order to identify 
differentially expressed genes between WT1-high and WT1-low breast tumours.  
Out of 500 modulated transcripts (listed in appendix A), only 5  
showed a negative correlation with WT1 expression, being up-regulated in the WT1-
low tumours and down-regulated in the WT1-high; this group includes one gene 
involved in Fas-mediated apoptosis (MUDENG) and two regulators of vescicular 
trafficking (STX4, VPS37B) (Bennett, Garcia-Arraras et al. 1993, Stuchell, Garrus et 
al. 2004, Lee, Shin et al. 2008). 
The rest of the modulated genes correlated with WT1 expression, displaying up-
regulation in the WT1-high tumours and down-regulation in the WT1-low. The 
differentially expressed transcripts include several enzymes of the cytochrome P450 
as well as different types of metalloproteases (both MMPs and members of the 
ADAM gene family). 
Gene Ontology analysis revealed that the GO terms significantly enriched in this 
group ranged from neuroactive ligand-receptor interaction to calcium signalling 
pathway. Drug and xenobiotics metabolisms were also observed, along with 
unexpected terms related to heart conditions such as dilated and hypertrophic 




















Figure 3.5 WT1 transcript expression in published breast cancer cell line datasets. 
A) Gene expression analysis data from 3 combined microarray datasets (E-TABM-194, GSE10890, 
GSE12777, n = 173 cell lines). The bars under each cell line indicate their original dataset, shown on 
the right. The hierarchical clustering resulted from the 500 most variable genes, demonstrating that the 
same cell lines from different studies cluster together after batch correction. B) Boxplot of WT1 
expression in the different subtypes of breast cancer cell lines represented in the 3 datasets, log2 
expression values. C) Heatmap visualization of the relative expression of probes representing each 
WT1 exon across a panel of breast cancer cell lines in a published dataset (GSE16732). The different 
colours indicate the cell line subtype (red = basal, orange = basal B / mesenchymal, purple = HER2 
amplified, blue = luminal, yellow = claudin-low). (The bioinformatics analysis represented in this 


















Figure 3.6 Expression of WT1 and markers of EMT in human primary breast cancer datasets. 
A) Gene expression analysis data from 17 integrated datasets (n = 2999 tumors). The bars under each 
tumour sample indicate their original dataset, shown on the right. B) Boxplot of WT1 expression in the 
different subtypes and corresponding Mann-Whitney U tests with the significant p-values highlighted 
in bold, y-axis is log2 values. C) Boxplot of WT1 expression in ER-positive and ER-negative tumours 
designated by IHC of ERalpha amongst those tumours with detectable expression of WT1. The 
different colours in A) and B) indicate the tumour subtype (red = basal, purple = HER2 amplified, 
blue = luminal, green = normal-like, yellow = claudin-low). (The bioinformatics analysis represented 
















Figure 3.7 Expression of EMT-associated genes in WT1-positive vs negative tumours. 
Statistically significant differences were observed only for VIM and SNAI1, which showed higher 
expression in the WT1-negative samples. (The bioinformatics analysis represented in this figure was 
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Table 3.4 GO terms from SAM analysis of WT1-high vs WT1-low tumours. 
Term p-value Genes 
Neuroactive ligand-receptor 
interaction 
3E-11 MCHR1, TACR3, THRB, GABRB2, TACR2, 
DRD2, GRIK3, OPRK1, DRD5, TRHR, TSHB, 
HTR1B, HTR1A, P2RY4, GALR3, CNR2, 
MC5R, TAAR5, PRL, TAAR2, HTR1F, HTR1E, 
GABRD, HTR4, GRIN2A, GABRR2, CHRM5, 
P2RX6, P2RX1, CHRM2, AVPR1B, P2RX2, 
MC2R, GRM6, MC4R 
 
Calcium signaling pathway 8E-5 ADCY2, SLC8A2, TACR3, TACR2, PHKG1, 
DRD5, TRHR, GRIN2A, CHP2, HTR4, 
CHRM5, P2RX6, P2RX1, CHRM2, AVPR1B, 
P2RX2, CAMK2B, CACNA1F, CAMK2A 
 
Linoleic acid metabolism 4E-04 CYP3A4, CYP2C19, CYP2C18, CYP2C9, 
PLA2G6, CYP1A2, PLA2G2E  
Retinol metabolism 0.003 CYP3A4, CYP4A11, CYP4A22, CYP2C19, 
CYP2C18, CYP2C9, CYP2A7, CYP1A2   
Arachidonic acid metabolism 0.004 CYP4A11, CYP4A22, CYP2C19, CYP2C18, 
CYP2C9, PLA2G6, CYP4F2, PLA2G2E   
Dilated cardiomyopathy 0.006 ADCY2, MYL3, MYBPC3, CACNB1, 
CACNG3, CACNG2, ITGB3, CACNB4, 
CACNA1F, CACNG1 
 
Hypertrophic cardiomyopathy  0.013 MYL3, MYBPC3, CACNB1, CACNG3, 




ventricular cardiomyopathy  
0.022 CACNB1, CACNG3, CACNG2, ITGB3, 
CACNB4, CACNA1F, CACNG1, CTNNA3  
Cardiac muscle contraction 0.025 MYL3, ATP1B2, CACNB1, CACNG3, 
CACNG2, CACNB4, CACNA1F, CACNG1   
Caffeine metabolism 0.025 XDH, CYP2A7, CYP1A2  
 
Drug metabolism 0.026 CYP3A4, GSTA3, CYP2C19, CYP2C18, 
CYP2C9, CYP2A7, CYP1A2  
Metabolism of xenobiotics by 
cytochrome P450 
0.070 CYP3A4, GSTA3, CYP2C19, CYP2C18, 
CYP2C9, CYP1A2  
Melanogenesis 0.074 DCT, FZD9, WNT10B, ADCY2, CAMK2B, 




Our multi-approach analysis showed that WT1 expression in breast cancer occurs at 
low frequency (≤ 20%), which is in agreement with some of the earlier studies on the 
topic (Silberstein et al. 1997, Cheng et al. 2001). 
The only inconsistency in our data is represented by the second set of human breast 
cancer samples, which all stained positive for WT1; since this result could be due to 
IF artefacts, I am currently in the process of obtaining matched tissue samples on 
which to perform RT-PCR. 
Overall, WT1 did not show particularly high expression, either in vivo or in vitro; 
moreover, the mRNA levels observed in the tumour samples were lower than in the 
healthy mammary gland. This finding is in keeping with what described by 
Silberstein, who reported reduced WT1 staining in breast cancer specimens 
(Silberstein et al. 1997). 
In terms of isoform expression pattern, this work led to several results: firstly, all our 
data corroborate the hypothesis that the truncated transcript starting from intron 5 is a 
tumour-specific isoform; this short WT1 variant was first detected in the blood of 
patients affected by acute leukaemia, then in breast and pancreatic cancer cell lines 
(Bae et al. 1994, Dechsukhum et al. 2000, Artibani 2010) and we have now shown 
that it is expressed in human breast cancer biopsies but is absent in the healthy 
mammary gland.  
Secondly, both our in vitro and in silico experiments seem to demonstrate that the 
truncated intron 5 is the only WT1 isoform expressed in MDA-MB-231 cells; if 
confirmed, any assay targeted against exon 1/5 would give a negative result, which 
may explain why the reports on WT1 expression in this cell line are so contradictory 
(Laux et al. 1999, Oji et al. 1999, Loeb et al. 2001, Zapata-Benavides et al. 2002, 
Tuna, Chavez-Reyes et al. 2005, Caldon et al. 2008). 
Lastly, exon 1A has been detected in few human breast cancer samples and in only 




One of the main goals of this study was to assess whether WT1 is associated with 
any specific histological or molecular subtype of breast cancer. In this regard, the in 
vivo experiments were inconclusive due to their limited sample size, but the 
bioinformatics analysis revealed that WT1 expression correlates with luminal and 
ER-positive breast cancer.  
This finding is in stark contrast with what reported by the only paper published on 
the subject (Qi et al. 2012), which claims that WT1 is associated with basal and ER-
negative tumours. The discrepancy is likely to be caused by the different size of the 
studies: our analysis was performed on 17 datasets of primary human breast cancer 
and included also the single dataset used by Qi, which makes the results of this study 
more robust. 
The finding that WT1 expression is higher in ER-positive tumours is particularly 
interesting, given that WT1 has been shown to both interact with ERα (Reizner et al. 
2005) and modulate its expression in vitro (Kang et al. 2011, Han et al. 2008).  
The bioinformatics analysis also determined that WT1-negative tumours show higher 
levels of mesenchymal markers than the WT1-positive; this observation would 
suggest that WT1 does not play a pro-EMT role in breast cancer cells, but, on the 
contrary, its expression is associated with a more epithelial phenotype. 
Finally, SAM analysis revealed that the tumours expressing high levels of WT1 show 
an up-regulation of several genes belonging to the cytochrome P450 family (CYP).  
These oxidizing enzymes play an important and complex role in the metabolism of 
anti-cancer agents: they participate to the biological activation of many pro-drugs but 
also to the inactivation of some cytotoxic compounds, two processes that occur 
predominantly, but not exclusively, in the liver (McFadyen, Melvin et al. 2004). Not 
surprisingly, polymorphisms and different expression levels of the CYP genes have 
been shown to influence the outcome of chemotherapeutic treatments (reviewed in 
Rodriguez-Antona and Ingelman-Sundberg 2006, Seredina, Goreva et al. 2012).  
The substrates of one of these up-regulated genes, CYP3A4, include drugs routinely 
used in the management of breast cancer such as tamoxifen, docetaxel, paclixatel, 
111 
 
cyclophosphamide and doxorubicin (reviewed in Rodriguez-Antona and Ingelman-
Sundberg 2006).  
More specifically, CYP3A4 activity in the liver is responsible for the activation of 
tamoxifen and cyclophosphamide (Crewe, Ellis et al. 1997, Roy, Yu et al. 1999), 
whereas it transforms docetaxel into inactive hydroxylated derivatives (Engels, Ten 
Tije et al. 2004); interestingly, high CYP3A4 levels in breast cancer biopsies can 
predict a poor therapeutic response to docetaxel, which suggests that also the enzyme 
within the tumour is involved in the inactivation of this drug (Miyoshi, Ando et al. 
2002, Miyoshi, Taguchi et al. 2005). 
The association between high WT1 and CYP3A4 expression in breast cancer seems 
intriguing, especially considering the potential repercussions at the clinical level. 
However, since the WT1 literature lacks studies on patients treated with docetaxel, 
any correlation between WT1 expression and the therapeutic response to this drug 
remains speculative; further research is needed to investigate whether this association 
has any molecular basis and if the tumour levels of WT1 can be used to predict the 











Chapter 4: Studying the effects of WT1 loss in 
human breast cancer cell lines 
 
4.1 Introduction 
Several studies have tried to determine the role played by WT1 in breast cancer, 
however, at the current state of research, no conclusive evidence has been provided. 
Even though high WT1 expression has been shown to predict poor prognosis in 
breast cancer patients (Miyoshi et al. 2002), WT1 is still at the centre of a debate 
over potential oncogenic or tumour suppressing functions (as described in detail in 
chapter 1.4). 
In order to avoid any redundancy, this section will only recapitulate what is 
necessary to contextualise the in vitro experiments described in the next paragraphs. 
The first, and so far only, WT1 knockdown in human breast cancer cell lines dates 
back to 2002, when Zapata-Benavides and colleagues down-regulated WT1 
expression using liposome-incorporated antisense oligonucleotides targeting the 
translation initiation site in exon 1 (Zapata-Benavides et al. 2002). After a 72-hour 
incubation, the knockdown cells exhibited significant growth inhibition and cyclin 
D1 protein level reduction, which suggests that WT1 is important for the proliferation 
of breast cancer cells. 
Diametrically opposite findings have been reported by the Wang group and describe 
WT1 as a potent tumour suppressor: in their studies, a WT1 expression vector 
containing the –Exon 5/-KTS isoform was transfected in MDA-MB-231 and 
MCF10A-T3B cells, resulting in suppression of clonal growth in soft agar assays and 
inhibition of tumour formation in nude mice (Zhang et al. 2003, Wang & Wang 
2008). 
Particularly significant was the discovery that ectopic expression of different WT1 
isoforms has opposite effects on mammary cells (Burwell et al. 2007). While the 
+Exon 5/+KTS variant was shown to display oncogenic features such as induction of 
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EMT and redistribution of CDH1, the –Exon 5/-KTS isoform decreased proliferation 
by causing a cell cycle arrest in G2 and up-regulating p21. 
This study unveiled the mechanism behind the tumour suppressing activity reported 
by Wang, but the knockdown phenotype observed by Zapata-Benavides remains 
unexplained: given the structure of the WT1 locus, in fact, the targeting of exon 1 
should result in the equal degradation of both +Exon 5/+KTS and –Exon 5/-KTS 
isoforms. 
Clearly, further research is needed to achieve a complete understanding of the role 
played by WT1 in breast cancer and, in particular, to comprehend why WT1 
expression correlates with poor survival.  
As mentioned in chapter 1.2.3.4, the main hypotheses are related to a potential role 
of WT1 in angiogenesis, proliferation/apoptosis and EMT/CSCs; while studying 
blood vessel formation requires an in vivo approach, the other two theories can be 
tested with in vitro techniques, as shown in the next paragraphs.  
 
4.1.1 Aim 
The aims of the experiments described in this chapter were: 
• to develop lentiviral RNAi constructs targeting the zinc finger region of WT1 (and 
therefore all its known different isoforms)  
• to transduce these constructs in human breast cancer cell lines and achieve stable 
WT1  knock-down 
• to analyse the consequences of WT1 loss, paying particular attention to any change 






4.1.2 Experimental approach 
An RNAi based gene knockdown strategy was used to investigate the functional role 
of WT1 in breast cancer cell lines. Unlike previous studies based on transient 
transfections, we aimed to achieve stable WT1 knockdown, which is essential to 
investigate the long-term effects of WT1 loss. 
To this end, shRNAs targeting the zinc-finger region of the WT1 transcript were 
cloned into commercially available lentiviral constructs, creating both a constitutive 
and an inducible version. 
 
 
4.2 Cloning RNAi lentiviral vectors for the 
constitutive and inducible knockdown of WT1 
The lentiviral RNAi vectors pGIPZ and pTRIPZ were purchased from Thermo 
Scientific Open Biosystems and used as backbones for the cloning of shRNAs 
targeting the human WT1 transcript.  
While pGIPZ (Figure 3.1) is constitutively expressed, pTRIPZ (Figure 3.2) is 
engineered for Tet-controlled expression, so that the shRNA is produced only in the 
presence of doxycycline. 
In previous transient knockdown experiments, the pcDNA6.2-GW/EmGFP-miR 
vector (Invitrogen, Figure 4.3) had been successfully used to express miRNAs 
against WT1 and a reliable miR-lacZ control (Peter Hohenstein, personal 
communication). Since this pcDNA construct is Gateway-compatible, the already 
validated shRNA sequences could be cloned into the lentiviral vectors through easy 







Figure 4.1 Schematic of the pGIPZ lentiviral shRNA vector. 
RRE - Rev response element to enhance titer; hCMV - Human cytomegalovirus promoter to drive 
strong transgene expression; tGFP - TurboGFP reporter for visual tracking of transduction and 
expression; IRES - Internal ribosomal entry site to allow the expression in a single transcript of 
TurboGFP and puromycin resistance genes; Puro - Puromycin resistance; shRNA – small hairpin 
RNA for gene knockdown; WPRE -  Woodchuck hepatitis post-transcriptional regulatory element to 
enhance transgene expression in the target cells; 3’ SIN LTR - 3' self-inactivating long terminal repeat 




Figure 4.2 Schematic of the pTRIPZ lentiviral shRNA vector. 
RRE - Rev response element; IRES - Internal ribosomal entry site to allow the expression in a single 
transcript of  rtTA3 and puromycin resistance genes; Puro - Puromycin resistance; shRNA – small 
hairpin RNA; WPRE -  Woodchuck hepatitis post-transcriptional regulatory element; 3’ SIN LTR - 3' 
self-inactivating long terminal repeat; 5’ LTR - 5' long terminal repeat; TRE - Tetracycline-inducible 
promoter; tRFP - TurboRFP reporter for visual tracking of transduction and shRNA expression; UBC 
- Human ubiquitin C promoter to constitutively express rtTA3 and puromycin resistance genes; rtTA3 
- Reverse tetracycline-transactivator 3 for tetracycline-dependent induction of the TRE promoter 




Figure 4.3 Map of the pcDNA6.2-GW/EmGFP-miR vector. 
 
4.2.1 Gateway cloning 
The Gateway cloning system provides a rapid and efficient way to transfer DNA 
fragments by taking advantage of the site-specific recombination properties of 
bacteriophage lambda (Hartley, Temple et al. 2000). 
After infecting E. coli cells, the phage can use the lysogenic pathway to integrate its 
DNA into the genome of the host (Figure 4.4); in response to certain stimuli, the viral 
DNA can excise itself from the bacterial chromosome and start a lytic cycle, during 
which new virions are assembled and then released upon lysis of the host cell. 
As shown in Figure 4.4, lambda recombination relies on the activity of several 
enzymes that bind to specific attachment (att) sequences; however, the combination 
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of proteins and att sites used in the lysogenic pathway (Int, IHF, attB, attP) is 
different from that of the lytic pathway (Int, Xis, IHF, attL, attR). 
 
 
Figure 4.4 The recombination of bacteriophage lambda in E. coli. 
The components of this natural system have been adapted by Invitrogen to create the Gateway 
multisite cloning technology. 
 
The Gateway cloning exploits this natural system to carry out the in vitro 
recombination between attB and attP sites (called BP reaction) and between attL and 
attR (LR reaction), which can be controlled by providing the necessary combination 
of enzymes and attachment sequences. 
This technology was used to clone the miRNA sequences into the lentiviral vectors 
in three easy steps (Figure 4.5, see Appendix B for the maps of the constructs created 
at each step): 
1) generation of the new entry clones 
2) generation of the destination vectors 






























4.2.1.1 Step 1: generating the entry clones 
Since the lentiviral vectors already express a fluorescent reporter to identify infected 
cells (TurboGFP in pGIPZ, TurboRFP in pTRIPZ), all the pcDNA6.2-GW/EmGFP-
miR vectors (lacZ control, WT1 knockdown constructs 1407 and 1490) were 
digested with DraI and religated for the removal of their GFP cassette. Following 
ligation and transformation in DH5α Library Efficient bacteria, a second DraI digest 
was used to confirm the excision of the GFP cassette (data not shown). 
A BP reaction was then performed between the resulting vectors and pDONR-221, in 
order to generate the entry clones (designated pENTR-miR); the reaction mixture 
was used to transform DH5α Library Efficient bacteria and the correct clones were 
identified based on the NruI/BamHI digest (Figure 4.6). 
 
 
Figure 4.6 Gel image showing the NruI/BamHI digest for the three pENTR-miR vectors. 
All the clones were correct, showing a band at 1946 bp and one at 409 bp (lane 1: 1 kb DNA ladder; 
lane 2: uncut WT1 1407; lane 3: cut WT1 1407; lane 4: uncut WT1 1490; lane 5: cut WT1 1490; lane 
6: uncut lacZ; lane 7: cut lacZ). 
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4.2.1.2 Step 2: generating the destination vectors 
In parallel, the destination vector pMar 342 (a kind gift from Dr. M. Reijns) was 
digested with EcoRV and the smaller 1713 bp fragment, which carries a Gateway 
Entry cassette, was gel purified.  
The fragment was then ligated to the backbone of the lentiviral constructs and used 
to transform ccdB competent DB3.1 bacteria, grown at 30°C: the resulting 
destination vectors were mini-prepped and the correct clones were identified based 
on the EcoRI digest (for pGIPZ-DEST, Figure 4.7) or the EcoRI/XbaI double digest 
(for pTRIPZ-DEST, Figure 4.8). 
 
 
Figure 4.7 Gel image showing the EcoRI digest for the pGIPZ-DEST vector. 
Clones number 1 and 3 are correct, as the ligation of GIPZ and pMar342 in the right orientation would 
give a fragment of 3743 bp (lane 1: uncut clone #1; lane 2: cut clone #1; lane 3: uncut clone# 2; lane 




Figure 4.8 Gel image showing the EcoRI/XbaI double digest for the pTRIPZ-DEST vector. 
The ligation of TRIPZ and pMAR342 in the right orientation should give two fragments of 1553 and 
13221 bp, the wrong orientation two fragments of 2356 and 12414 bp. The clone is correct, as shown 
by the presence of the 1553 bp band (the 13221 bp fragment is too large to be visualised). 
 
4.2.1.3 Step 3: generating the expression clones 
Finally, a Gateway LR reaction was performed to subclone the pENTR-miR (LacZ, 
WT1-1407 and WT1-1490) into the GIPZ-DEST and TRIPZ-DEST vectors. 
Following transformation of Stbl2 chemically competent bacteria, grown at 30°C, 
restriction digests of mini-prepped DNA were used to confirm correct integration. 
The desired expression clones were identified based on XbaI and HindIII digests (for 











Figure 4.9 Gel images showing the digests for the final pGIPZ-mir constructs. 
All the clones were correct, showing bands at 2840 and 8779 bp for the XbaI digest (A), at 5361, 
2664, 2110, 588 and 556 bp for HindIII (B) (lane 1: 1 kb DNA ladder; lane 2: uncut WT1 1407; lane 











Figure 4.10 Gel image showing the PvuII digest for the final pTRIPZ-miR constructs. 
All the clones are correct, showing bands at 626, 2338, 2745 and 7536 bp (lane 1: 1kb DNA ladder; 
lane 2: uncut lacZ ctr; lane 3: cut lacZ ctr; lane 4: uncut hWT1 1407; lane 5: cut hWT1 1407; lane 6: 






4.3 Efficient WT1 knockdown is achieved with the 
lentiviral system 
Lentiviral particles were produced using a trans-lentiviral packaging system 
developed in the human embryonic kidney cell line SODK3 (Cockrell, Ma et al. 
2006). The packaging cells were transfected with the lentiviral vectors described in 
the previous paragraphs and the resulting viral supernatant was used to transduce 
four of the human breast cancer cell lines that showed the highest WT1 expression 
(MDA-MB-157, HBL100, ZR75, MDA-MB-231). 
 
4.3.1 Constitutive knockdown 
Following transduction, the targeted cells were cultured in puromycin selective 
medium and after one week, they were FACS sorted for GFP: since the fluorescent 
protein is a surrogate marker of miR expression, sorting the cells with high levels of 
GFP allowed us to select for maximal miR expression. 
The efficiency of the transduction procedure was confirmed by the fact that the vast 
majority of cells resulted GFP positive (data not shown); from this population, the 
brightest 15% was sorted and analysed for WT1 mRNA expression using primers 
targeting exon 7/8.  
Significant down-regulation of the WT1 transcript was achieved by both lentiviral 
vectors (expressing the 1407 and 1490 targets) in MDA-MB-231 cells, with the best 
silencing construct showing up to 95% reduction if compared to the virus untreated 
cells; oddly, only the 1490 vector was successful in MDA-MB-157 and HBL100 
cells, leading to 50% and 80% down-regulation respectively (Figure 4.11). 
Unfortunately, the ZR75 clones were lost due to infection and their transduction 
could not be repeated within the timeframe of this project.  
Ideally, protein levels should also be analysed to confirm the efficacy of the 
knockdown; however, as discussed earlier, no reliable WT1 antibody was available 
for Western blot.  
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Figure 4.11 Quantitative RT-PCR for WT1 mRNA expression in breast cancer cell lines 
transduced with pGIPZ-miR. 
Graph represents fold change of mean expression relative to untransduced cells (given a value of 1); 






















4.3.2 Inducible knockdown 
The pTRIPZ construct allows tightly regulatable miR expression that can be induced 
by doxycycline over a period of 48-72 hours.  
At the time of writing, only MDA-MB-157 cells had been transduced with the 
inducible vectors; following one week of puromycin selection, the cells were 
exposed to different concentrations of doxycycline (ranging from 0.1 μg/ml to 2 
μg/ml, as recommended in the Open Biosystem technical manual) in order to identify 
the optimal dose.  
After a 48-hour incubation, RFP (used to track miR expression) could be detected in 
the majority of cells, independently of the concentration used (Figure 4.12). RT-
PCR, however, showed that maximal WT1 knockdown was achieved only at the 
highest dose (2 μg/ml) and in cells transduced with the 1490 vector, while the 1407 
did not produce a particularly efficient result (Figure 4.13). 
Doxycycline was then administered at the optimal concentration in triplicate for nine 
consecutive days: in order to monitor WT1 expression throughout the experiment, 
RNA samples were collected at different time points before, during and after 
treatment.  
As shown in Figure 4.14, and similarly to what observed in the preliminary study, the 
1407 construct was not successful, but significant reduction in WT1 expression was 
observed for the cells transduced with the 1490 vector and the efficiency improved 
with prolonged exposure to doxycycline. Importantly, the WT1 levels in the 1490 
cells went back to normal after the withdrawal of the drug, while in the LacZ control 





Figure 4.12 Doxycyline-induced expression of RFP in MDA-MB-157 cells transduced with 
pTRIPZ-miR. 
The cells were imaged after a 48-hour incubation with different concentrations of doxycycline. 
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Figure 4.13 Quantitative RT-PCR for WT1 mRNA expression in MDA-MB-157 cells. 
The graph compares the WT1 levels of untreated and pTRIPZ-miR transduced cells exposed to 
different doses of doxycycline. Data points represent the relative expression of WT1, error bars 
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Figure 4.14 Quantitative RT-PCR for WT1 mRNA expression in MDA-MB-157 cells transduced 
with pTRIPZ-miR. 
The cells were cultured on 2 μg/ml doxycycline. Graph represents fold change of mean expression 
relative to untransduced cells, error bars represent the standard deviation of three biological replicates. 
(* p<0.05, ** p<0.01, *** p<0.001) 
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4.4 Characterisation of the WT1 knockdown cells 
In order to investigate the consequences of WT1 loss in breast cancer, several 
experiments were performed on the knockdown cells, including: 
• RNA-sequencing  
• analysis of EMT and CSCs markers 
• studies on proliferation, colony formation and apoptosis. 
 
4.4.1 RNA-sequencing 
This technique, based on deep-sequencing technologies, provides extremely precise 
measurements of transcript levels and has rapidly replaced microarrays in gene 
profiling experiments (Wang, Gerstein et al. 2009). 
In this project, RNA-sequencing was used to compare the transcriptomes of virus-
untreated, pGIPZ-miR-lacZ and pGIPZ-miR-WT1kd1490 cells in both MDA-MB-
231 and MDA-MB-157 lines. 
The data were analysed with two different web-based softwares, the more recently 
developed GeneProf (Halbritter, Vaidya et al. 2012) and the already established 
Galaxy analysis suite (Giardine, Riemer et al. 2005); the excel files containing the 
complete analyses can be found in the attached CD, as well as all the tables for the 
ToppFun functional enrichment analysis. 
 
4.4.1.1 GeneProf analysis 
For each cell line, pair-wise comparisons were performed to analyse the 
transcriptome of the three samples (untreated, lacZ and WT1 knockdown). 
No significantly modulated genes were identified for the MDA-MB-231 dataset, 
while 165 were found for the MDA-MB-157 line: these transcripts were up or down 
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regulated at least two fold with a p value ≤ 0.05 in both “WT1 kd/lacZ” and “WT1 
kd/untreated” comparisons (Figure 4.15).  
To rule out any effect due to the transduction procedure itself and identify the genes 
which were uniquely affected by the knockdown of WT1, I removed from this set all 
the genes which were differentially expressed in the “LacZ/untreated” comparison.  
 
 
Figure 4.15 Venn analysis of the genes modulated in MDA MB 157 cells. 
The distribution of the up-regulated transcripts is shown in A, the down-regulated in B. 
 
The remaining transcripts (9 up-regulated and 153 down-regulated, listed in appendix 
C) were analysed for gene list functional enrichment using ToppFun Suite 
(http://toppgene.cchmc.org); through this portal I applied a false rate discovery 
method (FDR) with a 0.05 cut-off level to correct for multiple comparisons and then 
grouped the modulated genes according to their Go terms (cellular component, 
molecular function and biological process).  
The analysis of the up-regulated genes could not identify any functional enrichment, 
most likely because the list is very small and contains heterogeneous genes (AGR2, 
CNTNAP3B, CXCL5, C8orf4, FLRT3, PAPPA, PTGS2, THSD7A). The down-
regulated group, on the other hand, was enriched for genes expressed in cellular 




fibers; in terms of biological processes, significant enrichment was found for 
transcripts involved in cell adhesion and migration, extracellular matrix organization 
and disassembly, angiogenesis, wound healing and neurogenesis. 
4.4.1.2 Galaxy analysis 
This analysis was performed by our collaborator Dr. Aitken following the same 
criteria described in the previous paragraph. 
In the MDA-MB-231 dataset, a total of 119 significantly modulated genes were 
identified (91 up-regulated and 28 down-regulated, listed in appendix D), including 
several microRNAs (MIR4763, MIRLET7A3, MIRLET7B, MIRLET7BHG, MIR221, 
MIR222). The ToppFun analysis could not reveal any functional enrichment for the 
up-regulated transcripts, while the down-regulated were found to be involved in 
biological processes such as cell adhesion and migration, extracellular matrix 
organization, apoptosis, vasculature development and response to wounding.  
In the MDA-MB-157 dataset, 427 genes were differentially expressed (105 up-
regulated and 322 down-regulated, all listed in appendix E). Once again, the 
ToppFun analysis showed an enrichment in genes related to cell adhesion and 
migration, extracellular matrix organization and disassembly, angiogenesis, wound 
healing and neurogenesis. 
 
4.4.1.3 Summary and comparison of results 
The newly developed GeneProf software allowed easy and rapid analysis of the 
RNA-seq data, providing a user-friendly interface and straightforward workflows; 
however, it did not perform as well as Galaxy in the identification of modulated 
transcripts: the difference was particularly marked for the MDA-MB-231 dataset, 
whose differentially expressed genes could only be identified through Galaxy. 
As shown by the overlap in Figure 4.16, very few transcripts resulted modulated in 
both MDA-MB-157 and MDA-MB-231 cells (COL5A1, FAM133A, GPR110, 




Figure 4.16 Venn analysis of the modulated genes identified by GeneProf and Galaxy. 
 
Nonetheless, the ToppFun analysis detected similar functional enrichment in both 
datasets and most of the modulated genes seem to be involved in one of the 
following biological processes: 
• cell adhesion (GO terms: biological, cell-matrix and cell-substrate adhesion, 
positive and negative regulation of cell adhesion) 
• cell migration (ameboidal cell migration, cell motility, cell projection 
morphogenesis and organization, chemotaxis, locomotion, cell migration involved in 
sprouting angiogenesis) 
• cell proliferation (epithelial cell proliferation, negative regulation of epithelial cell 
proliferation)  
• apoptosis (extrinsic apoptotic signaling pathway, regulation of apoptotic process, 
negative regulation of programmed cell death) 
• extracellular matrix organization and disassembly  




• wound healing (response to wounding) 
• neurogenesis (axon development and guidance, axonogenesis, neuron development 
and differentiation, neuron projection development, guidance and morphogenesis, 
regulation of neurogenesis). 
A potential role for WT1 in some of these processes has already been hypothesized 
(apoptosis, proliferation, angiogenesis); others, like cell adhesion and migration, are 
particularly intriguing given their involvement in metastasis formation.  
Functional assays, however, are needed to determine if any of these processes is 




4.4.2 Migration assays 
The RNA-sequencing data suggest that WT1 may play a role in the adhesion and 
migration of breast cancer cells; since the modulated genes include both positive (eg. 
MMP2, WNT5B) and negative (eg. THBS1, GSTP1) regulators of these processes, the 
effects of WT1 loss could be either pro- or anti-migratory. 
In order to assess if and how WT1 knockdown affects cell motility, migration assays 
were performed on MDA-MB-157 cells transduced with the pGIPZ-miR constructs. 
In brief, the cancer cells were seeded in both wells of an IBIDI insert, allowing them 
to attach only in the designated areas; after removing the insert, the closure of the 
gap was monitored through time-lapse microscopy. Images were collected every 30 
minutes for 40 hours (from t=0 to t=80) and then analysed with ImageJ. 
A one-way ANOVA conducted to compare the migration capacity of untreated, 
control and knockdown cells revealed a statistically significant difference among the 
groups (Figure 4.17, p value of 0.022); post-hoc comparisons using the Tukey test 
indicated that the mean gap closure percentage for the knockdown cells at t=80 was 
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significantly higher than the other two samples, while untreated and lacZ cells did 
not differ significantly from each other. 
As shown by the representative images in Figure 4.17, the WT1kd1490 cells migrate 
faster than the controls, suggesting that WT1 may play a role in the negative 
regulation of cell motility, at least in MDA-MB-157 cells. 
 





















Figure 4.17 Cell migration assay performed on MDA-MB-157 cells transduced with pGIPZ-
miR. 
Bar diagram representing the mean gap closure percentage of two independent experiments (top); 





4.4.3 RT-PCR for EMT markers and RNA-seq validation 
In order to assess whether the loss of WT1 affects the epithelial/mesenchymal 
balance of breast cancer cells, RT-PCR was performed on all the lines transduced 
with the lentiviral constructs (MDA-MB-157, MDA-MB-231 and HBL100); the 
RNA levels of several EMT drivers, epithelial and mesenchymal markers were 
analysed, as well as some of the modulated genes identified through RNA-
sequencing (only the statistically significant results are reported below, the complete 
set of RT-PCR graph can be found in the attached CD). 
4.4.3.1 EMT drivers 
Significant change in gene expression was observed only in one of the 5 transcripts 
analysed (SNAI1, SNAI2, ZEB1, ZEB2, TWIST1). 
ZEB2 was up-regulated in MDA-MB-157 cells transduced with the inducible 
constructs: the mRNA expression was significantly higher after 5 and 7 days of 
doxycycline treatment, and went back to the untreated levels upon withdrawal of the 
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Figure 4.18 Quantitative RT-PCR for ZEB2 mRNA expression. 
Data points represent the relative expression of the gene, error bars represent the standard deviation of 
three biological replicates. (** p<0.01) 
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4.4.3.2 Epithelial markers 
Among the five genes analysed (CDH1, CTNNA1, CTNNA2, CTNND1, KRT18), 
only CTNNA1 showed a statistically significant difference in expression, being 
down-regulated in the MDA-MB-157 knockdown cells (Figure 4.19). 



































Figure 4.19 Quantitative RT-PCR for CTNNA1 mRNA expression in MDA-MB-157 cells. 
Data points represent the relative expression of the gene, error bars represent the standard deviation of 
two biological replicates. (* p<0.05) 
 
Unexpectedly, the CDH1 transcript could not be detected in any of the samples 
tested (data not shown): even though its expression is lost in the vast majority of 
breast carcinomas (De Leuuw et al. 1997), this adhesion molecule has been 
repeatedly found in several cell lines, including MDA-MB-231 cells (Lombaerts et 
al. 2006, Tate et al. 2012); hence, this result is likely a false negative due to a 
defective RT-PCR assay and the analysis should be repeated using a new set of 
primers.  
 
4.4.3.3 Mesenchymal markers 
RT-PCR was performed on ten different mesenchymal markers (VIM, TNC, VTN, 
MMP2, MMP9, TGFB1, ACTA2, CDH2, CXCL1, FN1); statistically significant 
results were only obtained for TNC and TGFB1, which displayed higher expression 
levels in the WT1 knockdown cells. 
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TNC was up-regulated in both 1407 and 1490 clones of the MDA-MB-231 line, as 
well as in MDA-MB-157 cells transduced with both constitutive and inducible 
constructs (Figure 4.20). 
TGFB1 over-expression was only observed in MDA-MB-157 inducible knockdown 
cells: after 5, 7 and 9 days of doxycycline treatment, the mRNA expression was 
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Figure 4.20 Quantitative RT-PCR for TNC mRNA expression in MDA-MB-157 and MDA-MB-
231 cells. 
Data points represent the relative expression of the gene, error bars represent the standard deviation of 
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Figure 4.21 Quantitative RT-PCR for TGFB1 mRNA expression in MDA-MB-157 cells. 
Data points represent the relative expression of the gene, error bars represent the standard deviation of 
three biological replicates. (** p<0.01) 
 
 
4.4.3.4 RNA-seq validation  
Five of the modulated genes identified through RNA-sequencing were selected for 
RT-PCR validation (TNC, MMP2, VTN, COL3A1, SNAI2). 
As previously shown (Figure 4.20), both MDA-MB-231 and MDA-MB-157 
knockdown cells showed a significant up-regulation of the mesenchymal marker 
TNC, which is in accordance with the RNA-sequencing results. 
No significant change in gene expression was observed for the other four genes 




4.4.4 Colony forming assay and stem cell marker analysis 
The RT-PCR results revealed that, at least in the MDA-MB-157 line, knocking down 
WT1 triggers a partial EMT, characterised by the up-regulation of EMT drivers and 
mesenchymal markers (ZEB2, TNC, TGFB1) as well as the down-regulation of the 
epithelial CTNNA1.   
Since EMT has been linked to the acquisition of cancer stem-cell properties (e.g., an 
increased ability to form spheres in colony-forming assays, the expression of stem-
cell markers) (Morel et al. 2008, Mani et al. 2009), we analysed such stem-cell 
properties in the WT1 knockdown cells. 
In brief, colony forming assays (CFA) were performed in 96-well plates coated with 
Polyhema in order to prevent cell attachment; semi-solid medium (containing 1% 
methylcellulose) was used to reduce cell movement and allow the individual cells to 
develop into colonies. For each clone, 1,000 cells/well were seeded at least in 
triplicate and incubated for 11 days, after which, the number of colonies > 75 μm in 
diameter were counted.  
As shown in Figure 4.22, the WT1 knockdown cells seem to form fewer spheres than 
the control in both MDA-MB-157 and HBL100 lines, however, this difference was 
not statistically significant (p value of the one-way ANOVA > 0.05). 
The knockdown cells were then analysed for the expression of cancer stem cell 
markers. In human breast cancer, the sub-population of CD44+/CD24- cells has been 
reported to be highly enriched in CSCs and can easily be isolated through FACS (Al-
Hajj et al. 2003, Mani et al. 2008). 
The percentage of CD44+/CD24- cells did not change significantly in MDA-MB-157 
and HBL100 cells transduced with the GIPZ constructs. In the MDA-MB-231 line, 
both WT1 knockdown clones showed an increase in the stem cell population if 
compared to the untreated cells; however, since a similar increase was also observed 
in the lacZ control, this difference cannot be attributable to the lower expression 
levels of WT1 (Figure 4.23). 
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Finally, no statistically significant difference could be observed in MDA-MB-157 
cells transduced with the inducible constructs (Figure 4.24). 
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Figure 4.22 Colony forming assay (CFA) of breast cancer cells suspended in semi-solid medium. 
Data points represent the average number of spheres formed per well, error bars represent the SEM of 
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Figure 4.23 FACS analysis of CD24 and CD44 expression in breast cancer cells transduced with 
the GIPZ constructs. 
Bar graphs represent the average percentage of CD44+/CD24- cells in the different clones, error bars 
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Figure 4.24 FACS analysis of CD24 and CD44 expression in breast cancer cells transduced with 
the TRIPZ constructs. 
Bar graphs represent the average percentage of CD44+/CD24- cells in the different clones, error bars 
represent the SEM of three biological replicates. 
 
 
4.4.5 Apoptosis and cell cycle analysis 
FACS analysis of Annexin V and DAPI stained cells was performed to investigate 
apoptosis and cell cycle respectively. 
As shown in Figure 4.25 and 4.26, no statistically significant difference could be 
observed in the percentage of apoptotic cells, independently of the cell line and the 
knockdown constructs used. 
The analysis of cell cycle distribution in MDA-MB-231 cells showed that the WT1 
knockdown clone G-1490 has a substantial accumulation of cells in G2/M, compared 
to both untreated and lacZ control samples (Figure 4.27); no difference was however 







Figure 4.25 FACS analysis of Annexin V-APC in cells transduced with the GIPZ constructs. 





















Figure 4.26 FACS analysis of Annexin V-APC stained cells. 
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Figure 4.27 FACS analysis of the cell cycle using DAPI staining in cells transduced with the 
GIPZ constructs. 
The results are presented as mean values ± SEM of at least three independent experiments.  (*** 




























































































Figure 4.28 FACS analysis of the cell cycle using DAPI staining in cells transduced with the 
TRIPZ constructs. 
The results are presented as mean values ± SEM of two independent experiments.   
 
 
4.5 Summary of experimental findings 
The cloning of RNAi lentiviral vectors was successful and led to the efficient 
knockdown of WT1 in three different breast cancer cell lines (MDA-MB-231, MDA-
MB-157 and HBL100).  
Several experiments were performed to characterise the WT1 knockdown cells and 
the results can be summarised as follow: 
• the RNA-sequencing identified many modulated genes, mainly involved in cell 
adhesion/migration, extracellular matrix organization/disassembly, angiogenesis, 
proliferation, apoptosis, wound healing and neurogenesis 
• migration assays carried out on the MDA-MB-157 line showed that the WT1 
knockdown cells migrate faster than the controls, suggesting that WT1 may play a 
role in the negative regulation of cell motility 
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• the RT-PCR results revealed that, at least in the MDA-MB-157 line, knocking 
down WT1 triggers a partial EMT, characterised by the up-regulation of EMT 
drivers and mesenchymal markers (ZEB2, TNC, TGFB1) as well as the down-
regulation of the epithelial CTNNA1 
• the up-regulation of the mesenchymal marker TNC in the knockdown cells is 
observed in two different lines (MDA-MB-231, MDA-MB-157) and through both 
RNA-sequencing and RT-PCR 
• no significant difference was detected in colony forming assay, stem cell marker 
and apoptosis analyses  
• the analysis of cell cycle distribution showed a substantial increase of the G2/M 















In this project, an RNAi based gene knock-down strategy was used to investigate the 
functional role of WT1 in breast cancer. 
A lacZ control and two WT1 knockdown lentiviral vectors were successfully 
generated through Gateway cloning and then transduced in four different breast 
cancer cell lines (ZR75, MDA-MB-231, MDA-MB-157, HBL100). 
Unfortunately, the clones of the only luminal, ER+ line (ZR75) were lost due to 
infection; efficient WT1 down-regulation was achieved in the remaining three lines 
(all belonging to the basal, triple negative subgroup). Despite some similarities, 
discussed in more details in the following paragraphs, the three cell lines did not 
show identical responses to the loss of WT1 and these differences may be due to the 
cell genotypes or to the presence/absence of different WT1 co-factors in each cell 
line. 
 
4.6.1 WT1 loss triggers a partial EMT in MDA-MB-157 cells 
As shown by RT-PCR and migration assays, the loss of WT1 affects the 
epithelial/mesenchymal balance by pushing the cells towards a more mesenchymal 
and migratory phenotype: the knockdown clones, in fact, migrate faster than the 
controls and express higher levels of EMT drivers and mesenchymal markers (ZEB2, 
TNC, TGFB1). 
However, while TNC is up-regulated in both GIPZ and TRIPZ-transduced cells, the 
modulation of ZEB2 and TGFB1can only be observed in the inducible knockdown. 
This inconsistency is probably due to the fact that ZEB2 and TGFB1 activation 
occurs at the very beginning of the EMT process (reviewed in Kalluri and Weinberg 
2009).  
If, as it seems, WT1 loss triggers an EMT, the early stages of this induction could not 
be monitored in a constitutive system, at least not with the protocol used in this 
project: to achieve an optimal knockdown, the GIPZ-transduced cells were subjected 
to lengthy selection procedures (puromycin culture, FACS sorting) and several 
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weeks elapsed between the delivery of the lentiviral constructs and the analysis of the 
clones. This constitutive system is therefore ideal to study the long-term effects of 
WT1 knockdown on cell proliferation and migration, but the inducible vectors 
represent a better tool to investigate the immediate response of breast cancer cells.  
An additional advantage of the inducible system is the possibility to turn off RNAi 
production by simply stopping the administration of doxycycline: upon withdrawal 
of the drug, WT1 expression has been shown to increase, while the expression levels 
of ZEB2, TNC and TGFB1 go down to the pre-treatment levels, strengthening the 
correlation between WT1 and the epithelial/mesenchymal balance of breast cancer 
cells. 
Nevertheless, all the data gathered so far suggest that the EMT triggered in the 
knockdown clones is only partial: firstly, the changes in gene expression are limited 
to very few transcripts; secondly, there is no major down-regulation of epithelial 
markers (which, however, could be due to the mesenchymal nature of the MDA-MB-
157 line, whose cells express very low levels of epithelial genes to begin with). 
Lastly, and more importantly, EMT has been reported to affect several characteristics 
of cancer cells, including their cancer stem-cell properties, cell proliferation, 
migration and resistance to apoptosis induction (Mani, Guo et al. 2008, Morel, 
Lievre et al. 2008, Xie, Ji et al. 2014); since only a migratory phenotype could be 
observed in the knockdown cells, the loss of WT1 does not seem sufficient to induce 
a full-fledged EMT. 
Additional experiments, some of which are being performed at the time of writing, 
will help to better characterise this potential new role of WT1 as a regulator of the 
epithelial/mesenchymal balance in breast cancer.  
In particular, it would be important to: 




• perform migration assays on MDA-MB-231 cells, transduce them with the 
inducible constructs and see if the results obtained with MDA-MB-157 cells are 
replicated  
• knock down WT1 in more epithelial cell lines (BT20, T47D) and investigate 
whether a full/partial EMT is induced 
• perform tail vein injections in NOD/SCID mice to assess if the metastatic potential 
of the breast cancer cells is affected by the loss of WT1. 
 
4.6.2 TNC as a potential WT1 target 
In our study, the mesenchymal marker Tenascin-C (TNC) appears significantly up-
regulated in both MDA-MB-157 and MDA-MB-231 knockdown cells. 
TNC is an extracellular matrix glycoprotein which is strongly expressed during 
embryonic development, wound healing and in cancer (reviewed in Jones and Jones 
2000). Its expression in breast carcinoma is particularly evident at the invasive front 
of the tumour, where EMT is supposed to occur, and correlates with more aggressive 
lung metastasis as well as poorer survival (Jahkola, Toivonen et al. 1996, Jahkola, 
Toivonen et al. 1998, Oskarsson, Acharyya et al. 2011). Also, breast cancer cells 
supplemented with TNC have been reported to show EMT-like changes and faster 
migration (Nagaharu, Zhang et al. 2011). 
These findings would suggest that TNC up-regulation may be responsible for the 
phenotype observed in the WT1 knockdown cells. In order to verify this hypothesis, 
at least two additional experiments should be performed: first, the TNC levels need to 
be analysed through Western blot to confirm protein up-regulation; then, double 
knockdown cells (for both WT1 and TNC) should be subjected to migration assays, to 
assess if, and to which extent, the loss of TNC can rescue the phenotype. 
Since TNC upregulation was observed in the knockdown cells of two different lines 
(MDA-MB-231, MDA-MB-157), through different techniques (RNA-sequencing, 
RT-PCR) and in both constitutive and inducible systems, there is strong 
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circumstantial evidence suggesting that WT1 is involved in the regulation of TNC 
expression.  
WT1 could regulate TNC expression in either a direct or indirect way: in the 
inducible knockdown cells, significant up-regulation could be detected at the earliest 
time-point analysed (after only three days of doxycycline treatment), suggesting that 
TNC may be a direct WT1 target; in order to verify this theory, ChIP analysis should 
be performed on the breast cancer cells. Alternatively, WT1 regulation could be 
indirect and maybe act via VEGF; this growth factor is in fact an established WT1 
target (Hanson et al. 2008, McCarty et al. 2011) and is likely upstream of TNC 
(Calvo, Catena et al. 2008). 
 
4.6.3 Possible WT1 role in the regulation of neuronal genes 
and nc-RNAs 
The RNA-sequencing analysis of WT1 knockdown breast cancer cells has revealed 
that the modulated genes are unexpectedly enriched in neuronal genes and nc-RNAs. 
Several neuronal genes involved in axon guidance have been recently reported to 
play a role in cancer progression, mainly affecting tumour angiogenesis and cell 
migration. Among these genes, semaphorins are probably the most important: the 
SEMA family includes eight different classes of secreted and membrane-bound 
proteins, some of which can promote tumour progression, while others can inhibit it 
(reviewed in Tamagnone 2012, Rehman and Tamagnone 2013). 
Our RNA-sequencing analysis identified SEMA3D and SEMA5A as downregulated in 
the MDA-MB-157 knockdown cells: the former is usually considered as a tumour 
suppressive semaphorin and is down-regulated in high-grade gliomas (Karayan-
Tapon, Wager et al. 2008); the latter has been shown to promote cell migration in 
pancreatic cancer but to have the opposite effect in gliomas (Sadanandam, Varney et 
al. 2010, Li, Law et al. 2012). 
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These two genes may play a role in the phenotype observed in the WT1 knockdown 
cells, however, before further speculations, RT-PCR should be performed to validate 
the RNA-sequencing results. 
The presence of nc-RNAs among the modulated genes is somewhat less surprising, 
given that WT1 is known to play a role in RNA metabolism (reviewed in Hohenstein 
and Hastie 2006).   
The nc-RNAs identified through RNA-sequencing include the microRNA LET7 and 
the long nc-RNA XIST, respectively up and down-regulated in the WT1 knockdown 
cells. The LET7 family members have been reported to negatively regulate RAS 
oncogenes and are therefore considered tumour suppressors (Johnson, Grosshans et 
al. 2005); XIST, on the other hand, is the main mediator of X chromosome 
inactivation (reviewed in Plath, Mlynarczyk-Evans et al. 2002). 
A possible WT1 role in the regulation of nc-RNAs is in line with the results obtained 
by other members of our lab: RNA IP experiments have demonstrated that several 
nc-RNAs interact with the Wt1 protein and there is strong evidence for a role of WT1 
in microRNA processing (Ruthrothaselvi Bharathavikru, personal communication). 
In particular, the loss of WT1 in E14 and M15 cells seems to have different effects 
on LET7, depending on the maturity of the transcript: while the pre-miR is 
upregulated, the expression levels of the mature miR are much lower in the WT1 
knockdown than in control cells (Ruthrothaselvi Bharathavikru, personal 
communication). 
Since our RNA-sequencing analysis did not distinguish between pre-miR and mature 
miR, specific RT-PCR assays should be performed on the breast cancer cells to 
investigate the expression levels of LET7 at different stages of processing.   
 
4.6.4 The effect of WT1 loss on proliferation 
In our experiments, knocking down WT1 did not seem to have a significant impact 
on cell growth: no major differences were detected in colony forming assays or cell 
158 
 
cycle analyses, where only MDA-MB-231 cells transduced with the 1490 construct 
showed a block in G2/M. 
These findings are in sharp contrast with what reported by Zapata-Benavides, who 
observed significant growth inhibition and cyclin D1 reduction in transient WT1 
knockdown cells; this phenotype occurred in the vast majority of the cell lines used 
in the study, but not in MDA-MB-231 cells (Zapata-Benavides et al. 2002). 
This discrepancy can be due to several factors:  
• with the exception of MDA-MB-231 cells, the two studies relied on different breast 
cancer cell lines 
• Zapata-Benavides used a transient knockdown and analysed the cells after a 72-
hour incubation with antisense oligonucleotides, whereas in our study several weeks 
elapsed between the delivery of the constitutive constructs and the analysis of the 
clones; during this time, if the loss of WT1 did decrease cell growth, the low-
expressing WT1 cells would be disadvantaged and cells characterised by reduced 
knockdown levels/growth inhibition could be selected. This explanation, however, 
cannot be applied to the inducible constructs, which represent a closer system to 
what was used in the older study and yet did not cause any change in proliferation. 
• our lentiviral constructs target the zinc finger region of WT1 (and consequently all 
its different isoforms), while the antisense oligonucleotides used by Zapata-
Benavides are directed against the translation initiation site in exon 1 and therefore 
cannot knockdown the truncated WT1 variants. 
All in all, uncertainty remains over a potential WT1 role in the proliferation of breast 
cancer cells; in order to provide a definitive answer, one crucial experiment could be 






4.7 Concluding remarks 
The results described in this chapter seem to be more supportive of the tumour-
suppressor rather than the oncogene hypothesis: upon WT1 loss, no major changes 
are observed in terms of proliferation or apoptosis, however, the knockdown cells 
undergo a partial EMT, which is usually associated with a more aggressive 
phenotype. 
This finding is in agreement with the in silico analysis illustrated in the previous 
chapter, which suggested that the lack of WT1 in breast cancer samples may be 
associated with a more mesenchymal phenotype. On the other hand, these results are 
in stark contrast with what reported by Miyoshi, who found a correlation between 
high WT1 expression and poor prognosis in breast cancer patients (Miyoshi et al. 
2002). 
The reasons for this divergence are still unclear, but the analysis of larger cohorts of 













Chapter 5: Characterisation of a breast cancer 




Over the last two decades, genetically engineered mice have been extensively used to 
study different aspects of breast cancer biology, from tumour initiation to potential 
therapeutic options. 
Several models of this malignancy have been generated, relying on mammary-
specific or mammary-selective promoters such as MMTV, WAP and K14; depending 
on the experimental model, these promoters have been combined with the transgenic 
overexpression of oncogenes (Erbb2, Myc, Ccnd1) or the targeted ablation of tumour 
suppressor genes (Trp53, Brca1, Pten) (reviewed in Cardiff, Moghanaki et al. 2000, 
Borowsky 2011).  
Given the extreme heterogeneity of breast cancer and the differences between human 
and mouse mammary physiology, it would be impossible for the mouse models to 
recapitulate all the aspects of the human disease: comparative pathology, for 
example, has shown that the overall histology is quite different and that fibrosis and 
inflammation are far more common in human tumours than in the mouse 
counterparts; moreover, the metastases of the murine models are almost exclusively 
limited to the lungs and do not include sites like liver, bone and brain, which are 
often affected in breast cancer patients (Cardiff, Anver et al. 2000, reviewed in 
Vargo-Gogola and Rosen 2007). 
Despite these differences, the mouse models can reproduce several aspects of human 
breast cancer, including the molecular features of specific subtypes (Herschkowitz, 
Simin et al. 2007), and represent an invaluable tool to investigate this disease. 
As mentioned in chapter 1, a considerable amount of data suggests a potential role 
for WT1 in breast cancer; most of these studies, however, are based on in vitro 
experiments (Zapata-Benavides et al. 2002, Zhang et al. 2003, Burwell et al. 2007, 
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Wang et al. 2008), with the in vivo work usually being limited to xenografts or the 
analysis of WT1 expression in breast cancer patients (Miyoshi et al. 2002, Zhang et 
al. 2003, Wang et al. 2008).  
In order to gain a better understanding on this subject, it would be extremely useful 
to exploit the potential of breast cancer mouse models, where WT1 could be knocked 
out and the effects of its loss could be assessed within an in vivo context.  
 
5.1.1 Aim 
The aims of the experiments described in this chapter were: 
• to develop a mouse model of breast cancer with a mammary-specific Wt1 
conditional knockout 
• to analyse the consequences of Wt1 loss in this model, paying particular attention to 
the size and the epithelial/mesenchymal balance of the tumours. 
 
5.1.2 Experimental approach 
Our group had already generated a Wt1 conditional mouse, in which Exon 1 is 
flanked by LoxP sites and can therefore be deleted through Cre-mediated 
recombination (Martinez-Estrada et al. 2010).  
In this study, the conditional Wt1 knockout mice were crossed to the C3(1)/Tag 
breast cancer model (Maroulakou, Anver et al. 1994) and a C3(1)-driven 
doxycycline-inducible Cre (the same C3-Cre line used for the experiments described 
in chapter 2) (Figure 5.1).  
In the C3(1)/Tag system, tumour formation is induced by the expression of the 
simian virus 40 large tumour antigen, which binds and inactivates the tumour 





Figure 5.1 Generation of a breast cancer model with a mammary-specific Wt1 conditional 
knockout. 
The conditional Wt1 knockout mice were crossed to the C3(1)/Tag breast cancer and a C3(1)-driven 
doxycycline-inducible Cre line. 
 
The C3(1) gene, encoding the C3 subunit of the Prostatic Steroid Binding 
Protein (PSBP), is expressed in both prostate and mammary glands: since the SV40 
Tag is regulated by the C3(1) promoter, its expression is targeted to the epithelium of 
both organs, driving the development of prostate tumours in male mice and 
mammary tumours in females (Maroulakou et al. 1994).  
Unlike the vast majority of breast cancer models, which rely on the MMTV or WAP 
promoters, this system does not require hormone treatment or pregnancy to induce 
tumour formation and is therefore considered a more faithful representation of the 
human disease (Green, Shibata et al. 2000, Holzer, MacDougall et al. 2003). 
From a histological point of view, the lesions observed in this model resemble the 
human ductal carcinoma in situ and evolve quite rapidly: at about 8 weeks of age, the 
mice show atypia of the mammary ductal epithelium, which soon becomes 
intraepithelial neoplasia and by 16 weeks of age all the animals have developed an 
invasive carcinoma (Green et al. 2000). 
By crossing this model to the conditional mice and the inducible Cre line, we have 
obtained a breast cancer model in which Wt1 deletion can be spatially and temporally 
regulated through the administration of doxycycline: in this study, the drug was 
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added to the drinking water for 5 consecutive weeks (from the third to the eight after 
birth) and this timeframe allowed us to knockout Wt1 in the SV40 Tag-positive 
population before any cellular transformation takes place. 
 
5.1.3 Breeding scheme 
Before the start of my PhD, triple heterozygous mice (Cre+/- Wt1co/+ Tag+/-) were 
backcrossed for 6 generations to an FVB background, where a more severe and 
earlier onset mammary phenotype can be achieved (Maroulakou et al. 1994; Peter 
Hohenstein, personal communication).  
In order to facilitate the backcrossing, we used a speed-congenic protocol following 
384 polymorphic markers, after which only the regions around Wt1 and the Cre 
insertion were still on their original background and the mice could be considered 
congenics FVB. 
After 6 generations, triple heterozygous males and homozygous conditional females, 
all on congenic FVB background, were inter-crossed to generate experimental 
animals (Figure 5.2A). From these crosses we obtained Cre+ Wt1co/co Tag+ mice 
(which should develop mammary tumours with Cre-mediated Wt1 loss) and Cre- 
Wt1co/co Tag+ mice (whose tumours retain Wt1 expression). 
At a later point during the PhD, given the increasing number of reports on the off-
target and toxic effects of Cre recombinase (Schmidt et al. 2000, Loonstra et al. 
2001, Semprini et al. 2007, Huh et al. 2010), we decided to add a Cre control group 
to the study; these Cre+ Wt1+/+ Tag+ mice, which do not carry the conditional allele, 
were obtained by crossing Cre and Tag double heterozygous mice (Figure 5.2B).  As 
all models were on congenic FVB background, it was possible to directly compare 





Figure 5.2 Breeding schemes used to obtain the experimental animals. 
Triple heterozygous males and homozygous conditional females were inter-crossed to generate 
control and knockout experimental animals (A); the Cre control group was obtained by crossing Cre 
and Tag double heterozygous mice (B).   
 
As a whole, three groups of experimental animals were generated and they will be 
addressed with the following terminology: 
CONTROL – Cre-negative Wt1co/co Tag-positive 
KNOCKOUT – Cre-positive Wt1co/co Tag-positive 










5.2 Characterisation of the Wt1 knockout mammary 
tumours 
As previously mentioned, the three groups of experimental animals were dosed with 
doxycycline for 5 consecutive weeks (from the third to the eight after birth) to induce 
the Cre-mediated Wt1 knockout. 
All the mice were examined daily and a record of the tumour onset time was kept for 
each animal; before the malignancy could cause clear signs of pain or distress, the 
mice were culled and tumour samples were collected for both immunohistochemistry 
and gene expression analysis, while the main organs were fixed for metastasis 
screening. 
Full characterisation of the tumour samples was undertaken and included: 
• assessment of the Wt1 knockout through different techniques   
• comparison of the tumour onset time in the different groups    
• histopathological examination 
• RT-PCR and immunohistochemistry analysis of EMT markers. 
 
5.2.1 Assessing Wt1 knockout  
The knockout efficiency was examined at DNA, RNA and protein level through 
different techniques. 
Firstly, a three primer PCR was conducted on the genomic DNA of the tumours: in 
order to detect the loss of exon 1, the assay was designed with a common forward 
primer (F2) and two reverse primers (R1, downstream of the 3' loxP site, and R4, in 
the region between the loxP sites) (Figure 5.3).  
Secondly, Wt1 mRNA levels were assessed through RT-PCR, using primers that 
target the zinc-finger domain (exon 7/8) and can therefore amplify all the known 
isoforms; lastly, immunohistochemistry was performed on tumour sections using the 
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C19 polyclonal antibody from Santa Cruz, which recognises the last 19 residues of 
the forth Zinc finger. 
 
 
Figure 5.3 Scheme of the three primer PCR used to assess the Cre-mediated loss of Wt1 exon 1. 
A) Wildtype Wt1 allele B) Conditional Wt1 allele C) Recombined conditional Wt1 allele. (The FRT 
site is a remainder of the neo selectable marker used for targeting and removed by Flp expression, see 
Martinez-Estrada et al. 2010). 
 
On a completely wild type allele, the three primer PCR assay can only give a 300 nt 
F2/R4 fragment, since a hypothetical F2/R1 product would be 2000 nt and therefore 
too large to amplify under the assay conditions. Similarly, the conditional allele 
before recombination will only give a 327 nt F2/R4 fragment, as the F2/R1 
combination would be 2110 nt long; upon Cre-mediated loss of exon 1, the binding 
sequence for primer R4 is lost, but primer R1 becomes close enough to F2 to give an 
amplification product of 420 nt.  
As expected, the control tumours only show the conditional band at 327 nt, while all 
the knockout tumours display the recombined band at 420 nt; however, the shorter 
327 fragment can also be observed in some of the knockout samples, suggesting that 
the Cre is not active in all the tumour cells (a representative gel is shown in Figure 
5.4).  
The presence of both conditional and recombined bands is most likely due to the fact 
that this model relies on an epithelial Cre: as described in chapter 2, Wt1 expression 
in the mammary gland occurs in different cell types, including myoepithelial, 
endothelial and luminal epithelial cells; upon doxycycline administration, Cre-
mediated recombination takes place in the epithelial compartment, but not in the 
myoepithelial and endothelial cells, which have un-recombined conditional alleles 







Figure 5.4 Representative gel image showing the products of the three primer PCR assay in 
control and knockout tumours. 
 
The RT-PCR revealed that Wt1 mRNA expression is quite low and extremely 
variable, with just four out of ten control tumours showing relatively high Wt1 levels 
(indicated by the red stars in Figure 5.5); moreover, within the knockout group, only 
eight samples have lower Wt1 expression than the controls (indicated by the black 
stars).  
The fact that some knockout tumours have expression levels comparable to the high-
Wt1 controls may be due to the presence of “escapee cells”: these tumours may in 
fact arise from cells in which the Cre is not completely active and if the expression of 
Wt1 confers an advantage, this subpopulation could then outgrow the low-Wt1 
expressing cells. 
The immunohistochemistry performed on the tumour sections revealed that most 
myoepithelial and endothelial cells stain heavily for WT1 in both control and 
knockout samples, while the epithelial cells that form the bulk of the tumour show 
less intense staining (Figure 5.6); even though immunohistochemistry cannot be 
considered as a quantitative method, no major difference could be observed in the 
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Figure 5.5 Quantitative RT-PCR for Wt1 mRNA expression (exon 7/8) in the C3(1)Cre Tag 
tumours. 
Data points represent the relative expression, error bars represent the standard deviation of three 
technical replicates. Red stars indicate the high-Wt1 expressing controls, black stars indicate the low-
Wt1 expressing knockouts. 
 
Overall, there is no conclusive evidence demonstrating the loss of Wt1 in the 
knockout tumours and the lack of a reliable antibody for Western blot further 
complicates the investigation.  
Nonetheless, all the samples were thoroughly examined and the comparison between 
the controls and the putative knockouts was performed in two different ways: first 
considering all the samples (n=10 CTR, n=16 KO), then narrowing down the groups 
according to the RT-PCR results and including only the high-Wt1 expressing controls 
(n=4) and the low-Wt1 expressing knockouts (n=8). 
⃰    ⃰  
 ⃰ 
* * * * * 
* * *  










Figure 5.6 WT1 immunohistochemistry of C3(1)Cre Tag tumours. 
Images of representative control and knockout samples are shown: the tumour stroma (ST),   
myoepithelial and endothelial cells stain heavily for WT1 in both control and knockout samples, while 
the epithelial cells that form the tumour bulk (TB) show less intense staining.  






















5.2.2 Comparing the tumour onset time 
In order to keep a precise record of the tumour onset time, all C3(1)Cre Tag mice 
were examined and palpated daily to detect the presence of mammary tumors.  
Kaplan-Meier curves were calculated by plotting the percentage of tumour-free 
animals as a function of time for each of the three experimental groups: the tumor 
latency in the putative knockout animals did not differ significantly from either the 
control or the Cre control mice and similar results were obtained when the analysis 
was repeated including only the high-Wt1 expressing controls and the low-Wt1 
expressing knockouts (Figure 5.7).  
 
 
Figure 5.7 Kaplan-Meier curves relative to the C3(1)Cre Tag animals. 
The curves plot the percentage of tumour-free animals as a function of time, with time zero indicating 
the time each mouse was born; the analysis includes all the C3(1)Cre Tag tumours (top) or only the 
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5.2.3 Histopathological analysis 
All the samples were analysed by J. Bailey, Specialist in European Veterinary 
Pathology, and Dr. M. Diaz (Queen’s Medical Research Institute, The University of 
Edinburgh), following the recommendations resulting from the Annapolis meeting 
on the mammary pathology of genetically engineered mice (Cardiff et al. 2000). 
The histopathological study compared the tumour number, size, grade and cell 
morphology of the three experimental groups: when the statistical analysis was 
performed on all the samples (n=10 CTR, n=16 KO), the only significant difference 
was observed in the size of the malignances; the knockout tumours resulted smaller 
than the controls, but there was no statistically significant difference between the 
knockouts and the Cre controls, suggesting that this phenotype may not be due to the 
loss of Wt1 but to the expression of Cre (Figure 5.8). 
When the analysis was repeated including only the high-Wt1 expressing controls and 
the low-Wt1 expressing knockouts, the difference in tumour size lost its significance, 
but the knockout tumours showed a significant decrease in spindaloid cells; 
unfortunately, the cell morphology of the Cre controls has not yet been examined 
(Figure 5.8). 
In terms of metastasis screening, only one knockout and one control animal 
presented secondary tumours, respectively to the lung and the mammary lymph 
nodes; given the very low metastatic potential showed by this model, it is impossible 
to determine whether the loss of Wt1 has any effect on the dissemination of cancer 
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Figure 5.8 Graph summary of the histopathological analysis carried out on the C3(1)Cre Tag 
tumours. 
The analysis included all the samples (top) or a selection based on the RT-PCR results (bottom) (** 





















5.2.4 EMT markers analysis 
As mentioned in chapter 1, there is some evidence suggesting that WT1 may play a 
role in the induction of cancer-related EMT, while the experiments described in the 
previous chapter show that the WT1 knockdown cells undergo a partial EMT.  
In order to investigate whether the epithelial/mesenchymal balance of the tumours is 
somehow affected by the loss of Wt1, the expression of several markers was 
examined through RT-PCR and immunohistochemistry.  
The mRNA levels of EMT drivers (Snai1, Snai2, Zeb1, Zeb2, Twist1), epithelial 
(Cdh1, Ctnna1, Ctnnd1) and mesenchymal markers (Cdh2, Fn1, Vim) were analysed 
in the high-Wt1 controls and the low-Wt1 knockouts: the RT-PCR results showed 
that the expression levels in the tumours are quite variable and no statistically 
significant difference could be observed between the two experimental groups 
(Figure 5.9, 5.10, 5.11). 
Similarly, the immunohistochemistry performed with antibodies against SNAIL, 
TWIST1, ZEB2 and VIMENTIN did not detect any major difference between the 
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Figure 5.9 Quantitative RT-PCR of EMT drivers in the C3(1)Cre Tag tumours. 
Data points represent the relative expression of the gene, error bars represent the standard deviation of 
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Figure 5.10 Quantitative RT-PCR of epithelial markers in the C3(1)Cre Tag tumours. 
Data points represent the relative expression of the gene, error bars represent the standard deviation of 
the biological replicates indicated in brackets.  
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Figure 5.11 Quantitative RT-PCR of mesenchymal markers in the C3(1)Cre Tag tumours. 
Data points represent the relative expression of the gene, error bars represent the standard deviation of 







Figure 5.12 Immunohistochemistry of EMT markers in C3(1)Cre Tag tumours. 
Images of representative control and knockout samples are shown; no significant differences are 






















5.2.5 Additional experiments 
As mentioned in paragraph 5.2.1, the fact that some knockout tumours have 
relatively high Wt1 levels may be due to the presence of escapee cells and two 
different strategies have been adopted to address this issue. 
Firstly, primary cultures were established from control and knockout tumours 
developed in mice which had not received any doxycycline treatment; after one week 
of cell propagation, doxycycline was added daily to the culture media at a 
concentration of 2µg/ml, in the hope that a direct in vitro sub-ministration would 
give rise to a more homogeneous population of Wt1 knockout cells. 
RT-PCR showed that only three of the five primary cultures analysed were positive 
for Wt1 and when detectable, the expression levels were extremely low (with relative 
expression values < 3x10-5). The administration of doxycycline to the knockout 
tumours seemed to reduce Wt1 mRNA in sample #362 and increase it in #371 
(Figure 5.13), but the expression levels were so low that the results cannot be 
considered reliable and the only conclusion that can be drawn from this experiment is 
that Wt1 expression in the primary cultures is almost undetectable. 
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Figure 5.13 Quantitative RT-PCR for Wt1 mRNA expression (exon7/8) in the primary cultures 
of C3(1)Cre Tag tumours. 
Data points represent the relative expression, error bars represent the standard deviation of three 
technical replicates.  
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Secondly, we aimed to cross the conditional Wt1 knockout mice to the MMTV-NIC 
breast cancer model, where tumour formation is driven by an activated version of 
Her2 (Neu) under the control of the mouse mammary tumour virus promoter 
(Schade, Rao et al. 2009).  
As shown in Figure 5.14, the presence of an internal ribosome entry sequence 
between the cDNA of Her2 and Cre ensures that they are both expressed within the 
same mammary epithelial cell; using this model would prevent the formation of 
escapee cells because every tumour cell will express similar levels of Cre 
recombinase, leading to a more homogeneous knockout of Wt1. 
 
 
Figure 5.14 Scheme of the MMTV-NIC mouse model of breast cancer. 
In the MMTV-NIC breast cancer model, tumour formation is driven by an activated version of Her2 
(Neu) under the control of the mouse mammary tumour virus promoter; the presence of an internal 
ribosome entry sequence between the cDNA of Her2 and Cre ensures that they are both expressed 
within the same mammary epithelial cell. 
 
Before crossing this model to the conditional Wt1 knockout mice, RT-PCR was 
performed on two different MMTV-NIC tumours to assess the Wt1 mRNA levels; 
unfortunately, both samples resulted negative for Wt1 expression (data not shown) 








The experiments described in this chapter were not particularly successful, in that a 
breast cancer model with a Wt1 conditional knockout was generated, but we could 
not unequivocally demonstrate that the knockout was efficient. 
Additional experiments may help in this respect (eg. WT1 immunofluorescence, 
Western Blot with a reliable antibody), however, it is probably not worthwhile 
investigating this model any further.  
Even if definitive evidence of Wt1 loss was to be gathered, no major differences have 
been observed between the control and knockout tumours: the size reduction may in 
fact be caused by the expression of Cre recombinase and the decrease of spindle 
cells, while interesting, is unlikely to reflect any real shift in the 
epithelial/mesenchymal balance of the tumours, since both RT-PCR and 
immunohistochemistry have shown no difference in the EMT markers. 
The main limitation of this work lies in the use of an epithelial Cre when, at least in 
the C3(1)Tag animals, Wt1 is mainly expressed in the myoepithelial and endothelial 
compartments. This expression pattern was first observed through 
immunohistochemistry and later confirmed by the extremely low Wt1 levels of the 
primary cultures, where the myoepithelial and endothelial cells are not propagated as 
efficiently as the epithelial cancer cells. 
The fact that the epithelial cells of C3(1)Tag tumours have very low levels of Wt1 
and that no expression whatsoever was found in the MMTV-NIC model would 
suggest that Wt1 is unlikely to play any major role in breast cancer.  
However, microarray studies have detected significant Wt1 expression in different 
breast cancer models, such as WAP-Int3, WAP-Myc, MMTV-Wnt1 and DMBA-
induced (Herschkowitz et al. 2007).  
Future studies may be planned to cross these models with the Wt1 conditional mice, 
but preliminary experiments are required to determine if the truncated transcript we 
have detected in several human breast cancer lines (see chapter 3) is also present in 
the mouse mammary tumours; should this be the case, the current conditional (in 
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which exon 1 is flanked by LoxP sites) would not be able to target the intron 5 
isoform and a new one should be generated. 
Wt1 expression in the myoepithelial compartment is particularly fascinating because 
these cells have been shown to exhibit many anti-tumorigenic properties (reviewed in 
Adriance, Inman et al. 2005); a study on PABC, an extremely aggressive form of 
breast cancer which is associated with pregnancy, has revealed that the myoepithelial 
expression of Wt1 is drastically reduced in these tumours, suggesting that it may be 
important for the tumour-suppressing activity of the myoepithelial cells (Xu, Wang 
et al. 2009). 
Future projects should consider the generation of endothelial- and myoepithelial- 
specific knockout models, in order to investigate the exact role played by Wt1 in 
these two cell types. 
All in all, this part of the project was not very informative, but it helped in the 
identification of new experiments which could improve our understanding of Wt1 












Chapter 6: General discussion 
 
6.1 Summary of results  
The major findings described in this thesis can be summarised as follows:  
• WT1 expression in the mammary gland is mainly restricted to MaSCs, 
myoepithelial and endothelial cells 
• Wt1 knockout glands form a higher number of side branches during pregnancy, 
which could be due to an alteration of the epithelial-mesenchymal balance at the 
branching sites  
• WT1 expression in breast cancer is not particularly high, neither in vivo nor in vitro, 
and is lower than in the healthy mammary tissue 
• bioinformatics analysis showed that the WT1-positive tumours mainly belong to the  
luminal/ER-positive subtypes and express lower levels of mesenchymal markers than 
the WT1-negative tumours 
• the truncated transcript starting from intron 5 is likely to be a tumour-specific WT1 
isoform 








6.2 A new perspective on WT1 role in normal and 
neoplastic mammary cells 
At the start of this PhD, WT1 role in breast cancer was still unclear and had been 
described as oncogenic by some authors (Loeb et al. 2001, Miyoshi et al. 2002, 
Zapata-Benavides et al. 2002), as tumour suppressing by others (Huang et al. 1997, 
Laux et al. 1999, Cheng et al. 2001, Zhang et al. 2003, Wang & Wang 2008). 
Based on the analysis of WT1 knockdown breast cancer cells, this work seems to rule 
out a potential oncogenic function and be more in line with the tumour suppressor 
hypothesis: upon WT1 loss, in fact, the knockdown cells undergo a partial EMT, 
which is usually associated with a more aggressive phenotype characterised by 
increased tumour invasion and metastasis (Trimboli et al. 2008, Brabletz et al. 2005, 
Prall 2007, Micalizzi et al. 2010, Iwatsuki et al. 2010).  
However, since no major changes are observed in terms of proliferation or apoptosis, 
the label of tumour suppressor is probably not the most appropriate in this context. 
As pointed out by Huff, applying this whole oncogene/tumour suppressor 
terminology to WT1 can be quite misleading: these categories are usually used for 
genes such as receptor tyrosine kinases or p53, which have a direct role in the 
regulation of cell proliferation, cell cycle and apoptosis, while WT1 effect on these 
pathways, when detectable, is mainly indirect (Huff 2011).  
At the current state of research, the WT1 role supported by the strongest 
experimental evidence is that of regulator of the epithelial-mesenchymal balance 
during embryonic development (reviewed in Hohenstein and Hastie 2006).  
Several of our findings would indicate a similar function for WT1 in the adult 
mammary gland, in both healthy and neoplastic cells: firstly, the increased number of 
pregnancy-associated side branches observed in the Wt1 knockout glands may be due 
to an alteration of the epithelial-mesenchymal balance at the branching sites. 
Secondly, WT1-negative breast cancer show higher levels of mesenchymal markers 
than the WT1-positive and, lastly, the loss of WT1 induces a partial EMT in breast 
cancer cells.  
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Taken together, these results depict a scenario where WT1 expression is important to 
maintain the epithelial state of the mammary cells: with its loss, there is a shift 
towards a more mesenchymal phenotype, which leads to increased branching in the 
healthy gland and increased motility in the cancer cells. 
Further investigation is still required to validate this theory, in particular to verify 
any alteration of the epithelial-mesenchymal balance at the branching sites of the 
Wt1 knockout glands and to assess if the mesenchymal/migratory phenotype 
observed in the knockdown cells is translated in increased tumour invasion and 
metastasis in vivo. 
However, if confirmed by the additional experiments, this theory would provide a 
brand new perspective on WT1 role in the mammary tissue as well as identify a 
potential therapeutic target to tackle the migration of breast cancer cells. 
 
 
6.3 Future work 
As mentioned in the discussion sections of the respective chapters, several 
experiments have already been planned to address the outstanding questions 
emerging form this thesis, first and foremost how does the loss of WT1 cause the in 
vivo and in vitro phenotypes just described? 
 
6.3.1 Further investigation on WT1 contribution to mammary 
gland development  
One of the most interesting findings in this thesis was the observation that Wt1 is 
expressed in the MaSCs, however, there was insufficient time to establish which cell 
lineage originates from the WT1-positive stem cells. 
This question will be addressed using a lineage-tracing approach similar to the one 
adopted by Van Keymeulen, who first determined the fate of the K14- and K8- 
188 
 
expressing progenitor cells in the mammary gland (Van Keymeulen, Rocha et al. 
2011). 
The first step is to generate an inducible Cre line under the transcriptional regulation 
of the Wt1 promoter, by using either a CreERT2 (already available in our laboratory) 
or a TetO-Cre (Van Keymeulen et al. 2011), and then cross it with the 
Rosa26RYFP/YFP reporter strain.  
Depending on the Cre line adopted, tamoxifen injections or doxycycline 
administration can be used to follow the fate of the WT1-expressing stem cells 
throughout the different phases of the mammary cycle. 
Given the similarities between MaSCs and embryonic mammary cells (Wansbury, 
Mackay et al. 2011), future experiments should also assess if WT1 is expressed in 
the mammary structures of the embryo. 
Considering some key features of the developing gland, a positive result would not 
be totally unexpected: both the mammary primordial epithelium and the associated 
mesenchyme have been shown to express EMT-associated genes (Wansbury et al. 
2011), while the Wnt/β-catenin signalling pathway, which is essential for the 
embryonic gland (reviewed in Incassati, Chandramouli et al. 2010), is negatively 
regulated by Wt1 in the developing testis (Chang, Gao et al. 2008). 
 
6.3.2 Further investigation on the branching phenotype 
One of the main outstanding questions concerns the molecular mechanisms behind 
the branching phenotype observed in the knockout gland.  
At least two different hypotheses could be formulated to explain the increased 
number of branches: if WT1 expression in the mammary gland is indeed important to 
keep the cells in an epithelial state, for example by repressing Snai1, its loss may 
shift the cell towards a mesenchymal phenotype, which is more permissive for 
branching formation (Micalizzi et al. 2010, Nisticò et al. 2012, Kouros-Mehr & 
Werb 2006, Lee et al. 2011). Alternatively, WT1 may directly repress the expression 
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of important branching promoters such as Wnt4 and Agr2 (Brisken et al. 2000, 
Verma et al. 2012); with the deletion of Wt1, both genes would be upregulated, 
leading to the formation of more branches. 
Significantly, Wnt4 and Snai1 are established Wt1 targets in the developing heart and 
kidney (Essafi et al. 2011, Martinez-Estrada et al. 2009), and our RNA-sequencing 
experiment has identified Agr2 as a potential WT1 target in breast cancer cells. 
ChIP will be required to verify if WT1 directly regulates the transcription of these 
genes in the mammary tissue or if alternative mechanisms should be investigated. 
 
6.3.3 Further investigation on the role of WT1 in breast 
cancer 
A major disappointment during this project was the failure to generate a robust Wt1 
knockout mouse model of breast cancer. 
Our C3(1)Tag animals developed mammary tumours with low and extremely 
variable levels of Wt1 mRNA and, since the protein expression could not be assessed 
due to the lack of a reliable WT1 antibody for Western blot, we could not 
demonstrate the efficiency of the knockout. 
The main limitation of this work, however, lies in the use of an epithelial Cre when, 
at least in the C3(1)Tag tumours, Wt1 is mainly expressed in the myoepithelial and 
endothelial compartments.  
Since an in vivo approach remains the best option to investigate WT1 role in breast 
cancer, future work should aim at the generation of a new knockout model and take 
into account the issues encountered in this project: firstly, by choosing a breast 
cancer model where significant Wt1 expression has already been observed, such as 
WAP-Int3, WAP-Myc and MMTV-Wnt1 (Herschkowitz et al. 2007); secondly, by 
using either a Cre line that can target both the epithelial and myoepithelial 
populations (eg. MMTV-Cre, Wagner et al. 2001) or endothelial-specific lines such 
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as VE-Cadherin and Tie-1 Cre (Gustafsson, Brakebusch et al. 2001, Alva, Zovein et 
al. 2006). 
Besides the generation of the new knockout model, additional experiments should 
also be performed to further investigate the results obtained from the in vitro work. 
The analysis of breast cancer cells transduced with lentiviral RNAi constructs has 
revealed that the loss of WT1 triggers a partial EMT: the knockdown cells migrate 
faster than the controls and express higher levels of mesenchymal markers and EMT 
drivers (TNC, ZEB2, TGFB1), suggesting that WT1 may negatively regulate these 
transcripts. 
Interestingly, WT1 has already been shown to repress TGFB1 expression in kidney 
cells (Dey et al. 1994), while breast cancer cells supplemented with TNC display 
EMT-like changes and faster migration (Nagaharu et al. 2011). 
ChIP experiments will determine if WT1 directly regulates these genes in breast 
cancer or if, alternatively, the overexpression observed in the knockdown cells is due 
to downstream indirect effects. 
Independently of the molecular mechanism causing this partial EMT, it needs to be 
established if the mesenchymal/migratory phenotype observed in vitro is somehow 
translated in vivo: in this optic, tail vein injections in NOD/SCID mice are currently 
being performed to assess if the metastatic potential of the knockdown cells is 









6.4 Concluding remarks 
Using a conditional knockout model, this study has established that Wt1 is not 
necessary for the post-natal development of the mammary gland, but may have a role 
in the regulation of the side branching that occurs during pregnancy: the Wt1 
knockout glands form a higher number of branches, which could be due to an 
alteration of the epithelial-mesenchymal balance. 
Moreover, in silico and in vitro analyses have showed that the loss of WT1 pushes 
breast cancer cells towards a more mesenchymal and migratory phenotype. 
As a whole, the results of this thesis suggest that WT1 expression may be important 
to maintain the epithelial state of the mammary tissue, identifying WT1 as a potential 
















Chapter 7: Materials and methods 
 
7.1 Cell culture 
7.1.1 Tumour cell lines 
All the cancer cell lines used in this study were cultured in the appropriate medium 
(Table 7.1) supplemented with 10% FCS, glutamine, penicillin/streptomycin and 
maintained at standard cell culture conditions (37°C, 5% CO2 in humidified 
incubator).  
Tet System Approved FBS (Clontech 631106) was used in the culture media of 
TRIPZ-transduced cells, to ensure that the inducible regulation of the system was not 
altered by the presence tetracycline-derived contaminants. 
 
7.1.2 Primary cultures from C3TCo mammary tumours 
The tumours were minced with a McIlwain Tissue Chopper  (kindly provided by Dr. 
Patel) and then transferred to a digestion mix consisting of 5ml serum-free DMEM 
(Sigma D567) supplemented with 20mg Collagenase B (Roche 11088815001), 20 
mg Dispase (Gibco 17105-041) and 2mg Hyaluronidase (Sigma H3884).                 
This was incubated for 2 hours at 37oC in a shaking incubator and then centrifuged 
for 5 minutes at 1200 rpm; after discarding the supernatant, 5 ml trypsin were added 
to the pelleted cells and incubated for 5 minutes at 37 oC while shaking. 
Trypsin was inactivated by washing the cells in 10 ml PBS/ 2% FCS; the pellet was 
then resuspended in 2 ml PBS/2% FCS containing 5µl DNase (Ambion AM1907) 
and incubate at room temperature for 2 minutes. After dissociating the pellet with a 
p1000 pipette, the cells were washed in 10 ml PBS/2% FCS, passed through a 70 µm 





Table 7.1 List of cancer cell lines used in the project. 
CELL LINE  MEDIUM CELL TYPE 
MDA MB 231 DMEM (Sigma D5796) Breast cancer cells (ER-, PR-, HER2-) 
MDA MB 157 (a kind 
gift from D. Sproul) 
DMEM (Sigma D5796) Breast cancer cells (ER-, PR-, HER2-) 
MDA MB 435S DMEM (Sigma D5796) Breast cancer cells (ER-, PR-, HER2-) 
MDA MB 453 DMEM (Sigma D5796) Breast cancer cells (ER-, PR-, HER2-) 
HBL100 DMEM (Sigma D5796) Breast cancer cells (ER-, PR-, HER2-) 
MCF7  DMEM (Sigma D5796) Breast cancer cells (ER+, PR+, HER2-) 
BT549 (a kind gift 
from D. Sproul) 
RPMI (Sigma R0883) Breast cancer cells (ER-, PR-, HER2-) 
BT474 RPMI (Sigma R0883) Breast cancer cells (ER+, PR+ , HER2+) 
BT20  DMEM (Sigma D5796) Breast cancer cells (ER-, PR-, HER2-) 
SKBR3 DMEM (Sigma D5796) Breast cancer cells (ER-, PR-, HER2+) 
T47D DMEM (Sigma D5796) Breast cancer cells (ER+, PR+, HER2-) 
ZR75 DMEM (Sigma D5796) Breast cancer cells (ER+, PR-, HER2-) 
HS578T DMEM (Sigma D5796) Breast cancer cells (ER-, PR-, HER2-) 








The cells were cultured in DMEM/10% FCS supplemented with 1% 
penicillin/streptomycin and maintained at standard cell culture conditions (37°C, 5% 
CO2 in humidified incubator). 
Cre recombinase was induced by the addiction of Doxycycline Hyclate (Sigma 
D9891) to the culture medium. Doxycycline was added to PBS, filter sterilised and 
kept in the dark at 4 °C until use; the appropriate volume was added daily to the 
culture media to obtain a final concentration of 2 µg/ml. 
 
7.1.3 Cell migration assay 
Migration assays were performed on 24well plates containing culture inserts made of 
biocompatible silicone material (Ibidi 80209). 
For each experiment, cells were washed with PBS, trypsinised and resuspended in 
culture medium to obtain a concentration of 5 x 105 cells/ml; 70 µl of this cell 
suspension were applied to each well of the insert and incubated under normal 
conditions for 24 hours to allow cell attachment. 
The next day, the inserts were removed using sterile tweezers and 2ml of medium 
were added to each well; the plate was then placed in the incubation chamber of a 
Nikon TiE (Perfect Focus System) microscope and three areas per well were 
randomly identified. 
Time-lapse photography was carried out by taking serial images across each area 
every 30 minutes, over 40 hours. 
Quantification of cell migration was performed using ImageJ. 
 
7.1.4 Colony-forming assay  
Sphere formation was induced by culturing the cancer cells in suspension in serum-
free medium (DMEM-F12 + GlutaMAX-I, Life Technologies 10565-018) 
supplemented with B27 (1:50, Life Technologies 12587-010), 20 ng/mL EGF (R&D 
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236-EG-01M), 0.4% bovine serum albumin (Sigma A9576-50ML), 4 μg/mL insulin 
(Sigma I3536-100MG) (Yu et al. 2007).  
To quantify colony formation, cells were plated at a density of 1,000 cells per well in 
96-well plates coated with poly(2-hydroxyethyl metacrylate) to prevent cell 
attachment to the surface (Sigma P3932-10G); cells were diluted in supplemented 
serum-free media containing 1% methylcellulose (Sigma M0512-100G) and the 
number of colonies > 75 μm in diameter was counted after 11 days (Wellner et al. 
2009). 
 
7.1.5 FACS analysis 
Flow cytometer analysis and sorting were performed by Dr. Freyer, MRC HGU Core 
Technical Services, using a FACSAriaII Flow Cytometer (Becton Dickinson) 
equipped with violet (404 nm), blue (488 nm), green (532 nm), yellow (561 nm) and 
red (635 nm) lasers. Data were analysed using FlowJo software. 
 
7.1.5.1 Sorting of GFP-positive cells 
Cells were washed with PBS, trypsinised and resuspended in 1ml PBS/0.5% FCS; 
for all the experiments, GFP-negative control cells were used to set the parameters 
for the FACS gating. 
Cells were sorted either in RNAlater (for RNA extraction) or FCS (for further 
expansion in culture). 
 
7.1.5.2 Cancer stem cell markers analysis 
For each sample, 1x106 cells were resuspended in 100µl PBS/5% FCS and incubated 
in the antibody dilution shown in Table 7.2. 
The GIPZ-transduced cells were incubated with CD44-APC and CD24-PE 
antibodies, the TRIPZ-transduced cells with CD44-APC and CD24-FITC (the RFP 
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of the TRIPZ vectors would have overlapped with the signal of the PE-conjugated 
antibody). 
After a 15 minute incubation on ice, the cells were washed twice in PBS, 
resuspended in 100µl PBS/5% FCS and analysed. 
 
Table 7.2 Antibodies used for CSCs analysis 
Antibody (clone) Species Source (Cat. no.) Dilution 
CD44-APC (G44-26) Mouse BD Pharmingen (559942)  2.5 µl/100 µl 
CD24-PE (ML5) Mouse BD Pharmingen (555428)  10 µl/100 µl 
CD24-FITC (ML5) Mouse BD Pharmingen (555427) 1.25 µl/100 µl 
 
 
7.1.5.3 Apoptosis and cell cycle analysis 
The Annexin V Apoptosis Detection Kit APC (eBioscience 88-8007) was used 
according to the manufacturer’s instructions: cells were washed once and 
resuspended at a concentration of 1x106 cells/ml in the binding buffer provided with 
the kit; 5 µl of the APC-conjugated antibody were added to 100 µl of cell suspension 
and incubated for 15 minutes at room temperature. 
After one wash, cells were resupended in 200 µl of binding buffer and 1 µg/ml DAPI 
(Sigma D9542) was added immediately before the analysis. 
For cell cycle analysis, cells were trypsinised and resuspended in 1.2 ml PBS; 3ml 
ice cold 95% ethanol were then added dropwise while vortexing, to obtain a final 
70% ethanol solution where the cells were incubated for 30 minutes. 
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After two washes in PBS, cells were pelleted and counted; 1x106 cells were 
resuspended in 1ml DAPI stain solution (0.1% Triton-X, 1 µg/ml DAPI in PBS) and 





















7.2 RNA interference 
 
7.2.1 Lentiviral packaging 
A trans-lentiviral packaging system was used to transduce the micro-RNA constructs 
shown in Table 7.3.  
 










The system was developed in the human embryonic kidney cell line SODK3 
(Cockrell et al. 2006), which expresses GFP and all trans-lentivirus packaging 
proteins from a Tet-Off system. The cells were cultured in DMEM-HIGH (Sigma 
51435C) supplemented with 10% FCS, glutamine, penicillin / streptomycin, 1μg/ml 
puromycin, 600μg/ml neomycin and 1 μg/ml doxycycline (which was used to inhibit 
the expression of the lentiviral proteins and prevent toxic effects).  
To activate the packaging system, the cells were washed twice with PBS, split 1:3 
and grown for 3 days without doxycycline; on the fourth day the cells were FACS 
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sorted for GFP expression and the brightest 15% was plated on a 0.001% poly-L-
Lysine coated plate and grown overnight without doxycycline. 
The following day, the SODK3 cells were transfected with the lentiviral vectors 
using FuGene6 (Roche 11815091001) as per manufacturer’s instructions; the 
medium, containing 5mM sodium butyrate (Sigma B5887) but no doxycycline, was 
changed at 12 and 36 hours post-tranfection. 72 hours after the last medium change, 
the virus-containing supernatants were harvested and centrifuged for 20 minutes at 
4°C to pellet cell debris. Virus stocks were aliquoted and stored at -80° C. 
 
7.2.2 Transduction of target cells 
The human breast cancer cells were plated in full medium in 6-well plates (3 x 105 
cells per well) and cultured overnight; the following day the medium was removed, 
the cells incubated with 0.5 ml viral supernatant + 0.5 ml OPTIMEM (Life 
Technologies 31985062) + 4μg/ml polybrene (Sigma 107689) and after 6 hours 1 ml 
of full medium was added to each well.  
From day 2 post-transduction cells were maintained on selective media, using 











7.3 Mouse lines 
 
7.3.1 MMTV-Co & MMTV-Cre 
Our group had already generated a Wt1 conditional mouse (referred to as Wt1co/co), in 
which the exon 1 is flanked by LoxP sites and can therefore be deleted through Cre-
mediated recombination (Martinez-Estrada et al. 2010). Crossbreeding with the 
MMTV-Cre mouse (a kind gift from Dr. Brunton, CRUK, The University of 
Edinburgh) generated the MMTV-Co line; in order to check for the off-target and 
toxic effects of Cre recombinase, MMTV-Cre mice were used in the Cre control 
group. 
 
7.3.2 C3-Co & C3-Cre  
Wt1co/co mice were crossed with a C3(1)-driven doxycycline-inducible Cre (a kind 
gift from Dr. Els Robanus, LUMC, Leiden, The Netherlands), creating the C3-Co 
line, while C3-Cre mice provided the respective Cre control. 
 
7.3.3 C3-CreR26RYFP/YFP 
The C3-Cre mouse was crossed with a Rosa26YFP/YFP reporter to obtain YFP 
expression at the sites of Cre-mediated DNA recombination. 
 
7.3.4 C3-Rosa26:Wt1-KTS 
The C3(1)-driven doxycycline-inducible Cre was crossed with a Wt1-KTS knockin 
(a kind gift from Dr. Schedl), which requires Cre activity to trigger the ectopic 





7.3.5 C3TCo & C3TCre  
Wt1co/co mice were crossed with the C3(1)/Tag breast cancer model (Maroulakou et 
al. 1994) and the C3(1)-driven doxycycline-inducible Cre, creating the C3TCo line. 
The Cre control group (C3TCre) was generated by crossing the Wt1co/co mice only to 
the C3(1)/Tag line. 
 
7.3.6 MMTV-NIC 
This additional model of breast cancer was a kind gift from Dr. Brunton (CRUK, The 

















7.4 Animal experiments 
 
7.4.1 Animal husbandry 
The MMTV-Co, MMTV-Cre, C3-Rosa26:Wt1-KTS and MMTV-NIC mice were 
housed in the Biomedical Research Facility (BRF, University of Edinburgh), while 
the C3-Co, C3-Cre, C3-CreR26RYFP/YFP, C3TCo and C3TCre lines were in the 
Transgenic Unit (TGU, MRC Human Genetics Unit). 
In both facilities, the animals were housed with food and water ad libitum, in a 12h 
light/12h dark cycle and at constant temperature (21°C) and humidity (53%).  
Animal care, plug-checking and culling of the experimental animals were performed 
by TGU & BRF staff, while matings set-up and earclipping were carried out by our 
technician Anna Thornburn. 
The females used in the gestation studies were checked every morning for the 
presence of vaginal plugs and, if positive, were staged at 0.5dpc (days post-coital). 
 
7.4.2 Doxycycline administration 
Doxycycline Hyclate (Sigma D9891) was dissolved in the drinking water at a 
concentration of 2 mg/ml; the bottles were wrapped in foil and sealed with black tape 
to keep the doxycyline solution in the dark. 
 
7.4.3 Tissue harvesting 
The experimental animals were usually culled by cervical dislocation; CO2 inhalation 
had to be used for few mice which had developed big mammary tumours in 
proximity to the neck. 
The mammary glands were dissected by performing a midline inverted Y incision 
into the skin, pulling away the skin flaps from the peritoneum and then gently 
excising the mammary tissue. The glands to be used for histological analysis were 
203 
 
fixed in 4% PFA, those for RNA extraction were either stored in RNAlater (Ambion 
AM7021) or snap frozen, the glands for wholemount analysis were spread out on a 
microscope slide and fixed in Carnoy’s solution (24ml ethanol, 12ml chloroform, 
4ml acetic acid, made up fresh each time). 
The mammary tumours, liver, brain and lungs were either fixed in 4% PFA, stored in 
RNAlater (Ambion AM7021) or snap frozen, depending on their further application.  
 
7.4.4 FACS analysis of mammary cells 
Mammary cell suspensions were prepared in the Smalley laboratory (European 
Cancer Stem Cell Research Institute, Cardiff) from the fourth mammary fat pad of 
10-week-old virgin female FVB mice. 
After removing the intra-mammary lymph nodes, the fat pads were minced with a 
McIlwain Tissue Chopper and transferred to a digestion mix of serum free Leibowitz 
L15 medium (Gibco 11415-049) supplemented with 3 mg/ml collagenase A (Roche 
11 088 793 001) and 1.5 mg/ml trypsin. 
The tissue was incubated for 1 hour at 37oC in a shaking incubator, washed in  
Leibowitz L15/10% FCS and then incubated with red blood cell lysis buffer (Sigma 
R7757) for 5 minutes. After a second wash in Leibowitz L15/10% FCS, the cells 
were plated in DMEM/10% FCS for 1 hour at 37oC, to allow the contaminating 
fibroblasts to attach to the tissue culture plastic; the epithelial cells were then 
removed, washed in Versene and incubated for 15 minutes in Joklik’s Modification 
of Minimal Essential Medium (Sigma M8028) to obtain a single cell suspension. 
After a 2 minute-incubation at 37 oC in 2 ml trypsin, 1 μg/ml DNase I (Sigma 9003-
98-9) was added to the cells and a p1000 pipette was used to gently break up any 
clumps; trypsin was deactivated by incubating the samples for 5 minutes at 37oC in 
an equal volume of Leibowitz L15/10% FCS. 
After filtrating the cell suspension through a 40 µm strainer, the resulting single cells 
were resuspended in fresh Leibowitz L15/10% FCS and counted. 
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Mammary cell suspensions at 106 cells/ml were incubated at 4C with the antibodies 
listed in Table 7.4; after 45 minutes, the samples were washed in L15/10% FCS and 
resuspended in L15/10% FCS/0.01% DAPI. 
 
Table 7.4 Antibodies used for the sorting of mammary cells. 
ANTIBODY (clone) SPECIES MANUFACTURER (Cat. #) DILUTION 
CD24-FITC (M1/69) Rat BD Biosicences (553261) 1.25 µl/ml 
CD45-PE-Cy7 (30-F11) Rat BD Biosciences (552848) 5.0  µl/ml 
CD49f-PE-Cy5 (GoH3) Rat BD Biosciences (551129) 5.0  µl/ml 
c-Kit-PE (2B8) Rat BD Biosciences (553355) 5.0  µl/ml 
Sca-1-APC (D7) Rat Insight Biotechnology (108112) 5.0  µl/ml 
 
 
Cells were sorted on a FACSAria (Becton Dickenson) equipped with violet (404 
nm), blue (488 nm), green (532 nm), yellow (561 nm) and red (635 nm) lasers. The 
analysis was performed with the FACSDiva software using single stained samples as 











7.5 Microbiology and cloning 
 
7.5.1 Culture methods 
Aseptic technique was used to carry out all the microbiology work, including the 
preparation of agar plates and glycerol stocks, the set-up of liquid and dry cultures 
and the picking and growing of single colonies. 
Agar plates for bacterial selection were prepared by melting agar at low power in the 
microwave, cooling to 55°C and adding the appropriate antibiotics (kanamycin 50 
μg/ml, ampicillin 50 μg/ml, spectinomycin 100 μg/ml, chloramphenicol 12.5 μg/ml). 
Liquid cultures were grown in LB broth with antibiotic selection and vigorous 
shaking (220rpm), while dry cultures grown on Agar plates were incubated overnight 
in inverted position. The bacterial cultures of Library Efficiency DH5α competent 
cells (Life Technologies 18263-012) were grown at 37˚C, MAX Efficiency Stbl2 
competent cells (Life Technologies 10268-019) and One Shot ccdB survival cells 
(Life Technologies 11828-029) at 30˚C. 
Plasmid mini-prep were obtained by inoculating a single colony in 5ml LB 
containing the appropriate antibiotic; the starter culture was then incubated overnight 
with vigorous shaking.  
For plasmid maxi-prep, 500 µl of an overnight starter culture were added to 400ml 
LB and grown for 16-20hours with the appropriate antibiotic selection and vigorous 
shaking. 
 
7.5.2 Bacterial transformation 




After thawing the bacteria on ice, 1-10ng DNA was added to the cells; following a 
30 minute incubation on ice, the vial was heat-shocked at 42°C for 45 seconds and 
then immediately placed on ice for 2 minutes. 
After adding 250μl warmed SOC media, the cells were incubated at 30ºC for one 
hour, then plated on agar plates and grown overnight at 30ºC with the appropriate 
antibiotic selection. 
 
7.5.3 Reagents prepared by the MRC HGU Core Scientific 
Services 
LB (Luria-Bertani) Broth: 
• 10g Tryptone 
• 5g yeast extract 
• 10g NaCl 
• 1g Glucose 
• Made up to 1000ml in dH20 and autoclaved 
 
Agar: 
• 1l LB broth 
• 15g Agar 
• Autoclaved 
 
7.5.4 Gateway cloning 




In each BP reaction, 150ng of pDONR-221 were combined with 150ng of the 
pcDNA6.2 vectors containing the lacZ or WT1 miR; after adding 2 µl BP clonase 
(Life Technologies 11789-020) and TE to a total volume of 8 µl, the reaction was left 
overnight at room temperature.  
In the LR reactions, 150ng of the destination vector (pGIPZ-DEST or pTRIPZ-
DEST) were combined with 150ng of the entry clone (lacZ, WT1-1407 or WT1-
1490); after adding 2 µl LR clonase (Life Technologies 11791-043) and TE to a total 




















7.6.1 Isolation of genomic DNA for genotyping of 
experimental animals 
Ear clips were collected at weaning for both identification and genotyping purposes. 
After adding 75μl of 25mM NaOH, 0.2mM EDTA to each sample and incubating at 
95˚C for 30 minutes, the solution was neutralized with 75μl of 40mM Tris.HCl, 
vortexed and stored at -20˚C. 
 
7.6.2 Isolation of genomic DNA from mammary tumours 
preserved in RNAlater 
The DNA extraction from tissues stored in RNAlater was performed following the 
manufacturer’s recommendations. 
The tumours were finely minced and placed in a 2ml tube containing 1.5 ml 
digestion buffer (60 mM Tris pH 8.0, 100 mM EDTA, 0.5% SDS, 500μg/ml 
proteinase K).  
After a 24 hour incubation at 55°C, each sample was divided in two aliquots and 
equal volumes of 50:50 phenol/chloroform (Sigma P2069) were added; following 2 
minutes of mixing by inversion, the samples were centrifuged for 10 minutes, then 
the resulting upper phase was aspirated with a wide-bore pipette tip and moved to a 
new tube.  
The phenol/chloroform extraction was performed other 2 times, followed by a final 
choloroform extraction; after adding 1/10 volume 3M sodium acetate (pH 5.2) and 1 
volume 95% ethanol, the samples were mixed by inversion and centrifuged for ten 
minutes. 
The resulting DNA pellet was washed in 70% ethanol for 10 minutes, air-dried and 




7.6.3 Isolation of plasmid DNA 
The DNA from plasmid mini- and maxi-prep was extracted using the Plasmid Mini 
Kit (Qiagen 27106) and the Plasmid MaxiKit (Qiagen 12163) respectively, as per 
manufacturer’s instructions. 
 
7.6.4 Measuring DNA concentration 
DNA concentration was measured using a Nanodrop 2000 Spectrophotometer 
(Thermo Scientific). 
 
7.6.5 Digestion with restriction enzymes 
The digestion of DNA with restriction enzymes was performed according to the 
supplier’s recommendations; both single and double digests were carried out using 
the most suitable buffer and the appropriate incubation temperature (Table 7.5). 
 






DraI   SuRE/Cut M 37°C Roche 
EcoRV SuRE/Cut B 37°C Roche 
EcoRI SuRE/Cut H 37°C Roche 
XbaI SuRE/Cut H 37°C Roche 
HindIII SuRE/Cut B 37°C Roche 
PvuII 2 37°C Neb 
EcoRI/XbaI SuRE/Cut H 37°C Roche 
NruI/BamHI SuRE/Cut B 37°C Roche 
 
 
7.6.6 DNA ligation, purification and precipitation 
DNA ligation was performed by combining appropriate quantities of DNA with T4 
DNA ligase (Roche 0716359001), the supplied buffer and dH2O for a total reaction 
volume of 30 µl; the ligation mix was left at 16°C overnight. 
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DNA was gel purified using QIAquick Gel Extraction Kit (Qiagen 28704). 
DNA precipitation was carried out mixing 1 volume of DNA with 1/10 volume 3M 
Sodium Acetate and 2.5 volumes cold 100% ethanol; after overnight incubation at -
20°C, the samples were centrifuged for 15 minutes at 4°C and the resulting DNA 
pellet was washed in 70% ethanol. After air-drying the pellet, DNA was resuspended 
in the appropriate volume of TE.  
 
7.6.7 PCR 
Polymerase chain reactions were performed using 0.2mM dNTPs (Life Technologies 
10297-018), 0.25 µM primers, Taq DNA Polymerase and the supplied buffer (Life 
Technologies 10342-053), 2.5 mM Mg2+ (Life Technologies), template DNA and 
dH20 for a total reaction volume of 20 µl. 
The primers, listed in Table 7.6, were designed with either Geneious Pro software or 
Primer 3 Programme (http://primer3.sourceforge.net/) 
 
Table 7.6 Primers used for genotyping 
GENOTYPING FORWARD PRIMER REVERSE PRIMER PCR  
Wt1  tgggttccaaccgtaccaaaga gggcttatctcctcccatgt Geno58 
Cre gcattaccggtcgagcaacgagtgatgag gagtgaacgaacctggtcgaaatcagtgcg Geno58 
Fabpi (internal 
control) 
tggacaggactggacctctgctttcctaga tagagctttgccacatcacaggtcattcag Geno58 
Rosa26 ggcttaaaggctaacctgatgtg ggagcgggagaaatggatatg MTRosa 








PCR Program - Geno58 
Temperature (°C)     Incubation Time     
94                             2 min 
94                             15 sec 
58                             30 sec  (35 cycles) 
72                             1 min 
72                             5 min 
4                               10 min 
 
PCR Program - MTRosa 
Temperature (°C)     Incubation Time     
94                             4 min 
94                             1 min 
60                             45 sec  (30 cycles) 
72                             1 min 
72                             10 sec 







7.6.8 Gel electrophoresis 
DNA fragments were separated by size using agarose gel electrophoresis.  
Depending on the size of the fragments to be separated, different percentages of 
agarose (weight/volume) were used for each gel; the required amount of agarose was 
dissolved in TBE and melted in a microwave. 
After cooling, ethidium bromide (BDH) was added to obtain a final concentration of 
50μg/100ml; the agarose was then poured into a tray and left to set. 
The DNA samples were mixed with loading Buffer (3ml Glycerol, 6ml dH2O, 1ml 
10X TBE, bromophenol blue [Sigma B0126]) and loaded onto the gel with either a 
1kb (Neb N3232L) or a 100bp (Neb N3231L) DNA ladder; after filling the 
electrophoresis tank with 1X TBE, electrophoresis was run 70-150V. 
Gels were visualized under UV illumination and photographed with a BioDocit 












RNA work was carried out taking all the necessary precautions to avoid 
contamination with RNases: surfaces and equipment were cleaned with 70% ethanol 
and the RNsase-inactivating agent RNAZap (Ambion AM9782), filter tips and 
RNase-free reagents were reserved solely for RNA work, all samples were kept on 
ice during the experiments to minimise the activity of endogenous RNases and stored 
at -80˚C. 
 
7.7.1 RNA isolation 
RNA was extracted with the following Qiagen kits as per manufacturer’s 
instructions: the RNeasy Mini Kit (Qiagen 74104) was used for cell lines, mouse 
mammary tumours and human breast cancer samples, the RNeasy Lipid Tissue Mini 
Kit (Qiagen 74804) for the healthy mouse mammary glands. 
Before the extraction, glands and tumours were finely minced, added to a 2ml tube 
containing 1ml Qiazol Lysis Reagent + two stainless steel beads (Qiagen 69989) and 
homogenized for 10 minutes using a Tissue Lyser LT (Qiagen 85600). 
DNAse digestion was performed during the extraction (Qiagen 79254), RNA was 
eluted in 30μl RNase-free water and its concentration measured using a Nanodrop 
2000 Spectrophotometer (Thermo Scientific). 
 
7.7.2 Retrotranscription 
cDNA was synthesized from 2 µg total RNA using AMV reverse transcriptase 
(Roche 11495062001) and oligo d(T) priming. 
For each reaction, the appropriate volume of RNA (made up to 12.5μl with RNAse 
free water) was added to a mix containing 4μl AMV Reverse Transcriptase 5x 
Reaction Buffer, 0.25μl RNAse inhibitor (Promega N2611), 1μl oligo d(T), 1.25μl 
RNase free dNTPs and 1μl AMV reverse transcriptase. 
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The samples were incubated at 48°C for 2 hours, then, the resulting cDNA was 
diluted in TE to a final concentration of 10ng/μl. 
 2μl of diluted cDNA was used per Real Time PCR reaction. 
 
7.7.3 Real Time PCR 
All the quantitative Real Time PCR experiments were performed on the Roche 
Lightcycler 480 system. 
Universal Probe Library probes and primers, shown in Table 7.7 and 7.9, were 
designed with the Universal Probe Library Assay Design Centre (Roche) and ordered 
from Roche and Sigma respectively. The assays used for ER, PR and HER2 (Table 
7.8) were based on previous publications (de Cremoux et al. 2002, 2003) and were 
supplied by IDT. 
All primers were shipped as lyophilized powders, rehydrated in TE to obtain a stock 
solution of 100μM and diluted to 20μM working solutions. 
Each reaction was carried out following the manufacturers’ instructions and using 
0.2μl forward primer (target gene), 0.2μl reverse primer (target gene), 0.2μl target 
probe, 0.2μl forward and reverse primers (reference gene), 0.2μl reference probe, 2 
μl RNAse free dH2O, 5μl Lightcycler Master Mix (Roche 04887301001) and 2μl 
cDNA.  
Relative expression for each target gene was quantified using a reference gene 
(GAPDH for mouse [Roche 05046211001], ACTB for human [Roche 
05046165001]). All the experiments were performed and analysed in triplicate using 






Table 7.7 Primers and UPL probes used for the human transcripts. 
TRANSCRIPT FORWARD PRIMER REVERSE PRIMER UPL PROBE # 
WT1 exon 7/exon 8  agctgtcccacttacagatgc ccttgaagtcacactggtatgg 4 
WT1 exon 1A agggctctgaggattgtgc agggctctgaggattgtgc  37 
WT1 intron 5 caacttgccgaggatgaaac acggtctaggtctcgctcag 59 
CDH1 tggaggaattcttgctttgc cgctctcctccgaagaaac 84 
CTNNA1 agacgatgcctcacagcac aagctcaaggggtccacaat 25 
CTNNA2 ggtgaaacttaactatgtagcagcaa ccatctcatcccgacagtg 17 
CTNND1 ccctcattttcattgttcagg ggcaaacacagttctctacaagc 29 
VIM aaagtgtggctgccaagaac agcctcagagaggtcagcaa 16 
FN1 caccacagccatctcacatt cttccaacggcctacagaat 39 
CDH2 gcacagtggccacctaca tgaaaggtttttatctctatcagacct 29 
ZEB1 gcggcatatggtgacaca ttgccacactctgtgcattt 68 
ZEB2 caagaggcgcaaacaagc aacctgtgtccactacattgtca 79 
SNAI1 gctgcaggactctaatccaga atctccggaggtgggatg 11 
SNAI2 acagcgaactggacacacat gatggggctgtatgctcct 73 
TWIST1 gggccggagacctagatg tttccaagaaaatctttggcata 50 
VTN accttaccctttgccagctc ctttctccggtgggaacc 23 
ACTA2 gcctgagggaaggtcctaac ctggagctgcttcacaggat 36 
CXCL1 catcgaaaagatgctgaacagt cttcaggaacagccaccagt 69 
TNC gaaggtggaggggtacagtg gaaggatctgccattgtggt 62 
KRT18 cctgctgtccgtgtccat ggaccggtagttggtgga 39 
MMP2 cggaaaagattgatgcggta tgctggctgagtagatccag 63 
MMP9 tcttccctggagacctgaga gccacccgagtgtaaccata 53 




Table 7.8 Primers and non-UPL probes used for the human transcripts. 
TRANSCRIPT FORWARD 
PRIMER 
REVERSE PRIMER PROBE 
ER agcacccagtgaagctact tgaggcacacaaactcct 6FAM -
tggctacatcatcggttccgca-
BHQ-2 












Table 7.9 Primers and UPL probes used for the mouse transcripts. 
TRANSCRIPT FORWARD PRIMER REVERSE PRIMER UPL PROBE # 
Wt1 exon 7/exon 8   caccaaaggagacacacagg gggaaaactttcgctgacaa 47 
Cdh1 atcctcgccctgctgatt accaccgttctcctccgta 18 
Ctnna1  ggaccatcgcagaccatt gcgatgcgctgaaggtag 62 
Ctnnd1 ctcaacggaccccaggat tcctcggtgtaggtttccac 92 
Vim  ccaaccttttcttccctgaa tgagtgggtgtcaaccagag 109 
Fn1  gatgccgatcagaagtttgg ggttgtgcagatctcctcgt 46 
Cdh2  gccatcatcgctatccttct ccgtttcatccataccacaaa 18 
Zeb1 gccagcagtcatgatgaaaa tatcacaatacgggcaggtg 48 
Zeb2 caagaggcgcaaacaagc tgcgtccactacgttgtcat 79 
Snai1 atccttggggcgtgtaagt tgaaccactgtgatccttgg 6 
Snai2 gtaaggtgtgcggcaagg tgcagtgagaacaggtataggg 1 




Total RNA was isolated and sent to GATC Biotech (Germany) for library 
preparation and sequencing on the Illumina HiSeq 2000 platform. 














7.8.1 Paraffin embedding 
Tissue harvesting was performed as described in paragraph 7.4.3; the mammary 
tumours, mammary glands, liver, brain and lungs were fixed in 4% PFA (Sigma 
158127-500G) overnight at 4°C. 
The next day, the samples were washed twice in PBS, taken through serial dilutions 
of ethanol (15minutes 25% ethanol, 15mins 50% ethanol, 15mins 75% ethanol) and 
then stored at 4°C in ethanol 70%.  
An automated TissueTekVIP 5 Jr machine was used to embed the samples in 
paraffin; the blocks were then sectioned with a microtome at 4μm and dried at 50ºC 
before staining. 
 
7.8.2 OCT media embedding 
The mammary glands of C3-CreR26RYFP/YFPmice were fixed in 4% PFA overnight at 
4°C. The next day, the samples were washed twice in PBS, dehydrated in PBS/5% 
sucrose for 45 minutes and then in PBS/20% sucrose until the gland sank.  
Tissue samples were placed in a cryomold, submerged in OCT media (Tissue-Tek 
25608-930) and stored at -80ºC. Sections were cut at 10μm using a cryostat. 
 
7.8.3 Mammary gland wholemounts 
Tissue harvesting was performed as described in paragraph 7.4.3; the ninth 
mammary gland was spread out on a microscope slide and fixed for 4 hours in 
Carnoy’s solution (24ml ethanol, 12ml chloroform, 4ml acetic acid, made up fresh 
each time). 
Samples were taken through decreasing ethanol solutions (15minutes 70% ethanol, 
15mins 50% ethanol, 15mins 25% ethanol), washed once in dH2O for 5 minutes and 
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then incubated overnight in carmine alum (StemCell Technologies 07070) at room 
temperature. 
The following day, the glands were dehydrated with sequential 15 minute washes in 
70, 95 and 100% ethanol, left to defat in xylene for at least 48 hours and then 
mounted under a cover slip. 
 
7.8.4 Staining 
All immunohistochemistry and immunofluorescence stainings were performed by 
Ruth Hamblin and Nancy Evans (SuRF, QMRI, The University of Edinburgh), using 
a Leica BOND machine and the antibodies listed in table 7.10. 
 
Table 7.10 Antibodies used for IHC and IF 
ANTIBODY  SPECIES MANUFACTURER 
(Cat. #) 
DILUTION PROTOCOL 
WT1-C19  Rabbit Santa Cruz (sc-192) 
IHC 1:5000 
IF 1:10000 
IHC Rabbit refine 
IF Tyramide 
ER Mouse Abcam (ab9269) 1:100 Impress MoM 
PR Rabbit Santa Cruz (sc-0538) 1:500 Rabbit refine 
HER2 Rabbit Dako (A0485) 1:1000 Rabbit refine 
SNAIL Goat Abcam (ab53519) 1:250 Impress anti goat 
TWIST Rabbit Abcam (ab49254) 1:200 Rabbit refine 
ZEB2 Rabbit Sigma (HPA027524) 1:250 Rabbit refine 
VIMENTIN Rabbit Cell Signalling (5741) 1:500 Rabbit refine 
 
 
Rabbit refine protocol: 
• Peroxide block (5mins) 
• Primary Ab (120mins) 
• Polymer (15mins) 
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• Dab (5mins) 
• Haematoxylin (5mins) 
 
Tyramide protocol: 
• H2O2 (1:10, 10mins) 
• Serum block (neat, 10mins) 
• Primary Ab (120mins) 
• HRP 2ndary (1:500, 30 mins) 
• Tyramide Amplification (1:50, 10mins) 
• DAPI counter stain (1:1000, 10mins) 
 
Impress MoM protocol: 
• Peroxide Block (5mins) 
• Rodent Block (30mins) (Abcam  Mouse on Mouse polymer IHC kit 
ab127055/GR84050-2) 
• Primary Ab (120mins) 
• HRP Polymer (30mins) (Abcam  Mouse on Mouse polymer IHC kit 
ab127055/GR84050-2) 
• Dab (5mins) 




Impress anti goat protocol: 
• Peroxide Block (5mins) 
• Normal horse serum block (20mins) (Vector ImmPRESS MP-7405 ) 
• Primary Ab (120mins) 
• HRP Polymer (30mins) (Vector ImmPRESS MP-7405 ) 
• Dab (5mins) 
















Slides were visualized using an Olympus Dotslide microscope (for brightfield) or a 
Zeiss Axioplan 2 microscope (for fluorescence). 
 
7.9.1 Quantification of mammary branching 
The analysis of the mammary branching was performed by Dr. Morrison and Dr. Del 
Pozo using ImageJ.  
For each wholemount, four different quadrants were randomly selected using the 
lymph node as a reference; the number of primary and secondary ductular branches 
were counted for each of the four quadrants. 
 
7.9.2 Staining score 
The ER and PR status of the first set of human breast cancer samples was determined 
using the Allred method, which combines the percentage of positive cells and the 











Frequently used websites include the UPL Assay Design Centre 
(http://lifescience.roche.com/shop/CategoryDisplay?catalogId=10001&tab=Assay+D
esign+Center&identifier=Universal+Probe+Library&langId=-1, used to design 
probes and primers for Real Time PCR experiments), the genome browser Ensembl 
(http://www.ensembl.org/index.html), the NCBI (http://www.ncbi.nlm.nih.gov/, 
mainly used to search for articles on PubMed), Galaxy (https://usegalaxy.org/) and 
Geneprof (http://www.geneprof.org/GeneProf/) for the analysis of the RNA-
sequencing data. 
 
7.11 Statistical methods 
Statistical analyses were performed using Excel and MiniTab.  
Unless stated otherwise, data are represented as mean value ± standard error of the 
mean (SEM); ANOVA and Student’s t test were carried out to compare the values 
obtained for the different experimental groups. Only p values < 0.05 were considered as 
statistically significant. 
 
7.12 Solutions prepared by the MRC HGU Core 
scientific services 
Phosphate Buffered Saline (PBS): 
• NaCl 8g 
• KCl 0.2g 
• Na2HPO4 1.44g 
• KH2PO4 0.24g 
• Dissolve in 800ml dH20 
• Adjust pH to 7.4 
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• Bring final volume to 1000ml with dH20 
Tris HCL: 
• Dissolve Tris (hydroxymethyl) aminomethane in sterile water 
• Adjust pH with HCl 
 
EDTA: 
• Dissolve ethyldiaminetetraacetic acid di-sodium salt in sterile water 
• Add solid NaOH to adjust pH to 8.0 
 
TE Buffer: 
• 10mM Tris.HCl (pH 7.5) 
• 1mM EDTA 
 
TBE Buffer (20x Stock): 
• Tris (hydroxymethyl) aminomethane 242g 
• Glacial acetic acid 57.1ml 
• 0.5M EDTA 100ml 
• Bring volume to 1000ml with dH2O 
 
Trypsin: 
• Tryspin 1:250 2g 
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• Phenol Red 5ml 
• Penicillin 0.06g 
• Streptomycin 0.13g 
• Make up to 1000ml in PBS 
• Adjust pH to 7.3 using NaHCO3 
 
Versene: 
• Dulbeccos Tablets 10 
• Sodium EDTA 0.4g 
• 0.2% Phenol Red 5ml 














List of the differentially expressed genes between WT1-high and WT1-low breast 
tumours (in silico analysis conducted by Dr Sims, chapter 3.4). 
  
GENE ID                                     FOLD CHANGE                GENE ID                      FOLD CHANGE  
ENSG00000184937 WT1 3.2627606 
ENSG00000166426 CRABP1 2.7068319 
ENSG00000170367 CST5 2.1108505 
ENSG00000198077 CYP2A7 1.8083495 
ENSG00000142973 cyp4b1 1.7070984 
ENSG00000198251 NA 1.6062471 
ENSG00000172379 ARNT2 1.5676866 
ENSG00000130707 ASS1 1.5491251 
ENSG00000183242 WIT1 1.4143376 
ENSG00000102466 FGF14 1.2896552 
ENSG00000196090 PTPRT 1.2555033 
ENSG00000158089 Galnt14 1.2441012 
ENSG00000109424 UCP1 1.1480072 
ENSG00000019505 Syt13 1.1262895 
ENSG00000092421 SEMA6A 1.0752181 
ENSG00000091831 Esr1 1.0664327 
ENSG00000091129 nrcam 1.0528864 
ENSG00000165973 Nell1 1.0384021 
ENSG00000187097 Entpd5 1.0375941 
ENSG00000106571 Gli3 1.0083115 
ENSG00000168502 KIAA0802 0.9821728 
ENSG00000152953 STK32B 0.978741 
ENSG00000204421 LY6G6C 0.9410021 
ENSG00000185652 NTF3 0.9143917 
ENSG00000120262 C6orf97 0.8868726 
ENSG00000130558 OLFM1 0.8800146 
ENSG00000173599 Pc 0.865724 
ENSG00000171444 MCC 0.8565602 
ENSG00000134873 CLDN10 0.8024998 
ENSG00000168032 entpd3 0.7836371 
ENSG00000006071 ABCC8 0.7770491 
ENSG00000158125 XDH 0.775519 
ENSG00000151090 thrB 0.7641556 
ENSG00000108852 MPP2 0.7602601 
ENSG00000197993 KEL 0.7476327 
ENSG00000140600 Furin 0.7404536 
ENSG00000151789 ZNF385D 0.7380647 
ENSG00000115844 Dlx2 0.7352178 
ENSG00000154645 CHODL 0.7317931 
ENSG00000004776 hspb6 0.7201727 
ENSG00000153802 TMPRSS11D 
0.7096169 
ENSG00000204539 CDSN 0.7075104 
ENSG00000214313 NA 0.7041051 
ENSG00000198183 PLUNC 0.7028216 
ENSG00000163218 PGLYRP4 0.7023318 
ENSG00000162365 CYP4A22 0.7015143 
ENSG00000144681 Stac 0.7003124 
ENSG00000118160 SLC8A2 0.6988419 
ENSG00000111181 SLC6A12 0.6890078 
ENSG00000182575 NXPH3 0.6875476 
ENSG00000148702 habp2 0.6858277 
ENSG00000140835 SH3GL3 0.6838867 
ENSG00000167531 LALBA 0.6823775 
ENSG00000124564 SLC17A3 0.675671 
ENSG00000140564 ST8SIA2 0.6716713 
ENSG00000005073 HOXA11 0.6711294 
ENSG00000115850 Lct 0.6701857 
ENSG00000180999 C1orf105   0.6677879 
ENSG00000198910 L1cam 0.6631864 
ENSG00000130988 rgn 0.6621441 
ENSG00000171847 FAM90A1 0.6502502 
ENSG00000187045 TMPRSS6 0.649691 
ENSG00000085465 Ovgp1 0.6493229 
ENSG00000169469 Sprr1b 0.6418517 
ENSG00000128310 GALR3 0.6403372 
ENSG00000118298 CA14 0.6402423 
ENSG00000111291 GPRC5D 0.639007 
ENSG00000139292 LGR5 0.6385381 
ENSG00000115194 SLC30A3 0.6378245 
ENSG00000172867 KRT2 0.6355214 
ENSG00000137440 FGFBP1 0.6344793 
ENSG00000187908 DMBT1 0.6324247 
ENSG00000073670 ADAM11 0.625735 
ENSG00000125462 C1orf61 0.6245103 
ENSG00000162631 Ntng1 0.621992 
ENSG00000118271 TTR 0.6206785 
ENSG00000187048 CYP4A11 0.6203746 
ENSG00000064309 cdon 0.6191863 
ENSG00000113262 GRM6 0.6141273 
ENSG00000100665 SERPINA4 0.6093785 
ENSG00000151655 ITIH2 0.6090731 
ENSG00000116218 NPHS2 0.608211 
ENSG00000122126 OCRL 0.6045666 
ENSG00000018236 Cntn1 0.6030904 
ENSG00000165061 ZMAT4 0.6023889 
ENSG00000139985 ADAM21P1 0.5983589 
ENSG00000006432 MAP3K9 0.5974899 
ENSG00000158485 CD1B 0.5966805 
ENSG00000176009 ASCL3 0.5933009 
ENSG00000163209 Sprr3 0.5928909 
ENSG00000120903 CHRNA2 0.5927368 
ENSG00000144671 SLC22A14 0.5917461 
ENSG00000105467 SYNGR4 0.5894936 
ENSG00000179097 HTR1F 0.5865926 
ENSG00000104833 Tubb4 0.5864432 
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ENSG00000130055 Gdpd2 0.5847233 
ENSG00000135454 B4GALNT1 0.5843271 
ENSG00000104499 Gml 0.5809121 
ENSG00000135222 CSN2 0.5791323 
ENSG00000135406 prpH 0.5728184 
ENSG00000132429 POPDC3 0.5714618 
ENSG00000112078 KCTD20 0.5705174 
ENSG00000104044 OCA2 0.56873 
ENSG00000166391 MOGAT2 0.5672148 
ENSG00000183150 GPR19 0.5650472 
ENSG00000113196 HAND1 0.5637788 
ENSG00000171936 OR10H3 0.5623491 
ENSG00000184029 DSCR4 0.5584929 
ENSG00000087237 cetp 0.5584765 
ENSG00000105219 CNTD2 0.5557165 
ENSG00000169903 TM4SF4 0.5554724 
ENSG00000171532 NEUROD2 0.5543291 
ENSG00000130226 Dpp6 0.5540548 
ENSG00000186704 PMS2L11 0.5519221 
ENSG00000107187 lhx3 0.5511107 
ENSG00000132563 reep2 0.5500818 
ENSG00000169213 RAB3B 0.5479504 
ENSG00000143858 Syt2 0.5464042 
ENSG00000160808 Myl3 0.545696 
ENSG00000147596 PRDM14 0.5438953 
ENSG00000169676 DRD5 0.5381932 
ENSG00000204248 Col11a2 0.5381378 
ENSG00000168830 HTR1E 0.5357975 
ENSG00000215904 NA 0.5335831 
ENSG00000196220 SRGAP3 0.5333425 
ENSG00000188822 Cnr2 0.5314116 
ENSG00000213988 ZNF253 0.5289593 
ENSG00000162188 GNG3 0.5286025 
ENSG00000127529 OR7C2 0.5281672 
ENSG00000168530 MYL1 0.5279375 
ENSG00000005206 SPPL2B 0.5261692 
ENSG00000187021 PNLIPRP1 0.5255608 
ENSG00000170290 Sln 0.5215829 
ENSG00000015592 stmn4 0.520911 
ENSG00000175175 PPM1E 0.5205844 
ENSG00000130948 HSD17B3 0.5189425 
ENSG00000034971 MYOC 0.5184033 
ENSG00000167780 Soat2 0.5175625 
ENSG00000204542 C6orf15 0.516592 
ENSG00000079393 DUSP13 0.5156491 
ENSG00000168124 OR1F1 0.5137901 
ENSG00000141013 chst4 0.5137043 
ENSG00000162706 CADM3 0.5133538 
ENSG00000112619 PRPH2 0.5124375 
ENSG00000080561 Mid2 0.5114128 
ENSG00000149054 ZNF215 0.5110592 
ENSG00000102001 Cacna1f 0.5108228 
ENSG00000163975 mfi2 0.5104852 
ENSG00000163207 IVL 0.5099288 
ENSG00000103313 MEFV 0.509625 
ENSG00000102904 TSNAXIP1 0.5091238 
ENSG00000147869 Cer1 0.5086131 
ENSG00000203492  0.5085052 
ENSG00000205250 e2f4 0.5033823 
ENSG00000102891 MT4 0.5027977 
ENSG00000175189 INHBC 0.5024616 
ENSG00000155886 SLC24A2 0.5016286 
ENSG00000186912 P2RY4 0.5013635 
ENSG00000151224 mat1a 0.4990712 
ENSG00000166863 TAC3 0.4984578 
ENSG00000138109 CYP2C9 0.4979917 
ENSG00000189108 IL1RAPL20.4970828 
ENSG00000135622 SEMA4F 0.4950161 
ENSG00000033627 ATP6V0A10.4948015 
ENSG00000006659 LGALS14 0.4947493 
ENSG00000156925 ZIC3 0.4942947 
ENSG00000169474 Sprr1a 0.4937908 
ENSG00000182389 CACNB4 0.4920932 
ENSG00000102021 Luzp4 0.4919696 
ENSG00000100350 FOXRED2 0.4914017 
ENSG00000125965 GDF5 0.4905979 
ENSG00000143171 RXRG 0.4902254 
ENSG00000171097 CCBL1 0.4888681 
ENSG00000164458 t 0.487567 
ENSG00000146013 GFRA3 0.4873821 
ENSG00000151014 CCRN4L 0.4872194 
ENSG00000128285 MCHR1 0.4869873 
ENSG00000113303 BTNL8 0.4868108 
ENSG00000058404 Camk2b 0.4864793 
ENSG00000196188 CTSE 0.4857468 
ENSG00000183454 GRIN2A 0.4852238 
ENSG00000111886 GABRR2 0.4851845 
ENSG00000135312 HTR1B 0.4850555 
ENSG00000187730 Gabrd 0.4829325 
ENSG00000184381 pla2g6 0.4824674 
ENSG00000101280 Angpt4 0.4823877 
ENSG00000156282 cldn17 0.4822584 
ENSG00000116726 PRAMEF12 0.4821422 
ENSG00000155087 ODF1 0.4818998 
ENSG00000189433 GJB4 0.4777173 
ENSG00000169955 ZNF747 0.4775547 
ENSG00000184933 OR6A2 0.4768006 
ENSG00000087903 rfx2 0.4764647 
ENSG00000172367 PDZD3 0.4758359 
ENSG00000171462 DLK2 0.4753419 
ENSG00000177143 cetn1 0.4738809 
ENSG00000158516 Cpa2 0.4729744 
ENSG00000010379 SLC6A13 0.4721155 
ENSG00000131080 EDA2R 0.4716156 
ENSG00000134007 ADAM20 0.4704574 
ENSG00000169884 wnt10b 0.4703993 
ENSG00000185823 C15orf2 0.4698561 
ENSG00000172179 PRL 0.4689865 
ENSG00000112462 OR5V1 0.4679678 
ENSG00000132016 C19orf570.4679112 
ENSG00000108947 Efnb3 0.4646418 
ENSG00000105642 KCNN1 0.4638032 
ENSG00000186115 CYP4F2 0.4619074 
ENSG00000183813 ccr4 0.4617819 
ENSG00000108753 HNF1B 0.4613426 
ENSG00000198049 AVPR1B 0.4613318 
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ENSG00000108878 CACNG1 0.4612877 
ENSG00000126500 FLRT1 0.4610802 
ENSG00000170454 Krt75 0.4605806 
ENSG00000062096 ARSF 0.4602484 
ENSG00000181418 DDN 0.4602249 
ENSG00000152595 MEPE 0.4602186 
ENSG00000105723 GSK3A 0.4597491 
ENSG00000056345 ITGB3 0.4583277 
ENSG00000105810 Cdk6 0.4580759 
ENSG00000039987 BEST2 0.4580435 
ENSG00000143839 REN 0.4575807 
ENSG00000105641 Slc5a5 0.4561921 
ENSG00000204956 PCDHGA1 0.4560402 
ENSG00000154917 rab6b 0.4557763 
ENSG00000164776 phkg1 0.4554574 
ENSG00000116176 TPSG1 0.4552406 
ENSG00000019485 PRDM11 0.4547918 
ENSG00000143627 PKLR 0.4546033 
ENSG00000197273 GUCA2A 0.4529973 
ENSG00000138784 FLJ20184  0.4528865 
ENSG00000109132 Phox2b 0.4528522 
ENSG00000140522 Cyp1a2 0.4527531 
ENSG00000182257 C22orf26   0.4526219 
ENSG00000184984 Chrm5 0.4516589 
ENSG00000183230 CTNNA3 0.4505777 
ENSG00000106328 FSCN3 0.4505311 
ENSG00000171403 KRT9 0.4500175 
ENSG00000166930 Ms4a5 0.4494258 
ENSG00000152254 G6PC2 0.4492261 
ENSG00000070808 Camk2a 0.4486853 
ENSG00000172987 Hpse2 0.4478929 
ENSG00000103375 AQP8 0.4474493 
ENSG00000163884 klf15 0.4474369 
ENSG00000204444 APOM 0.4446222 
ENSG00000112499 slc22a2 0.4445184 
ENSG00000136531 SCN2A 0.4444786 
ENSG00000155980 Kif5a 0.4443835 
ENSG00000145692 bhmT 0.444374 
ENSG00000169777 TAS2R1 0.4443352 
ENSG00000096088 PGC 0.4435527 
ENSG00000183668 PSG9 0.4426178 
ENSG00000196184 OR10J1 0.4411586 
ENSG00000158571 pfkfb1 0.4405098 
ENSG00000163283 ALPP 0.4396378 
ENSG00000104888 slc17a7 0.4395806 
ENSG00000166313 APBB1 0.4393657 
ENSG00000120500 Arr3 0.4393023 
ENSG00000101440 Asip 0.4374516 
ENSG00000156269 NAA11 0.4370985 
ENSG00000169397 RNASE3 0.4370191 
ENSG00000144834 TAGLN3 0.4363283 
ENSG00000130287 NCAN 0.4362788 
ENSG00000105198 LGALS13 0.4357608 
ENSG00000178607 ERN1 0.4338798 
ENSG00000185069 KRT76 0.4338384 
ENSG00000080166 dct 0.4337677 
ENSG00000145864 GABRB2 0.4336275 
ENSG00000165970 SLC6A5 0.4335491 
ENSG00000181072 CHRM2 0.4333702 
ENSG00000170925 TEX13B 0.4332786 
ENSG00000131737 KRT34 0.4332197 
ENSG00000168484 SFTPC 0.4315164 
ENSG00000174156 GSTA3 0.4313968 
ENSG00000008226 DLEC1 0.4313711 
ENSG00000137080 IFNA21 0.4313375 
ENSG00000118557 PMFBP1 0.4309121 
ENSG00000173517 SGK269 0.4305675 
ENSG00000166869 chp2 0.4303418 
ENSG00000072080 spp2 0.4302633 
ENSG00000147113 CXorf36 0.4299574 
ENSG00000187516 CXorf27 0.4298952 
ENSG00000111046 MYF6 0.4293299 
ENSG00000120055 C10orf95   0.4292851 
ENSG00000131480 Aoc2 0.4286803 
ENSG00000008118 Camk1g 0.4273697 
ENSG00000140505 Adam21 0.426976 
ENSG00000130561 SAG 0.4269603 
ENSG00000133874 RNF122 0.4268767 
ENSG00000186723 OR10H1 0.4266471 
ENSG00000111145 ELK3 0.4263969 
ENSG00000189013 KIR2DL4 0.4244034 
ENSG00000163206 Smcp 0.4243736 
ENSG00000124134 KCNS1 0.4239395 
ENSG00000187010 RHD 0.4238045 
ENSG00000204538 PSORS1C2 0.4234329 
ENSG00000185800 DMWD 0.4233641 
ENSG00000198844 ARHGEF15 0.423218 
ENSG00000080618 CPB2 0.4226427 
ENSG00000135409 AMHR2 0.4224075 
ENSG00000173406 dab1 0.4220541 
ENSG00000134200 Tshb 0.4216173 
ENSG00000154165 GPR15 0.4214909 
ENSG00000104537 Anxa13 0.4201347 
ENSG00000142784 WDTC1 0.4197645 
ENSG00000099957 P2RX6 0.4189903 
ENSG00000068976 PYGM 0.4185931 
ENSG00000159248 Gjd2 0.4182148 
ENSG00000061938 TNK2 0.4176788 
ENSG00000163464 Cxcr1 0.4173818 
ENSG00000168038 Ulk4 0.417083 
ENSG00000162139 Neu3 0.4170207 
ENSG00000188763 FZD9 0.4162886 
ENSG00000091536 MYO15A 0.4153879 
ENSG00000174417 TRHR 0.414013 
ENSG00000125815 Cst8 0.4138338 
ENSG00000105650 PDE4C 0.4136546 
ENSG00000101327 Pdyn 0.4133892 
ENSG00000167346 MMP26 0.4124655 
ENSG00000197584 KCNMB2 0.4123594 
ENSG00000184156 KCNQ3 0.412281 
ENSG00000126767 elk1 0.4121938 
ENSG00000204290 BTNL2 0.4120363 
ENSG00000146378 Taar2 0.4118536 
ENSG00000130940 CASZ1 0.4118239 
ENSG00000142609 KIAA1751 0.4110397 
ENSG00000105428 Znrf4 0.4109898 
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ENSG00000166736 HTR3A 0.4104677 
ENSG00000176383 B3GNT4 0.4102418 
ENSG00000075290 wnt8b 0.4101921 
ENSG00000120328 PCDHB12 0.4100875 
ENSG00000171360 KRT38 0.4100363 
ENSG00000127362 TAS2R3 0.4090366 
ENSG00000180720 NA 0.4088639 
ENSG00000168748 CA7 0.408859 
ENSG00000070748 chat 0.4087487 
ENSG00000176136 Mc5r 0.4083293 
ENSG00000149124 Glyat 0.408111 
ENSG00000183434 TFDP3 0.4080805 
ENSG00000108405 P2RX1 0.407558 
ENSG00000109047 Rcvrn 0.4067586 
ENSG00000137561 ttpa 0.4061951 
ENSG00000153012 lgi2 0.4040055 
ENSG00000131899 Llgl1 0.4032065 
ENSG00000148795 CYP17A1 0.4027695 
ENSG00000197479 PCDHB11 0.4027176 
ENSG00000144596 GRIP2 0.4023646 
ENSG00000198854 C1orf68 0.4022644 
ENSG00000167034 NKX3-1 0.4012097 
ENSG00000187266 EPOR 0.4005779 
ENSG00000115665 SLC5A7 0.3996199 
ENSG00000105549 THEG 0.3994963 
ENSG00000167994 RAB3IL1 0.3991495 
ENSG00000172819 rarg 0.3985539 
ENSG00000135569 Taar5 0.3982276 
ENSG00000185527 Pde6g 0.3978273 
ENSG00000184566 NA 0.397718 
ENSG00000126231 PROZ 0.3971376 
ENSG00000146039 SLC17A4 0.3965438 
ENSG00000164076 CAMKV 0.396409 
ENSG00000160282 ftcD 0.3960544 
ENSG00000116183 PAPPA2 0.3958086 
ENSG00000105321 CCDC9 0.3953248 
ENSG00000112333 nr2e1 0.3947202 
ENSG00000163497 Fev 0.3943335 
ENSG00000161573 CCL16 0.3940819 
ENSG00000163873 Grik3 0.3940596 
ENSG00000169894 MUC3B 0.3930184 
ENSG00000182533 CAV3 0.3929687 
ENSG00000168263 KCNV2 0.3928466 
ENSG00000170322 Nfrkb 0.3928128 
ENSG00000130377 acsbg2 0.3922678 
ENSG00000149295 DRD2 0.3916209 
ENSG00000185313 Scn10a 0.39119 
ENSG00000125861 GFRA4 0.3909068 
ENSG00000124701 APOBEC2 0.3902581 
ENSG00000112212 Tspo2 0.3899292 
ENSG00000131864 usp29 0.3895764 
ENSG00000172146 OR1A1 0.389537 
ENSG00000205073 c1orf222    0.3894993 
ENSG00000163217 Bmp10 0.389487 
ENSG00000166402 TUB 0.3894465 
ENSG00000177791 myoz1 0.3889347 
ENSG00000166862 CACNG2 0.3883932 
ENSG00000186842 NA 0.387269 
ENSG00000123454 DBH 0.3870875 
ENSG00000110881 ACCN2 0.3864553 
ENSG00000104804 TULP2 0.3861663 
ENSG00000096996 IL12RB1 0.3842836 
ENSG00000196475 Gk2 0.383927 
ENSG00000099866 MADCAM1 0.3831429 
ENSG00000130385 BMP15 0.3830996 
ENSG00000116983 HPCAL4 0.3829261 
ENSG00000129535 Nrl 0.3822551 
ENSG00000178522 AMBN 0.3821295 
ENSG00000151388 ADAMTS120.3809926 
ENSG00000125618 PAX8 0.3808582 
ENSG00000165841 CYP2C19 0.3802325 
ENSG00000137634 FAM55D 0.3798088 
ENSG00000134940 Acrv1 0.37969 
ENSG00000156575 Prg3 0.3791942 
ENSG00000102385 DRP2 0.37841 
ENSG00000078295 ADCY2 0.3782568 
ENSG00000124140 SLC12A5 0.3779007 
ENSG00000073536 NLE1 0.3771268 
ENSG00000168158 OR2C1 0.3763339 
ENSG00000149305 HTR3B 0.3761535 
ENSG00000131398 Kcnc3 0.3751786 
ENSG00000128254 C22orf24   0.3751768 
ENSG00000104361 NIPAL2 0.3746246 
ENSG00000168903 BTNL3 0.3744093 
ENSG00000082556 oprk1 0.3739701 
ENSG00000075073 TACR2 0.3734025 
ENSG00000184895 SRY 0.3715192 
ENSG00000166603 MC4R 0.3700897 
ENSG00000143340 Fam163a 0.3696579 
ENSG00000169548 ZNF280A 0.369349 
ENSG00000134376 Crb1 0.3684604 
ENSG00000180245 RRH 0.3682381 
ENSG00000132703 Apcs 0.368163 
ENSG00000184166 OR1D2 0.3679829 
ENSG00000180509 KCNE1 0.3675812 
ENSG00000161572 LYZL6 0.3669826 
ENSG00000134249 Adam30 0.3661856 
ENSG00000163352 Lenep 0.3661724 
ENSG00000112232 khdrbs2 0.3659111 
ENSG00000198339 HIST2H4B 0.3655837 
ENSG00000006377 DLX6 0.3652651 
ENSG00000134571 MYBPC3 0.3652194 
ENSG00000105261 LOC728361 0.3646877 
ENSG00000178394 HTR1A 0.3637261 
ENSG00000148200 Nr6a1 0.3633277 
ENSG00000100249 C22orf31   0.3630733 
ENSG00000143536 CRNN 0.3620211 
ENSG00000118113 MMP8 0.3614806 
ENSG00000197852 c1orf183    0.3606969 
ENSG00000151615 POU4F2 0.3606859 
ENSG00000188784 pla2g2e 0.3600528 
ENSG00000169836 TACR3 0.3598443 
ENSG00000167580 AQP2 0.3593991 
ENSG00000006116 CACNG3 0.359335 
ENSG00000167419 LPO 0.3584167 
ENSG00000160868 CYP3A4 0.3583202 
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ENSG00000145826 Lect2 0.3579107 
ENSG00000016082 Isl1 0.3576786 
ENSG00000149922 tbx6 0.3575435 
ENSG00000155966 AFF2 0.3566581 
ENSG00000130032 PRRG3 0.3556359 
ENSG00000106341 C7orf16 0.3537939 
ENSG00000187848 P2RX2 0.3537733 
ENSG00000173862 FLJ20712  0.3529881 
ENSG00000129244 Atp1b2 0.3520614 
ENSG00000168594 ADAM29 0.3503074 
ENSG00000165495 pknox2 0.3492189 
ENSG00000142163 GAS8 0.3491661 
ENSG00000096264 NCR2 0.346509 
ENSG00000119121 TRPM6 0.3462056 
ENSG00000147432 CHRNB3 0.346169 
ENSG00000182674 Kcnb2 0.3450224 
ENSG00000100024 UPB1 0.3438957 
ENSG00000136750 GAD2 0.3435718 
ENSG00000105507 CABP5 0.3417005 
ENSG00000171587 dscam 0.3416663 
ENSG00000108242 CYP2C18 0.341074 
ENSG00000179148 Aloxe3 0.3408911 
ENSG00000123307 NEUROD4 0.3401013 
ENSG00000138669 PRKG2 0.3397503 
ENSG00000136695 IL1F5 0.33888 
ENSG00000135443 Krt85 0.3357302 
ENSG00000185231 MC2R 0.3354115 
ENSG00000196115 ADAM5P 0.3345217 
ENSG00000197410 DCHS2 0.3344258 
ENSG00000140557 Rlbp1 0.3329264 
ENSG00000120211 INSL4 0.3326295 
ENSG00000172150 OR1A2 0.332537 
ENSG00000065609 SNAP91 0.3321786 
ENSG00000126016 amot 0.3308822 
ENSG00000122121 XPNPEP2 0.3304179 
ENSG00000138030 Khk 0.3302165 
ENSG00000158486 DNAH3 0.3296735 
ENSG00000177301 KCNA2 0.3292115 
ENSG00000164270 HTR4 0.3279244 
ENSG00000204688 OR2H1 0.3232672 
ENSG00000189430 Ncr1 0.3200652 
ENSG00000151704 KCNJ1 0.3189544 
ENSG00000184194 gpr173 0.3186719 
ENSG00000150394 CDH8 0.3183765 
ENSG00000067191 CACNB1 0.3178703 
ENSG00000212128 Tas2r13 0.314547 
ENSG00000124440 HIF3A 0.3144289 
ENSG00000101446 Spint3 0.3056903 
ENSG00000117400 mpl 0.3025792 
ENSG00000171408 Pde7b 0.2945992 
ENSG00000154646 PRSS7 0.2912065 
ENSG00000036828 Casr 0.280495 
ENSG00000112077 RHAG 0.2725781 
ENSG00000103496 STX4 -0.710558 
ENSG00000053770 mudeng -0.7783777 
ENSG00000139722 vps37b -0.8385161 
ENSG00000151881 C5orf28 -0.9725618 










Maps of the intermediate constructs (pENTR-miR, pMAR342, GIPZ-DEST, TRIPZ-
DEST) and final lentiviral vectors (GIPZ-miR, TRIPZ-miR) generated through 
Gateway cloning (chapter 4.2). 
 
 













GeneProf analysis of the RNA-seq data: significantly modulated genes in the MDA-
MB-157 dataset (fold change relative to WT1 kd vs lacZ). 
GENE FOLD CHANGE GENE FOLD CHANGE 
AGR2 3.340328 CNTNAP3B 3.006891 
CXCL5 2.549697 C8orf4 2.675672 
FLRT3 5.084235 PAPPA 2.479477 
PTGS2 5.995349 THSD7A 3.696566 
AB019438.55 0.007443 ABI3BP 0.034932 
AC004696.1 0.014718 AC007879.7 0.019264 
AC022409.1 0.023116 AC104135.3 0.015594 
AC104135.4 0.014555 ADAMTS2 0.017123 
AFF3 0.029771 AIM1 0.157894 
AJAP1 0.017702 ALS2CR11 0.016374 
ANPEP 0.244917 ARMCX1 0.035404 
ATCAY 0.009924 ATP2B2 0.012842 
B3GALNT1 0.016581 BGN 0.006506 
C21orf56 0.035087 C9orf109 0.039102 
C9orf110 0.045963 CACNA1C 0.04517 
CAMK4 0.065497 CCNA1 0.021832 
CDH6 0.041366 CDKN2A 0.006318 
CDKN2B 0.005 COL1A1 0.04004 
COL23A1 0.017702 COL5A3 0.010141 
COL3A1 0.005484 COL6A1 0.218063 
COL6A2 0.179608 COL6A3 0.035791 
COL8A2 0.026916 COL9A2 0.059542 
COLEC12 0.012397 CPA4 0.099534 
CPXM1 0.011908 CRISPLD1 0.044404 
CRISPLD2 0.082529 CTB-36O1.5 0.16307 
CTHRC1 0.095929 CXCL12 0.014238 
CYP1B1 0.24449 CYP27A1 0.037074 
DCHS1 0.033138 DDR2 0.022781 
DLX1 0.192759 DLX2 0.043401 
DMD 0.059542 DNAJC15 0.061212 
EFNB2 0.214272 EGFLAM 0.034472 
ELAVL2 0.027636 ELAVL3 0.035087 
EMILIN2 0.233364 ENG 0.074549 
FAM101A 0.008911 FAM133A 0.02413 
FBLN2 0.023846 FLNC 0.098863 
GAS1 0.021128 GLI3 0.022945 
GNAO1 0.018194 GPR1 0.08618 
GYPC 0.007528 HLA-B 0.162063 
IFITM3 0.2399 IL7R 0.022848 
INHBA 0.011491 KCNE4 0.029437 
KIAA1644 0.138932 KIF26B 0.020153 
KIT 0.007518 L1CAM 0.182542 
LAMA4 0.018581 LAMC2 0.281636 
LUM 0.003342 LY6K 0.107176 
LZTS1 0.054018 MAFB 0.011491 
MAGEA3 0.007557 MAGEC2 0.003046 
MAN1A1 0.04517 MATK 0.009632 
MCAM 0.312072 METRNL 0.177358 
MME 0.009492 MMP16 0.016624 
MMP2 0.176415 MT-ATP8 0.00933 
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MXRA5 0.004781 MXRA8 0.189681 
MYL9 0.138228 MYO7B 0.011627 
NDN 0.018713 NFIX 0.213752 
NLGN4X 0.016794 NMNAT2 0.169345 
NPTX2 0.016374 ODZ2 0.043664 
OLFML2B 0.084722 OXCT1 0.096686 
PARP10 0.111221 PCDH7 0.047634 
PCOLCE 0.204851 PDGFRB 0.008329 
PFTK2 0.017012 PRLR 0.077055 
PRMT6 0.015782 PRSS23 0.105397 
PTX3 0.088368 QPRT 0.174658 
RAMP1 0.016374 RBP7 0.042631 
RCAN2 0.007891 RIPK4 0.214238 
RP11-414K1.3 0.012129 RP4-788L13.1 0.019264 
RSPO4 0.012596 SDC2 0.015748 
SECTM1 0.096319 SEMA3D 0.02911 
SEMA5A 0.007005 SHE 0.049619 
SIM1 0.013099 SLC1A3 0.008931 
SLC2A10 0.031189 SLCO2A1 0.006238 
SNAI2 0.054258 SORBS2 0.067176 
SPARC 0.017949 SV2A 0.032061 
TDRD12 0.017654 THNSL2 0.011101 
TIAM1 0.16172 TIMP3 0.103476 
TMEM200A 0.007043 TMEM46 0.019264 
TMTC1 0.012329 TNC 0.090205 
TRPS1 0.006009 VGF 0.140787 
WNT5B 0.132118 XIST 0.007104 
ZNF100 0.017702 ZNF257 0.013099 
ZNF439 0.027871 ZNF440 0.015411 
ZNF700 0.055742 ZNF793 0.060227 
ZNF804A 0.004517 ZNF812 0.022585 













Galaxy analysis of the RNA-seq data: significantly modulated genes in the MDA-
MB-231 dataset (fold change relative to WT1 kd vs lacZ). 
GENE FOLD CHANGE GENE FOLD CHANGE 
ADAM23   2.511692762 IGFN1 6.96368044 
ADAMTS1 1.686152473 IGSF3 4.119759159 
AIF1L 2.456833348 IL13RA2 4.400477255 
AMPH 3.362210381 IL18 1.759904324 
ARMCX2 3.335308015 KIAA1211 2.848672953 
B3GNT7 4.014721745 KIAA1462 3.179213712 
BHG 231.3318338 KRT81 1.877086326 
BMP2 2.942862222 LAMA1 3.221293245 
CA8 3.371311653 LCP1 3.785647288 
CALCR 4.516577612 LINC00261 2.085538579 
CD24 2.872864601 LMO2 2.733785406 
chr14:97744396 – 97745322 5.289055081 LRRN1 6.10783039 
chr15:56365586 – 56365765 4.029749054 MIR4763 231.3318338 
chr17:38278139 – 38278488 3.190229029 MIRLET7A3 231.3318338 
chr2:151086211 – 151086448 4.04483261 MIRLET7B 231.3318338 
chr2:235819436 – 235819635 3.785647288 MIRLET7 231.3318338 
chr2:51559914 – 51577291 9.066024123 MMP1 5.685668556 
chr2:75145080 – 75170865 2.511118306 MSI2 2.680811908 
chr3:152593079 – 152593567 3.722108214 NOV 2.322582752 
chr3:152593629 – 152594223 3.105832444 NRG2 3.834185136 
chr3:152691773 – 152692289 2.784754216 OLFML3 3.304014458 
chr3:154327061 – 154327580 2.662774025 PELI2 2.41288641 
chr3:17797074 – 17797481 2.540777426 PIK3AP1 3.20572351 
chr4:126630409 – 126631173 2.609114034 PKIB 3.105832444 
chr4:98054359 – 98056135 2.670685326 PLA2G4A 2.321922791 
chr5:92389310 – 92389681 2.872864601 PLCB1 2.998310928 
chr5:92389766 – 92390286 3.017533944 PPARGC1A 4.039369158 
chr5:97384044 – 97384667 3.190229029 PROS1 1.996134593 
chr6:113667099 – 113667513 3.381304635 PTGFR 5.087510969 
chr6:113667593 – 113667933 3.722108214 RAB27B 2.564326565 
chr6:34231052 – 34231519 5.093650596 SALL2 2.462954541 
chr6:72113343 – 72113457 4.349320426 SEL1L3 2.462357097 
chr7:93695904 – 93696621 7.723688602 SLC16A2 4.068705897 
chr9:84969780 – 84969996 4.108096297 SLC1A1 2.774715779 
CHRNA1 5.42261972 SLC4A4 2.523821714 
CPEB1 8.201512545 SLC9A2 2.811694794 
CREB5 2.373325535 SNTB1 1.958985881 
ENPP5 7.370129658 SOX4 2.677283657 
ESM1 6.641273902 SPANXA2 4.108096297 
FAM133A 4.354689938 STOX2 5.991511489 
FAM49A 4.668017598 TFPI2  2.144914291 
FOXQ1 1.797330847 TMEM98 3.44117199 
GNPTAB 1.674532063 TNC 1.932390948 
GPNMB 4.735051116 WNT5A 2.859791564 
GPR137B 2.169481073 WTAPP1 5.614994798 
HS6ST3 2.944392497   
AFAP1L2 0.512003295 MIR221 0.30450546 
AKT2 0.545414893 MIR222 0.30450546 
chr2:12246697 – 12271707 0.150272195 MUSK 0.219962577 
236 
 
chr22:20399807 – 20401615 0.369393401 PLCB4 0.319589076 
chr7:142494046 – 142500772 0.475847105 PTGS1 0.281672378 
chr7:22896548 – 22899240 0.259354984 RSAD2 0.240964079 
chrX:45624166 – 45629581 0.211646715 S100A2 0.547708054 
COL5A1 0.529931209 SERPINB9 0.551853794 
CST6 0.242737683 STMN3 0.502417284 
DAPK1 0.387540771 THBS1 0.495140547 
EHD1 0.595828897 TNXA 0.240964079 
EPHB3 0.206791673 TNXB 0.211646715 
GPR110 0.252875645 UCA1 0.313066273 

























Galaxy analysis of the RNA-seq data: significantly modulated genes in the MDA-
MB-157 dataset (fold change relative to WT1 kd vs lacZ). 
GENE FOLD CHANGE GENE FOLD CHANGE 
ABCC3 2.087896215 HLA-DMB 4.3472709 
AGR2 3.250068218 HS3ST6 10.91726824 
ALDH3A2 1.870413179 IGFBP4 2.237131405 
APOC1 3.563660742 INSL4 6.174918092 
ARSE 2.88457745 ITGB5 2.675984946 
ASB4 2.777005434 JUP 2.866339494 
BCAS1 6.663499302 KRT4 8.064192065 
BCL3 2.701891984 LIMD1 2.034832441 
BLVRB 2.101777573 LITAF 2.431691145 
C3 2.090068173 LOC100505817 2.082144219 
C8orf4 2.328385599 LRP5 2.432955613 
CA11 8.489208212 LRRK2 2.87033674 
CA12 1.791834014 LSAMP 3.570583854 
CACNG6 6.151848607 MALAT1 2.446535132 
CACNG7 6.028044219 MEGF9 1.793395894 
CDH1 2.638997529 MID1IP1 2.043666803 
CDR1 8.955599429 MMD 3.784886401 
CELSR2 2.411949999 MTUS1 2.837558233 
chr1:201978910 – 201979569 3.753561185 NCMAP 6.348650684 
chr10:43839191 – 43839950 11.07427233 NR0B1 2.017054408 
chr21:16189782 – 16191179 7.047248074 NR4A1 3.406003695 
chr21:16191248 – 16192059 6.443211713 NUP210 1.777533808 
chr7:128109116 – 128110111 12.30472065 NUPR1 6.901500205 
chr9:39796149 – 39817619 7.096609882 PADI2 11.13376784 
CNNM1 2.024842929 PALM3 4.712818104 
CNTN1 2.341868389 PAPPA 2.438814451 
CNTNAP3 3.068705077 PCDH9 2.046757242 
CNTNAP3B 3.321212423 PCSK9 3.434690253 
CPLX2 3.531497316 PDK4 3.086817094 
CSDC2 7.282430358 PGD 2.56112914 
CXCL5 2.33392791 PIFO 7.434573596 
CYB5B 3.533921517 PLA2G4A 4.533860493 
CYP24A1 2.227646017 PLEKHG2 1.902778989 
CYP2S1 2.374609032 PON3 2.469707181 
CYSTM1 1.830443192 PPFIBP2 2.109366817 
DLL4 20.96803846 PTGS2 5.424837791 
DPEP1 7.835145141 RAB26 5.585320234 
DUSP5 2.827486233 RAB37 4.946746605 
EFCAB12 5.728669072 RASGEF1A 2.827505832 
ELF3 3.073835586 SCD 4.716478202 
ELMO1 3.036501328 SLC12A2 2.40423847 
FGA 8.023546136 SOX2 3.766618714 
FGB 4.897583196 SREBF1 3.332257756 
FGL1 3.235704814 STEAP1 2.569700104 
FKBP10 1.836035559 SULT2B1 8.086749935 
FLRT3 4.563750748 SUSD2 8.817563131 
FZD8 2.352948917 SYT12 3.468952293 
GDF15 2.756676548 THSD7A 3.651759036 
GLI1 5.016391686 TMEM2 2.070041943 
GPCPD1 2.257068181 TNNC1 9.24280022 
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GPR20 20.96803846 TSKU 2.380970919 
GPRIN3 2.818270325 VTN 4.986854118 
HEATR5A 2.387052009   
AARD 0.083956742 LINC00460 0.142841788 
ABI3BP 0.043504848 LINC00552 0.045710519 
ACHE 0.134351096 LINC00565 0.063864588 
ADAM12 0.36472222 LOC100128252 0.007427488 
ADAMTS2 0.017677524 LOC100134259 0.152803554 
ADAMTS3 0.074816485 LOC100505806 0.057755414 
ADRB2 0.140419967 LOC339166 0.057777837 
AFP 0.069187729 LOC339535 0.145827024 
AIM1 0.162799526 LOC339975 0.010544248 
AJAP1 0.014536059 LRCH2 0.220860909 
ALS2CR11 0.009449838 LUM 0.002964922 
ANPEP 0.275115628 LY6K 0.110131571 
ARC 0.103249736 LYPD6 0.231302057 
ARHGAP29 0.443501227 LZTS1 0.048459388 
ARMCX1 0.035066081 MAFB 0.012999951 
ARMCX4 0.182636877 MAGEA3 0.009132085 
ATCAY 0.103476137 MAGEC2 0.001546186 
ATP2B2 0.017512028 MAL2 0.087259741 
B3GALNT1 0.021143822 MAMDC2 0.111316549 
BEX1 0.007373737 MAN1A1 0.042999092 
BGN 0.007468031 MATK 0.011726908 
BHLHE41 0.23943401 MCAM 0.345903136 
BNC1 0.094462138 METRNL  0.218120912 
C5orf58 0.010678849 METTL7A 0.201434123 
CAMK4 0.089128461 MFAP2 0.083810221 
CD248 0.0145279 MIR3606 0.006111321 
CD34 0.065268921 MME 0.006619876 
CDH6 0.032699446 MMP16 0.020518513 
CDK15 0.024425468 MMP2 0.194199313 
CDKN2A 0.008647147 MXRA5 0.004774515 
CDKN2B 0.006160338 MXRA8 0.186442155 
CHPF 0.499231198 MYBL1 0.263870139 
chr10:5636836 – 5638428 0.167206171 MYL9 0.151168557 
chr13:41958149 – 41958436 0.050931076 MYO7B 0.010031701 
chr13:41958605 – 41958839 0.067243098 NAP1L3 0.176890687 
chr14:106825766 – 106854876 0.016870423 NDC80 0.466898222 
chr14:106856142 – 107131115 0.037990434 NDN 0.020589035 
chr14:50504528 – 50507288 0.124928973 NFIX 0.259381951 
chr15:101624496 – 101626648 0.020518513 NID1 0.417908787 
chr17:61506209 – 61509453 0.057755414 NLGN4X 0.016930519 
chr18:14969325 – 14970440 0.114966863 NMNAT2 0.159678281 
chr2:208104168 – 208111511 0.024750131 NOV 0.268138447 
chr2:75145007 – 75170621 0.018644449 NPTX2 0.017440074 
chr2:96190805 – 96192490 0.201350366 NR2E1 0.024095708 
chr20:57203068 – 57210876 0.025552885 OLFML2B 0.091735249 
chr21:43188227 – 43189538 0.03728709 OXCT1 0.090116807 
chr21:43194207 – 43198404 0.039937006 PAG1 0.246990935 
chr3:197205853 – 197206504 0.01677911 PARP10 0.143843307 
chr4:119991134 – 119991452 0.154564403 PCDH18 0.06711644 
chr5:13986064 – 13987434 0.128794242 PCDH7 0.048296753 
chr5:42951009 – 42955759 0.245233844 PCDHB14 0.100159419 
chr6:45631241 – 45632621 0.119318529 PCDHB3 0.127221993 
chr7:55840864 – 55841459 0.017666867 PCDHB4 0.190481131 
chr8:49293258 – 49297732 0.069209313 PCDHB7 0.147401182 
chr8:60032480 – 60033396 0.099289158 PCLO 0.151693377 
chr9:137514718 – 137516870 0.029181139 PCOLCE 0.182991685 
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CLDN11 0.153997624 PDGFRB 0.008272735 
COL12A1 0.328071005 PDLIM3 0.184200643 
COL15A1 0.082190189 PEA15 0.454757709 
COL1A1 0.048813364 PEG3 0.002057787 
COL21A1 0.267961939 PITPNC1 0.399373358 
COL23A1 0.030542247 PLA2G7 0.080845988 
COL3A1 0.006111321 PLAC8 0.152069212 
COL5A1 0.493468534 PRKCDBP 0.126210164 
COL5A3 0.012029246 PRMT6 0.016870423 
COL6A1 0.262962685 PRR16 0.045710519 
COL6A2 0.217434082 PRRX1 0.044090755 
COL6A3 0.040967964 PRSS35 0.103214674 
COL8A2 0.031137135 PTH2R 0.083636703 
COL9A2 0.083636703 PTX3 0.086458403 
COLEC12 0.010678849 PXDN 0.537244234 
COX7B2 0.029181139 QPRT 0.210860388 
CPA4 0.103200367 RAB20 0.207312642 
CPXM1 0.038489 RAMP1 0.02078577 
CRABP1 0.093034524 RASSF8 0.389628199 
CRISPLD1 0.038992217 RBP7 0.040653405 
CRISPLD2 0.091988671 RCAN2 0.00918239 
CRLF1 0.134660628 RIPK4 0.247061138 
CSF1R 0.105638674 RORB 0.003519387 
CTHRC1 0.08431248 SALL3 0.016726971 
CTNNAL1 0.36187416 SAMD9L 0.263093954 
CXCL12 0.017456402 SDC2 0.0145279 
CXCR7 0.18557445 SDC4 0.453306892 
CYP1B1 0.235501801 SDR16C 0.233952897 
CYP27A1 0.050738687 SECTM1 0.111619423 
DACT1 0.18992214 SEMA5A 0.015934969 
DCHS1 0.04105495 SERTAD2 0.432034971 
DDR2 0.026610511 SH2B3 0.430098797 
DLL1 0.117876661 SHE 0.062946065 
DLX1 0.208007867 SHISA2 0.032203471 
DLX2 0.053439488 SHISA3 0.107085867 
DMD 0.075699102 SHROOM2 0.351603174 
DNAJC15 0.058350547 SIX 0.108707245 
DPF3 0.165630469 SLC12A8 0.115470001 
EDIL3 0.058141012 SLC1A3 0.008072493 
EFNB2 0.211838982 SLC2A10 0.022435078 
EGFLAM 0.020710411 SLC6A10P 0.072594799 
ELAVL2 0.020877605 SLCO2A1 0.006445916 
ELAVL3 0.041106775 SLFN12 0.065403425 
ELFN1 0.193884584 SNAI2 0.050010679 
EMILIN2 0.310167622 SNCA 0.067240767 
EMP1 0.414849514 SORBS2 0.054519646 
ENG 0.06763904 SPARC 0.01744491 
ENPP2 0.065445146 SPATC1L 0.042589157 
EPHA4 0.28813164 SPOCK1 0.480970395 
ETS1 0.409257284 SSTR2 0.161999358 
FAM133A 0.021825825 ST8SIA6-AS1 0.013365615 
FAM225A 0.045774565 SV2A 0.03150883 
FAM225B 0.060598252 TDRD12 0.022618076 
FAM43A 0.279687949 TENM2 0.037089124 
FAM90A1 0.065454219 THNSL2 0.090116807 
FAP 0.049157999 TIAM1 0.166580335 
FBLL1 0.095991469 TIMP3 0.100525959 
FBLN2 0.030132413 TMEM200A 0.009449838 
FBXL7 0.303468778 TMEM255A 0.114852168 
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FLI1 0.012471856 TMEM63C 0.229258956 
FLNC 0.110694849 TMPRSS3 0.103432394 
FOSL1 0.230975222 TMTC1 0.017547752 
FOXC2 0.123315837 TNC 0.089349905 
FRMD6 0.296743843 TNFRSF9 0.119690454 
G0S2 0.102951018 TOX 0.129809691 
GAS1 0.024710705 TRIB2 0.096910715 
GBP1 0.167155184 TRIM58 0.056235307 
GBP4 0.155524093 TRPS1 0.007373737 
GIPC3 0.182085759 TUBB2A 0.46323302 
GLI3 0.022296638 TXNIP 0.184888834 
GLIS1 0.0363271 UGT3A2 0.119690454 
GNAO1 0.031807262 VGF 0.189242758 
GPR1 0.104992632 VIT 0.135415989 
GPR110 0.053540707 WNT3A 0.086603552 
GUSBP5 0.044702831 WNT5A 0.127064243 
GYPC 0.009096573 WNT5B 0.131805556 
HEY1 0.196623818 XAF1 0.100523868 
HEY2 0.102047306 XIST 0.010209033 
HK2 0.312942607 ZIC1 0.127221993 
HLA-B 0.254018674 ZIM2 0.002057787 
HLA-C 0.254018674 ZNF100 0.066021055 
HOXC12 0.010565025 ZNF253 0.066020597 
ID4 0.195894663 ZNF257 0.021621494 
IFI44 0.160512772 ZNF320 0.154572974 
IFITM3 0.359312243 ZNF347 0.241278288 
IL11 0.382144455 ZNF429 0.122102107 
IL13RA2 0.0187727 ZNF440 0.03918214 
IL6 0.120426099 ZNF471 0.122730864 
IL7R 0.038489 ZNF486 0.085083902 
ITGA4 0.349593436 ZNF492 0.144869922 
JAM2 0.094194067 ZNF506 0.135415989 
JUN 0.268985442 ZNF667 0.019276675 
KAL1 0.092424555 ZNF681 0.234404147 
KCNE4 0.0483993 ZNF69 0.045987641 
KIAA1644 0.141874774 ZNF700 0.052628935 
KIF26B 0.011187739 ZNF702P 0.01370892 
KIF5C 0.281097007 ZNF737 0.125428752 
KIT 0.005927502 ZNF781 0.019906039 
L1CAM 0.206262006 ZNF788 0.083875891 
LAMC2 0.277313547 ZNF793 0.269313788 
LAPTM5 0.106301216 ZNF804A 0.004047341 
LGI2 0.106871568 ZNF812 0.034186487 
LIMA1 0.351620235 ZNF844 0.03077921 
LINC00221 0.005893458 ZNF91 0.268746897 
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